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ABSTRACT
In recent years, HIV-1 integrase (IN) has emerged as an attractive target for the treatment
of human immunodeficiency virus type 1 (HIV-1), the causative pathogen of acquired immunodeficiency syndrome (AIDS). Several classes of IN inhibitors are known but many of these
compounds are toxic, do not show antiviral activity or display decreased potency. Therefore, new
classes of potent IN inhibitors are desperately needed. The b-diketo (b-DK) class of compounds
has emerged as one of the most successful classes of IN inhibitors. Although several b-DK
inhibitors with potent antiviral activity are known, compounds containing b-DK motifs have
limitations in drug development. The overall objective of this dissertation was to design and
synthesize a novel series of IN inhibitors that retain the favorable characteristics of the b-DK
scaffolds but are devoid of the “undruggable” properties. The design of the target molecules was
established from crystal structure-based correlation and structure-activity relationship studies,
which led to scaffolds containing three specific functional groups. Each molecule was designed
to contain the core functional motif (a,b-diketoamide), optimal aryl groups (3-benzylphenyl or
substituted 3-benzylphenyl) and a terminal group (proton donor or acceptor or amphoteric
functional groups) in a planar or near planar configuration. Several oxalamate containing
compounds were successfully designed and synthesized; and many of these synthetic analogs
were sent to be screened for inhibitory activity against HIV-1 IN. The synthetic analogs
described herein may elicit alluring antiviral activity, serve as potential lead molecules for future
optimizations and ultimately elucidate mechanistic insight into HIV-1 IN inhibition.
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I. INTRODUCTION

Human immunodeficiency virus type-1 (HIV-1) is a lentivirus that infects CD4 (cluster of
differentiation 4) positive (CD4+) T-lymphocytes (T-cells) and macrophages of the human
immune system. Infection with the HIV-1 virus results in the progressive deterioration and
impairment of the host immune system, leading to an ‘immune deficiency’. A person infected
with HIV-1 is easily susceptible to infections, most of which are rare among healthy people.
Infections associated with an immunodeficiency are known as ‘opportunistic infections’ (OIs),
because they take advantage of the weakened immune system.5 HIV-1 is a slow disease that
continues to cause progressive damage to the immune system from the time of infection to the
manifestation of severe immunologic damage by OIs, neoplasms, wasting, or low CD4+ cell
count that will eventually lead to acquired immunodeficiency syndrome (AIDS).6

1.1. HIV-1 AND AIDS BACKGROUND
1.1.1. History
The simian version, simian immunodeficiency virus (SIV), of human immunodeficiency
virus type 1 (HIV-1) was conceivably transferred from its natural host, the chimpanzee, to man
in the early to middle years of the 20th century in the west central African countries of Cameroon
and Gambia.7 The spread of HIV-1 was initially slow and limited, but due to rapid urbanization
in the post-colonial era, the disease rapidly spread worldwide appearing in at-risk individuals in
most regions by the mid-to-late 1970s.8

1

HIV-1 infection was not recognized in medical publications until the clinical syndrome of
advanced immune deficiency, later termed AIDS, was reported in the early 1980s.8 Unusual
cases of infection and illness among young, previously healthy individuals began to appear in
large cities in the United States (U.S.) in 1981. Kaposi's Sarcoma (KS) was a rare form of
relatively benign cancer that tended to occur in elderly people. In March 1981 at least eight cases
of a more aggressive form of KS had transpired amid young homosexual men in New York.9 On
June 5, 1981, the first acquired immunodeficiency syndrome (AIDS) cases were reported by the
Centers for Disease Control and Prevention (CDC): five cases of Pneumocystis carinii (now P.
jiroveci) pneumonia (PCP) among previously healthy homosexual men in Los Angeles. The
accompanying editorial suggested that the illness might be related to the men’s sexual
behavior.10 Later in 1981, more cases of PCP and KS among homosexual men in New York and
California were seen.11, 12 When the CDC reported the new outbreak they called it “gay-related
immune deficiency” (GRID) or “gay cancer”, stigmatizing the gay community as carriers of this
deadly disease.13 However by December 1981, cases started appearing in heterosexuals, injecting
drug users (IDUs) and people who received blood transfusions, also the first case of AIDS was
reported in the United Kingdom (UK), proving the syndrome knew no boundaries.14, 15 The
disease continued to spread across the U.S. and by July 1982, a total of 452 cases from across the
U.S. had been reported to the CDC.16 By 1983 it was becoming increasingly clear that the
disease was not limited to spreading across the U.S. Cases were also being reported in Europe,
Uganda, Australia, Canada, Latin America and Japan.17 It took eighteen months from the first
report to identify the primary risk factors for AIDS; guidelines for prevention of occupational,
drug-related and sexual transmission of the illness were issued by the CDC in March 1983.18 It
was later that year, that Luc Montangier and Francoise Barre-Sinoussi isolated the suspected
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retrovirus19 which was later confirmed to be the causative agent of AIDS by Robert Gallo in
1984.20, 21 This virus was ultimately termed ‘human immunodeficiency virus’ (HIV).22

1.1.2. Transmission
The transmission of HIV-1 from an infected person to an uninfected person occurs when
an infected person’s bodily fluids, mainly semen, vaginal fluids, blood or breast milk enters an
uninfected person’s body.23-25 The most common routes of transmission are unprotected sexual
intercourse, injection drug use (IDU), and from infected mother to infant.26 Blood transfusions
and organ transplants were initially a way that HIV-1 was spread, but now due to careful tests
and screening the risk is extremely low.27
The first phase of HIV-1 infection is the asymptomatic incubation period. Most people
that become infected with HIV-1 do not know that they have become infected because they do
not feel ill immediately after infection.5 However, some people at the time of seroconversion
(development of antibodies to HIV-1; 1-6 weeks after HIV-1 infection) develop acute retroviral
syndrome characterized by fever, malaise, generalized lymphadenopathy, pharyngitis, diarrhea,
and rash.28 An acute infection is often unrecognized because the complex of symptoms is easily
confused with other illnesses and diseases (e.g., influenza or infectious mononucleosis).29 In
acute primary infection, plasma HIV-1 RNA (ribonucleic acid) concentrations can be very high,
making secondary transmission a high risk if an infected individual continues to engage in
behavior that could transmit HIV-1 to an uninfected person. After the symptoms of primary
infection resolve, the infected person enters the second phase of HIV-1, the asymptomatic latent
phase.8 An infected person displays no symptoms and this stage can persist for several years
(average eight to ten years), although rapid progression is usually common. During this stage,
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HIV-1 is actively replicating and will continue to weaken the immune system. The symptomatic
disease phase (one to three years) often emerges as the peripheral CD4+ cell count falls below
350 cells per µL and many people become susceptible to infections and begin to experience
HIV-1 disease related symptoms. The last stage of infection is the progression of HIV-1 to AIDS
when the immune-system’s ability to fight infection on its own is lost. A diagnosis of AIDS is
given when a patient CD4+ count falls below 200 cells per µL and individuals experience
multiple OIs (pneumonia, neurological diseases and cancers). The CDC classification system is
used to determine the severity and progression of HIV-1 and AIDS infection and disease (Table
1.1). This classification system is based on specific conditions that a patient has developed
(Table 1.2).30, 31
The clinical staging and case definition for resource-constrained settings were developed
by the World Health Organization (WHO) in 1990 and revised in 2007. 32 Staging is based on
clinical findings that guide diagnosis, evaluation, and management of HIV-1 and AIDS and it
does not require a CD4+ cell count. In many countries this staging will help to determine the
eligibility for antiretroviral therapy (ART), particularly in locations where CD4+ testing is not
available. Clinical stages, defined by clinical conditions, are categorized as 1 through 4,
progressing from primary HIV-1 infection to advanced HIV-1 and AIDS (Table 1.3).32
CD4+ Cell Counts

> 500 cells/µL
200-499 cells/µL
<200 cells/µL

Clinical Categories
B
Symptomatic
Conditions, not A or
C
B1
B2
B3

A
Asymptomatic,
Acute HIV-1 or
PGL*
A1
A2
A3

C
AIDS-Indicator
Conditions
C1
C2
C3

*PGL= persistent generalized lymphadenopathy; Patients in categories A3, B3, C1-C3 are considered to have
AIDS

Table 1.1 CDC Classification System for HIV-1 Infection30, 31
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Category B Symptomatic Condition Examples

Category C AIDS Indicator Conditions

Bacterial Pneumonia (> 2 episodes in 12 months)
Symptomatic condition as are attributed to HIV
Candidiasis of bronchi, trachea, or lungs
infection or indicate a defect in cell-mediated
Candidiasis, esophageal
immunity and/or
Cervical carcinoma, invasive
They are considered to have a clinical management that
Coccidioidomycosis (fungal disease)
is complicated by HIV infection
Cryptococcosis, extrapulmonary (fungal disease)
Bacterial angiomatosis
Cryptosporidiosis, chronic intestinal >1 month
Oropharyngeal candidiasis (thrush)
(parasitic disease)
Vulvovaginal candidiasis, persistent/resistant
Cytomegalovirus disease (other than liver, spleen, or
Pelvic inflammatory disease (PID)
nodes)
Cervial dysplasia/ cervical carcinoma
Encephalopathy, HIV-1 related
Hairy leukoplakia, oral
Herpes simplex: chronic ulcers (>1 month), or
Herpes zoster (shingles) > 2 episodes
bronchitis, pneumonitis, or esophagitis
Idiopathic thrombocytopenic purpura (low platelet count)
Kaposi sarcoma
Fever (>38.5°C) or diarrhea >1 month
Mycobacterium tuberculosis
Peripheral neuropathy
Salmonella septicemia, recurrent (nontyphoid)
Wasting syndrome caused by HIV (involuntary
weight loss >10% of baseline body weight)
Table 1.2 Selected Examples of Clinical Categories B and C Conditions30, 31

Stage

Symptoms

Primary HIV-1 Infection
Clinical Stage 1
Clinical Stage 2

Clinical Stage 3
Some persons with clinical stage
3 have AIDS

Clinical Stage 4
Includes 22 opportunistic
infections or cancers related to
HIV-1. All persons with clinical
stage 4 have AIDS.

Asymptomatic, Acute retroviral syndrome
Asymptomatic, Persistent generalized lymphadenopathy (PGL)
Weight loss (<10 % measured body weight)
Recurrent respiratory infections
Herpes zoster
Angular cheilitis (lesions)
Recurrent oral ulceration
Seborrheric dermatitis (inflammation)
Fungal nail infection
Severe weight loss (>10 % measured body weight)
Chronic diarrhea >1 month
Persistent fever >1 month
Oral candidiasis
Oral hairy leukoplakia
Pulmonary tuberculosis
Severe bacterial infections (pneumonia, bone or joint infection, meningitis)
Anemia (hemoglobin <8 g/dL)
Neutropenia (neutrophils <500 cells/µL)
Chronic thrombocytopenia (platelets <50, 000 cells/µL)
HIV wasting syndrome (>10 % measured body weight)
Pneumocystis pneumonia
Recurrent severe bacterial pneumonia
Chronic Herpes simplex infection
Esophageal candidiasis
Extrapulmonary tuberculosis
Kaposi sarcoma
Cytomegalovirus infection (retinitis or infection of other organs)
Candidiasis of bronchi, trachea, esophagus or lungs
Lymphoma (cerebral or B-cell non-Hodgkin)
Salmonella septicemia, recurrent (nontyphoid)
Cervical carcinoma, invasive
Symptomatic HIV-associated nephropathy
Symptomatic HIV-associated cardiomyopathy

Table 1.3 WHO Clinical Staging of HIV-1/AIDS32
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1.1.3. Statistics
Human immunodeficiency virus type 1 (HIV-1) is the etiological agent that causes AIDS. As of
2009, it is estimated that worldwide there are 33.3 million people living with HIV-1, with 22.5
million (68 % of the global total) in Sub-Saharan Africa (Figure 1.1).33 The CDC has estimated
that more than 1.1 million adults and adolescents were living with HIV infection in the U.S. at
the end of 2006, the most recent year for which national prevalence estimates are available.26
There is no cure for HIV-1 or AIDS and since the discovery of AIDS in 1981, it has led to the
deaths of more than 30 million people.33 HIV-1 is arguably the most intensely studied virus in
the history of biomedical research. Despite the wealth of knowledge, however, HIV-1 infection
remains a pandemic today and elusive in terms of a ‘cure’.34

Figure 1.1 Adults and Children Estimated to be Living with HIV-1, 200933
(Permission to reprint ID:87551 WHO, permissions@who.int; 02-20-2012)

1.1.4. Current Trends Worldwide
HIV-1 has become one of the most challenging and serious health concerns worldwide.
When the first cases of HIV-1 and AIDS were reported in 1981, no one could have predicted
6

how the epidemic would spread around the world and how many millions of lives it would
ultimately affect. Even though HIV-1 and AIDS cases have been reported in all regions of the
world, about 95% of people living with HIV-1 and AIDS reside in low- and middle-income
countries, where most new HIV-1 infections and AIDS-related deaths occur.33, 35 The major route
of transmission worldwide is heterosexual sex, although risk factors vary within and across
populations.36 In several regions of the world, men who have sex with men (MSM), IDUs, and
sex workers account for substantial proportions of infections.33
The most affected regions of the world are sub-Saharan Africa, Asia, Latin America and
the Caribbean, Eastern Europe and Central Asia (Table 1.4).33, 35, 36 Sub-Saharan Africa, the
most severely affected region in the world, has two-thirds (68%, 22.5 million) of people living
with HIV-1 but only about 12% of the world’s population.37, 38 At the end of 2009, there were
nine countries with more than 10% of adults are estimated to be HIV-positive.33 Most children
with HIV-1 live in this region (91%).39 About 1.7 million people are estimated to be living with
HIV-1 in Latin America and the Caribbean combined, including 112,000 newly infected in
2010.35 The Caribbean itself, with an adult HIV-1 prevalence rate of nearly 1%, is the second
most affected region in the world after sub-Saharan Africa.37 Nearly 5 million people are living
with HIV-1/AIDS across South/Southeast Asia and East Asia. While most national epidemics
appear to have stabilized, HIV-1 prevalence is increasing in Bangladesh, Pakistan, and the
Philippines.37 An estimated 1.5 million people are living with HIV-1 in Eastern Europe and
Central Asia, an increase of 250% since 2001.35, 37 The major transmission route for this
epidemic is primarily caused by injecting drug use, although heterosexual transmission also
plays an important role.35
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Region
Global Total
Sub-Saharan Africa
South/Southeast Asia
Eastern Europe/Central Asia
Latin America
North America
Western/Central Europe
East Asia
Middle East/North Africa
Caribbean
Oceania

Total No. (%) Living
with HIV end of 2010

Newly Infected in 2010

Adult Prevalence Rate
2010

34 million (100%)
22.9 million (67%)
4.0 million (12%)
1.5 million (4%)
1.5 million (4%)
1.3 million (4%)
840,000 (2%)
790,000 (2%)
470,000 (1%)
200,000 (0.6%)
54,000 (0.2%)

2.7 million
1.9 million
270,000
160,000
100,000
58,000
30,000
88,000
59,000
12,000
3,300

0.8%
5.0%
0.3%
0.9%
0.4%
0.6%
0.2%
0.1%
0.2%
0.9%
0.3%

Table 1.4 HIV-1 Prevalence and Incidence by Region35

In the early years of the AIDS epidemic, it was quickly recognized that HIV-1 was
having a severe impact on MSM. Currently, it is estimated that MSM accounts for between 510% of all HIV-1 infections worldwide.40 Interestingly, more people have become infected with
HIV-1 through male to male sex than through any other transmission route in many developed
countries, such as U.S., Canada, Australia, New Zealand and many areas of Western Europe.41 In
many countries however, MSM are less observable. Sex between men is stigmatized, officially
denied and criminalized in various parts of the world.41 There are several factors that distort the
statistics, in some countries the social identity of MSM is not acknowledged by the government
and therefore they are simply counted as the general population. Also, it is not always possible to
tell how a man initially became infected with HIV-1 especially if he is having sex with both men
and women.41 Many MSM often hide their same-sex relations from their families and friends to
avoid persecution. Many have wives, or have sex with women, and this means that they may
easily transmit HIV-1 to their female partners if they become infected. MSM is not an isolated
problem but one that is potentially linked to countries’ wider HIV-1 epidemics.42, 43
Women comprise an increasing proportion of people living with HIV-1 and AIDS.
Globally, HIV-1/AIDS is the leading cause of death among women of reproductive age.44 More
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than half of the population of people living with HIV-1 globally is women, from whom the most
usual route of infection is heterosexual intercourse.45 This trend is occurring in most regions of
the world, and is particularly pronounced in sub-Saharan Africa, where women represent 59% of
all adults living with HIV-1 and AIDS.33 In sub-Saharan Africa, more women than men are
living with HIV, and young women aged 15-24 are about eight times more likely to be HIV-1
positive.45 Gender inequalities in social and economic status and limited access to prevention and
care services increase women’s vulnerability to HIV-1.35 Sexual violence also increases a
women’s risk to contract HIV-1 and women, especially young women, are biologically more
susceptible to HIV-1 infection than men.

1.1.5. Current Trends in the United States
Homosexual, bisexual and other men of all races who have sex with men continue to be
the risk group most severely affected by HIV-1 in the U.S. (Figure 1.2).46 MSM represent
approximately 2% of the U.S. population,47 yet are the population most severely affected by
HIV-1, and are the only risk group in which new HIV-1 infections have been increasing steadily
since the early 1990s.48 In 2006, more than half (53%) of all new HIV-1 infections in the U.S.
were MSM. Additionally, MSM with a history of injection drug use (MSM-IDU) accounted for
an additional 4% of new infections.48 Since the beginning of the U.S. epidemic, MSM have
consistently represented the largest percentage of persons diagnosed with AIDS and persons with
an AIDS diagnosis who have died.48
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Figure 1.2 Estimated New HIV-1 Infections in the U.S., 2009.49
(Reprinted with Permission from CDC)

In the U.S., African Americans face the most severe burden of HIV-1 of all racial or
ethnic groups (Table 1.5). Despite representing 14% of the US population in 2009, African
Americans accounted for 44% of all new HIV-1 infections that year (Figure 1.2).50 For both
African American men and women, having unprotected sex with a man is the leading cause of
HIV-1 infection, with injecting drug use being the second most likely infection route. Key
factors such as high levels of poverty, limited access to healthcare, and stigma surrounding MSM
shape the epidemic among African Americans.4
Hispanics/Latinos are also disproportionately affected by the HIV-1 and AIDS epidemic
in America (Table 1.5). It is estimated that 1 in every 52 Hispanics/Latinos will be diagnosed
with HIV-1 in their lifetime.51 Interestingly, the risk for men and women differs widely; 1 in 36
Hispanic/Latino men will be diagnosed with HIV in their lifetime compared to 1 in 106
Hispanic/Latino women.52 Language barriers, cultural factors, low access to healthcare and
migration patterns have been identified as barriers to HIV-1 prevention and treatment within the
Hispanic/Latino community.52
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Race
White
African American/Black
Hispanic/Latino
Asian
American Indian/Alaska Native
Native Hawaiian/Other Pacific Islander
Multiple Races

Estimated % of new AIDS diagnosis in 2009 % of US population in 2008
27
65
47.9
12
21.2
15
1.2
4
<1
<1
<1
<1
2
2

Table 1.5 Percentage of AIDS in U.S. among Various Ethnic Groups2 Compared to Percentage of
Population Each Ethnic Group Represents3, 4

Geographic differences are a significant feature of the epidemic in the U.S. The epidemic
was once concentrated primarily in the homosexual populations on the East and West coasts.
However, in recent years HIV-1 has also become increasingly prevalent within African
American and Hispanic/Latino communities in many Southern states as well as certain urban
areas in the North-east and West-coast.4 The map in Figure 1.3 shows the states with the number
of people living with AIDS in 2009, relative to the population of each state. HIV-1 and AIDS
remains mostly an urban disease, with the majority of individuals diagnosed with AIDS in 2009
residing in areas with more than 500,000 people. Areas hardest hit (by ranking of AIDS cases per
100,000 people) include Miami and Jacksonville, Florida; Baton Rouge, Louisiana; New York
City, New York; and Washington, D.C.53 Ten states account for 71% of AIDS diagnosis reported
since the beginning of the AIDS epidemic. Nine of these states also rank in the top ten for new
diagnosis in 2009 (Table 1.6).54 As the epidemic has developed, it has become evident that the
quality of prevention and treatment services than an individual receives is influenced by their
socio-economic group and where they live. Poor urban communities are particularly affected by
HIV-1 and AIDS in the US, which can be attributed to a number of factors including inadequate
disease reporting, poverty, absence of adequate healthcare and lack of comprehensive sex
education in schools.55
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Figure 1.3 Estimated Numbers of AIDS Diagnoses, All Ages, 2009 56
(Permission to reprint Kaiser Family Foundation, 03-02-12)

Table 1.6 Top Ten States by Cumulative AIDS Diagnosis and by AIDS Diagnosis Rate Per 100,000 2
(Requested permission to reprint Kaiser Family Foundation, 03-02-12)

New infections due to injection drug use has declined significantly over time and
accounted for 9% of new infections in 2009.53, 57 Throughout the epidemic, prevention efforts
among IDUs has been controversial. For 21 years, programs where users exchange their needles
for clean ones (needle exchange programs) were not permitted any federal funding, even though
in some areas in the US these programs have been shown to reduce the rate of transmission.58, 59
12

The ban on federal funding for needle exchange programs was lifted in 2009, however, at the end
of 2011, in a controversial action by Congress, the ban was later reinstated.60

1.1.6. HIV-1 Structure and Genome
HIV-1 is spherical in shape and has a diameter of 1/10,000 of a millimeter. The outer coat
of the virus (the viral envelope) is composed of two layers of fatty acids, taken from the
membrane of a human cell when a newly formed virus particle buds from the cell. Embedded
within the viral envelope are proteins from the host cell, as well as about 72 copies of the
complex protein envelope glycoprotein (Env). Env consists of a cap made of three molecules
called glycoprotein 120 (gp120), and a stem consisting of three molecules gp41 that anchor the
structure into the viral envelope. HIV-1 has three structural genes (gag, pol and Env) and six
regulatory genes (tat (transcriptional activator), rev (regulator of viral gene expression), nef
(negative effector), vif (viral infectivity factor), vpr (viral protein R), and vpu (viral protein U))
that contain information needed to produce proteins that control the ability for HIV-1 to infect a
cell, produce new copies of virus, or cause disease (Figure 1.4). The ends of each strand of HIV1 RNA contain an RNA sequence called the long terminal repeat (LTR). Regions in the LTR act
as switches to control production of new viruses and can be triggered by proteins from either
HIV-1 or the host cell.61
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Figure 1.4. HIV-1 Genome: An overview of the organization of the ~9-kilobase genome of the HIV provirus and
summary of its nine genes encoding 15 proteins. (Reprinted with permission from NPG: License 2863790720427)

1.2. HIV-1 VIRAL LIFE CYCLE
HIV-1 is a retrovirus (“slow virus”), which means it has genes composed of RNA
molecules. Like all viruses, HIV-1 replicates inside host cells. It is considered a retrovirus
because it uses an enzyme, reverse transcriptase (RT), to convert RNA into DNA, which can
then be incorporated into the host cell’s genome. 62 The replication cycle of HIV-1 is a complex
multistep process that depends on both viral and host cell factors (Figure 1.5). The HIV-1
replication cycle has two distinct phases. During an early pre-integration stage, the virus infects
the cell, RT takes place and the proviral genome is transported into the nucleus and integrated
into the host cell genome. In the subsequent post-integration stage, the integrated provirus
expresses genes, and virus assembly and maturation takes place.63
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Figure 1.5 Schematic Representation of the HIV-1 Replication Cycle64
(Reprinted with permission from Elsevier license: 2857380636210)

1.2.1. Viral Entry Binding and Fusion
The life cycle of HIV-1 begins with adsorption of virions to the host cell (Figure 6), the
viral envelope (Env) gp120 interacts nonspecifically with heparan sulfate, a sulfated
polysaccharide widely expressed on animal cells and involved in virus cell binding of array of
enveloped viruses.65-67 This first interaction enables the virus to initially make contact with the
host cell.68 While attachment of HIV-1 to the cell surface can result for interactions with many
surface molecules,69, 70 specific binding of the gp120 subunit to CD4 is the first required step for
viral infection.71 CD4 is an integral membrane glycoprotein, belonging to the immunoglobulin
gene superfamily, which is expressed mainly on the surface of T cells and cells of the
macrophage/monocyte lineage.72 CD4 binding alone is not sufficient for virus infection as it does
not trigger the conformational changes needed for membrane fusion. For this to occur, the viral
Env gp120 must interact with its coreceptor, CXCR4 (chemokine receptor 4) for T-cell line
15

tropic (T-tropic) or X4 HIV-1 strains or CCR5 (C-C chemokine receptor 5) for macrophagetropic
(M-tropic) of R5 HIV-1 strains.71 R5 virus strains typically infect macrophages and primary T
cells, and are the virus type most commonly transmitted between individuals. The X4 virus
strains tend to evolve years after infection in a subset of individuals as a consequence to mutation
in Env, and infect primary T cells and transformed T cell lines.73, 74 While the viral glycoprotein
gp120 is responsible for viral interaction with the CD4 receptor and CCR5 or CXCR4
coreceptor, the viral glycoprotein gp41 (which has remained noncovalently attached to gp120
after their precursor glycoprotein gp160 has been cleaved by cellular proteases to yield the
gp120/gp41 heterodimer ) is responsible for the fusion of viral envelope with the cell
membrane.72 The interaction of gp120 with CCR5 or CXCR4 coreceptor triggers a series of
conformational changes in the gp120-gp41 complex that ultimately led to the formation of a
‘trimer-of-hairpins’ structure in gp41. The ‘trimer-of-hairpins’ is a bundle of six α-helices: three
α–helices formed by the amino-terminal regions. The fusion-peptide region, located at the
extreme amino terminus, will insert into the cellular membrane, while the carboxy-terminal
region remains anchored in the viral envelope, thus, bringing the two membranes together.75
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Figure 1.6 Schematic description of early events occurring after HIV infection of a susceptible target cell including interactions
between gp120, CD4 and chemokine receptors (CCR5 or CXCR4) leading to gp41 mediated fusion followed by virion uncoating,
reverse transcription of the RNA genome, nuclear import of the viral preintegration complex (PIC), and integration of the doublestranded viral complementary DNA strain (cDNA) into the host chromosome thus establishing the provirus.76
(Reprinted with permission from NPG: License 2863790346117)

1.2.2. Reverse Transcription
Once fusion delivers the viral core into the cytoplasm of the host cell, viral uncoating
takes place. The viral core is composed of a capsid (CA) protein shell that encapsulates the
single-stranded, dimeric viral RNA genome in complex with the viral nucleocapsid (NC) protein
and the viral enzymes RT and integrase (IN) (Figure 1.6).77, 78Although the viral uncoating
process if poorly understood, it likely involves the phosphorylation of matrix (MA) mediated by
a mitogen activation protein (MAP) kinase79 and additional actions of cyclophilin A,80 and the
viral negative factor (nef)81 and viral infectivity factor (vif) proteins.82 Successful uncoating
generates the viral reverse transcription complex, which contains the diploid viral RNA genome,
tRNALys (transfer RNA) primer, RT, IN, MA, NC, viral protein R (vpr) and various host
proteins; the reverse-transcription complex is thus liberated from the plasma membrane.83 Next,
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the complex docks with actin microfilaments and this interaction, which is mediated by the
phosphorylated MA, is required for efficient viral DNA synthesis.84 HIV-1 now uses the enzyme
RT to make a DNA copy of the RNA genome. Normal transcription in nature occurs when the
DNA genome is transcribed into messenger RNA (mRNA) which is translated into protein. In
HIV-1 RT, RNA is reverse-transcribed into DNA.68 To convert viral RNA to pregenomic
proviral DNA, three successive enzymatic reactions, all ensured by the p66 subunit of the
p66/p51 RT heterodimer, are required. RT has three enzymatic activities: (i) it has RNAdependent DNA polymerase activity that transcribes the viral (+) RNA strand to a (-) viral
complementary DNA strain (cDNA); (ii) it has ribonuclease activity that degrades the (+) RNA
strand during the synthesis of cDNA; and (iii) it has DNA-dependent DNA polymerase activity
that copies the (-) cDNA strand into a (+) DNA strand to form a double-stranded DNA
intermediate that enters the infected host cell's nucleus.68, 72

1.2.3. Integration
Approximately 40-100 IN molecules are packaged within an HIV-1 particle.85 The
principal role of IN is to catalyze the insertion of the proviral DNA (cDNA) into the genome of
infected host cells. Integration is essential for viral replication because efficient transcription of
the viral genome and production of viral proteins require that the proviral DNA is fully
integrated into the cellular genome (Figure 1.7).72 Following RT, the proviral DNA is primed for
integration by integrase-mediated 3’-processing, which correlates to an endonucleolytic cleavage
of the 3’ ends of the proviral DNA, thus generating CA-3’-hydroxyl ends. Following 3’processing, IN remains bound to the proviral DNA as a multimeric complex that bridges both
ends of viral DNA within intracellular particles termed preintegration complexes (PICs).72
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Isolated PICs contain both viral and cellular proteins in addition to the IN-DNA complexes. The
viral proteins RT, MA, NC and vpr can contribute to the transport of PICs through the nuclear
envelope.86 The cellular proteins packaged with the PICs, interactor 1 (Ini1),87 lens epitheliumderived growth factor (LEDGF or p75),88 embryonic ectoderm-development protein,89 and heatshock protein 60 (HSP60),90 can bind to IN and stimulate its enzymatic activities.91 Once in the
nucleus, IN catalyzes the insertion of the proviral DNA into the host cell chromosome. This
‘stand transfer’ reaction consists of the ligation of the viral 3’-OH DNA ends (generated from 3’processing) to the 5’-DNA phosphate of the host chromosome. Completion of integration can
only take place after trimming of the last two nucleotides at the proviral DNA 5’-ends and
extension (gap filling) from the 3’-OH end of the genomic DNA.86
The HIV-1 provirus can integrate into many different chromosomal locations in the cell
and most infected cells harbor more than one provirus.76 Integration can lead to either latent or
transcriptionally active forms of infection, 92 which is determined by genetic factors of the viral
strain, the type of cell infected, and the production of specific host cell proteins.68 The majority
of the proviral DNA is integrated into the chromosomes of activated CD4+ T cells. These
generally comprise between 93% and 95% of infected cells and are productively infected, not
latently infected. However, a small percentage of HIV-infected memory CD4+ T cells persist in
a resting state because of a latent provirus. These, along with infected monocytes, macrophages,
and dendritic cells, provide stable reservoirs of HIV-1 capable of escaping host defenses and
Antiretroviral (ARV) chemotherapy.68
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Figure 1.7 The Two IN Catalytic Reactions (3’-Processing and Strand Transfer). The figure shows the viral DNA recombination
attachment (att) sites. 3’-processing takes place in the cytoplasm following reverse transcription (Figure 1.) It is a water-mediated
endonucleolytic cleavage (green arrow in a and BOX 1, figure part a) of the viral DNA immediately 3’ from the conserved CA
dinucleotide (BOX 1, figure part a.). 3’-processing generates reactive 3’-hydroxyls at both ends of the viral DNA (red circles (b);
other 3’-hydroxyl ends and 5’-phosphate ends are shown as red and green dots, respectively.) IN multimers (not shown) remain
bound to the ends of viral DNA as the PICs translocate to the nucleus. The second reaction (c to d) catalyzed by IN is strand
transfer (3’-end joining), which inserts both viral DNA ends into a host-cell chromosome (acceptor DNA in blue). Strand transfer
is coordinated in such a way that each of the two 3’-hydroxyl viral DNA ends (red circles) attacks a DNA phosphodiester bond
on each strand of the host DNA acceptor with a five-base-pair stagger across the DNA major groove (d). Strand transfer leaves a
five-base, single-stranded gap at each junction between the integrated viral DNA, and a two-base flap at the 5’-ends of the viral
DNA (d and e). Gap filling and release of the unpaired 5’-ends of the viral DNA (arrows in e) are carried out in coordination with
cellular repair enzymes.86 (Reprinted with permission from NPG: License 2862620377001)

1.2.4. Transcription
The vast majority of CD4+ T cells, which are productively infected, immediately begin to
produce new viruses. In the case of resting memory CD4+ T cells, before replication can occur,
the HIV-1 provirus must become activated. This activation is accomplished by such means as
antigenic stimulation of the infected CD4+ T cells or their activation by factors such as
cytokines, endotoxins and superantigens.68
Once integrated, the HIV-1 proviral genome is subject to transcriptional regulation by
the host cell, as well as its own transcriptional control mechanism.63, 93 In the host genome, the 5’
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long-terminal repeat (LTR) functions like other
eukaryotic transcriptional units. It contains
downstream and upstream promoter elements,
which include the initiator (Inr), TATA-box (T)
and three Specificity Protein 1 (Sp1) sites.94 These
regions help position the RNA polymerase II
(RNAPII) at the site of initiation of transcription
and assemble the preinitiation complex. In the
HIV-1 promoter, RNAPII activity is quickly
stalled after initiation of transcription (Figure 1.8,
Panel A). There are two cellular complexes, DRB
sensitivity-inducing factor (DSIF) and negative
elongation factor (NELF), that function together to
block the elongation from occurring (Figure 1.8,
Panel B).95, 96 Although binding of DSIF and

Figure 1.8 Stimulation of Transcriptional
Elongation by HIV-1 Tat (Reprinted with
permission from NPG: License)

NELF to RNAPII shortly after initiating RNA

synthesis leads to inhibition of elongation, this step is regulated by the phosphorylation of
carboxy-terminal domain (CTD) of the largest subunit of RNAPII. Importantly, in the nuclear
extract, DSIF and NELF tightly bind to hypophosphorylated RNAPII, but not to the
hyperphosphorylated form, suggesting that phosphorylation of CTD caused dissociation of these
negative factors from RNAPII.97 The repression caused by DSIF and NELF is counteracted in
HIV-1 transcription by trans-activator of transcription (tat), an 81-101-amino acid peptide
(Figure 1.8, Panel C). In the absence of tat, HIV-1 transcription is highly inefficient because the
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assembled RNAPII complex cannot elongate efficiently on the viral template. 98 First, tat forms a
complex with the positive transcription elongation factor b (P-TEFb), which is composed of
cyclin T1 and cyclin-dependent protein kinase 9 (CDK9).The complex of Tat with P-TEFb,
which is composed of cyclin T1 and CDK9, then binds to the TAR (Tat response) element,
thereby positioning CDK9 to phosphorylate the cellular RNA polymerase and this ensuring
transcription elongation.97 The tat protein is acetylated on lysine resides within its TAR-RNAbinding arginine rich motif by transcriptional coactivators/acetyltransferases, p300/CBP (CREBbinding protein), and PCAF (p300/CREB-binding protein-associated factor) which help to
activate the HIV-1 promoter (Figure 1.8, Panel D).99 Other phosphorylation and acetylation
events accompany and may at least partially account for the activation of the HIV-1 transcription
process.72
The integrated proviral DNA is transcribed to generate full-length progeny viral RNA
and a number of spliced mRNA transcripts that are translated into the cytoplasm.100
Transcription and translation, performed by cellular machinery, results in the synthesis of several
major structural proteins: (i) the Gag polyprotein precursor, which is composed of four domainsMA, CA, NC and p6-and two spacer peptides, SP1 and SP2, (ii) the Gag-Pol polyprotein
precursor, which is produced via a 1-ribosomal frameshift during gag translation and encodes the
viral enzymes PR, RT and IN, and (iii) the Env glycoprotein precursor, gp160, which is cleaved
into the gp120 and gp41 subunits by a host protease during trafficking through Golgi
apparatus.100 These protein components, together with full-length viral genomic RNA, are each
transported to the site of virus particle assembly at the plasma membrane.77
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1.2.5. Assembly, Budding and Maturing
After the transcription of the viral genome, more than a dozen HIV-specific transcripts
are generated. Assembly is directed by Gag, which coordinates the incorporation of each of the
viral components, together with a number of host cell factors, into the assembling particle.77
All of the components of the virion are ultimately assembled at the plasma membrane of the host
cell where budding occurs. Prior to budding the Env polyprotein (gp160) goes through the
endoplasmic reticulum and is transported to the Golgi complex where it is cleaved by a protease
and processed into the two HIV envelope glycoproteins gp41 and gp120. These envelope
glycoproteins are transported to the plasma membrane of the host cell where gp41 anchors the
gp120 to the membrane of the infected cell.68 The Gag (p55) and Gag-Pol (p160) also interact
with the inner surface of the plasma membrane along with HIV genomic RNA as the forming
virion begins to bud from the host cell. Following budding from the plasma membrane, the viral
protease cleaves the Gag and Gag-Pol precursors into their respective protein domains. Gag and
Gog-Pol cleavage leads to virion maturation, a reassembly event that produces mature particles
containing the condensed, conical core.77, 78 In addition to the structural proteins listed above,
HIV-1 encodes two regulatory gene products (tat and rev (regulation of viral gene expression))
and several accessory proteins: viral infectivity factor (vif), viral protein U (vpu), negative factor
(nef), and viral protein R (vpr).100 The various structural components then assemble to produce a
mature HIV-1 virion which is now able to infect another cell.

1.3. CURRENT THERAPY
To date, there are 25 ARV drugs approved for the treatment of HIV-1 infection and
AIDS. These drugs can be divided into six different mechanistic classes that target distinct steps
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in the HIV-1 replication cycle (Figure 1.9): eight nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs),101 nine protease inhibitors (PIs),102 five non-nucleoside reverse transcriptase
inhibitors (NNRTIs),103 one integrase inhibitor,104 and two entry inhibitors.105 There are two
drugs that have been developed as entry inhibitors.
Enfuvirtide (T-20) is a fusion inhibitor that blocks
viral fusion by targeting glycoprotein 41 (gp41) and
maraviroc is an inhibitor of chemokine receptor
CCR5, making it the only approved ARV drug that
targets a host cell factor.105 The remaining four
mechanistic classes target each of the viral enzymes:
RT, PR and IN.

1.3.1. Nucleotide/Nucleoside Reverse Transcriptase
Inhibitors (NRTIs)
In 1986, there were 5,833 AIDS cases in the
U.S. and the 1-year mortality was 51%-which
translated to the public as ‘certain death’.34 In 1987,
four years after the identification of HIV,19 3’azidothymidine (AZT, zidovudine), a nucleoside
HIV-1 reverse transcriptase inhibitor (NRTI), was the
first ARV drug approved by the U.S. Food and Drug
Administration (FDA) for the treatment of AIDS.
Over the course of over 25 years that followed after this
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Figure 1.9 The HIV-1 Replication
Cycle and Drug Targets
(Reprinted with permission from NPG)

seminal discovery, seven nucleosides and one nucleotide have been approved by the FDA for the
treatment of HIV infection (Figure 1.10).

Figure 1.10 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

A total of thirteen NRTI drug products are available for clinical application: eight
individual NRTIs, four fixed-dose combinations of two or three NRTIs, and one complete fixeddose regimen containing two NRTIs and one non-nucleoside RT inhibitor (Table 1.7).101 NRTIs
target the HIV-1 RT, which offers two target sites for inhibitors: the catalytic substrate
(deoxynucleoside triphosphate) binding site, and an allosteric site, which is distinct from (yet
closely located to) the substrate binding site.106, 107 NRTIs are analogues of endogenous 2’deoxynucleosides and nucleotides (Figure 1.11). They are inactive in their parent forms and are
first metabolized inside cells and then converted to their active 5’-triphosphate forms, which
compete with the natural deoxynucleoside triphosphate (dNTP) substrates for HIV-1 RT and
inhibit DNA polymerization.108-110 In addition, after the drugs are incorporated into a growing
viral DNA, they serve as chain-terminators of viral reverse transcripts owing to lack of a 3’-
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hydroxy group (present in natural dNTPs) necessary for further DNA synthesis.110 The NRTIs
act early in the viral replication cycle by inhibiting a critical step of proviral DNA synthesis prior
to integration into the host cell genome.

Figure 1.11 Structure of Natural Deoxynucleoside Triphosphates (dNTP)

NRTIs are the backbone of current combination ART. The standard of care for HIV-1 patients is
highly active antiretroviral therapy (HAART), which consists of three or more HIV-1 drugs. The
common use of combinations of NRTIs has led to the clinical development of the fixed-dose
combination pills (Table 1.7).101 The success of NRTIs in HIV-1 therapy is due, at least in part,
to the unique pharmacology and intracellular persistence. The intracellular retention of the active
triphosphorylated NRTI metabolites allows for constant viral inhibition. Based on the Adult and
Adolescent Antiretroviral Treatment Guidelines updated by the Department of Health and
Human Services (DHHS) in October 2011, the two preferred NRTIs for the first-line regimens
are TDF and FTC.111
While the unique pharmacology of NRTIs has helped them become a cornerstone of
successful HAART treatment, the effectiveness of NRTIs can be limited by drug-drug
interactions, emergence of drug resistance, and adverse side-effects of ART.101 NRTIs are
metabolized by complex and often overlapping pathways shared with the endogenous dNTPs
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they compete with for activity, resulting in the potential for intra-class pharmacokinetic and
pharmacodynamics drug interactions.112 The error-prone reverse transcription due to lack of a
proofreading function of RT113 multiplied by the sheer number of replication cycles occurring in
an infected individual facilitate the selection of drug resistant mutant strains of HIV-1.114 A
major toxicity that has been recognized for more than a decade is NRTI-related mitochondrial
toxicity, which manifests as serious side effects such as hepatic failure and lactic acidosis.115
Trade Name
Retrovir
Videx
Hivid (Discontinued in 2006)
Zerit
Epivir
Combivir
Ziagen
Videx EC
Trizivir
Viread (Supplied as a Prodrug, Nucleotide NRTI)
Emtriva
Truvada
Epzicom (or Kivexa)

Generic Name
NRTI Base
AZT, ZDV, azidothymidine, zidovudine
Pyrimidine
ddI, didanosine, dideoxyinosine
Purine
ddC, zalcitabine, dideoxycytidine
Pyrimidine
d4T, stavudine
Pyrimidine
3TC, lamivudine
Pyrimidine
zidovudine + lamivudine
ABC, abacavir sulfate
Purine
ddI EC, enteric coated didanosine
Purine
abacavir + zidovudine + lamivudine
TDF, tenofovir disoproxil fumarate
Purine
FTC, emtricitabine
Pyrimidine
tenofovir disoproxil fumarate + emtricitabine
abacavair + lamivudine

Manufacturer
GlaxoSmithKline
Bristol Myers-Squibb
Hoffman-La Roche
Bristol Myers-Squibb
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
Bristol Myers-Squibb
GlaxoSmithKline
Gilead Sciences
Gilead Sciences
Gilead Sciences
GlaxoSmithKline

Approval Date
19-Mar-87
9-Oct-91
19-Jun-92
24-Jun-94
17-Nov-95
27-Sep-97
17-Dec-98
31-Oct-00
14-Nov-00
26-Oct-01
2-Jul-03
2-Aug-04
2-Aug-04

Table 1.7 Clinically Approved Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)101

1.3.2. Protease Inhibitors (PIs)
The discovery of HIV-1 protease inhibitors (PIs) in 1995 was a pivotal moment in the
development of ARV therapy because the PIs made possible the dual class therapy a reality.
Currently, there are nine PIs approved by the FDA for clinical use and most of them are
prescribed with a concomitant low dose of ritonavir as a boosting agent (Table 1.8).
HIV-1 PR, an aspartyl protease, plays a crucial role in the viral life cycle and is essential for the
generation of mature infectious virus particles. PR generates mature infectious virus particles
through the cleavage of the viral Gag and Gag-Pol precursor proteins.116 The Gag precursor
protein codes for all the structural viral proteins, MA, CA and NC, the p6 protein and the two
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spacer proteins p2 (SP1) and p1 (SP2).117 PIs have been designed to bind the viral PR with high
affinity but tend to occupy more space than the natural substrates. HIV-1 PIs prevent cleavage of
gag and gag-Pol precursors in acutely and chronically infected cells, arresting maturation and
thereby blocking the infectivity of nascent virions.118, 119
Trade Name
Invirase
Norvir
Crixivan
Viracept
Fortovase
Agenerase (Discontinued in 2007)
Kaletra
Reyataz
Lexiva (Prodrug of amprenavir)
Aptivus
Prezista

Generic Name
SQV, saquinavir mesylate
RTV, ritonavir
IDV, indinavir
NFV, nelfinavir mesylate
SQV, saquinavir
APV, amprenavir
LPV/RTV, lopinavir + ritonavir
ATV, atazanavir sulfate
FOS-APV, Fosamprenavir Calcium
TPV, tipranavir
darunavir

Manufacturer

Hoffman-La Roche
Abbott Laboratories
Merck
Agouron Pharmaceuticals
Hoffman-La Roche
GlaxoSmithKline
Abbott Laboratories
Bristol-Myers Squibb
GlaxoSmithKline
Boehringer Ingelheim
Tibotec

Approval Date
6-Dec-95
1-Mar-96
13-Mar-96
14-Mar-97
7-Nov-97
15-Apr-99
15-Sep-00
20-Jun-03
20-Oct-03
22-Jun-05
23-Jun-06

Table 1.8 Clinically Approved Protease Inhibitors (PIs)102

All of the FDA approved PIs, with the exception of tipranavir, are competitive
peptidomimetic inhibitors, mimicking the natural substrate of viral PR (Figure 1.13).102 The
peptidomimetic inhibitors contain a hydroxyethylene core, which prohibits cleavage of the PI by
the HIV-1 protease.120-127 Instead of a peptidomimetic hydroxyethylene core, tipranavir contains
a dihydropyrone ring as a central scaffold.128
Many of the first-generation PIs (saquinavir, indinavir, ritonavir and nelfinavir) suffered
from low bioavailability and high protein binding, high pill burden (3-4 times per day dosing),
the development of resistance and wide spectrum of side effects and toxicities.102 Since one of
the major initial problems with the PIs was poor bioavailability the second-generation drugs
were developed in attempt to address this issue by reducing the molecular weight of the inhibitor
and increasing the solubility.129 In 1999, these attempts led to a smaller more bioavailable
inhibitor, amprenavir. However, even though amprenavir was more bioavailable compared to the
previous PIs it was not very soluble or potent and formulation led to a high pill burden. In 2003,
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GSK introduced a phosphate prodrug fosamprenavir with improved solubility and a reduced pill
burden.130
Another concerning issue that were revealed with PIs had was the development of a
resistance profile. Lopinavir was developed with an alternative scaffold to try and overcome this
problem. The isopropylthiazolyl group of ritonavir was removed and then a conformational
constraint in the resulting urea by incorporation of a six-member ring was used in the scaffold.
Although lopinavir was more potent than ritonavir and less affected by the mutation commonly
found in ritonavir-resistant viruses, it suffered from poor bioavailability in humans.126 A
landmark breakthrough in the field of PIs was discovered with lopinavir. Since it is mainly
metabolized by CYP3A4 it was discovered that dosing with ritonavir (CYP3A4 inhibitor)
increased the bioavailability. This led to the development of a fixed-dose combination of the two,
marketed as Kalertra. Lopinavir was the first boosted PI that compared head-to-head with an
NNRTI as initial therapy.102 Currently, Kaletra and atazanavir have the major share in the PI
market. Atazanavir has good bioavailability and antiviral activity and
a unique resistance profile, which sensitizes the virus to all other
PIs.129
After the screening of a compound library, warfarin (Figure 1.12) was discovered as a
lead molecule and researchers realized that this pyrone derivative

Figure 1.12 Warfarin

was a good start for nonpeptidic and low molecular weight analogs.129 After extensive structureactivity relationship studies, tipranavir was discovered and approved in 2005. Tipranavir is
effective against resistant mutants and has a good bioavailability profile but unfortunately suffers
from significant incidences of side effects. Tipranavir is a strong CYP450 inducer, inducing its
own metabolism and requiring double the usual boosting dose of ritonavir (200 mg), resulting in
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multiple drug-drug interactions.131 These problems are so great the use of tipranavir is largely
restricted to deep salvage regimens.129
With the sole exception of tipranavir, the evolution of commercial PIs can be described in
as incremental structural changes in the initially described leads that led to greater potency,
increased activity against mutants, and in some cases improved bioavailability. The common
practice of using ritonavir to boost blood levels and trough levels exemplifies the struggle to
identify PIs with good bioavailability.129

Figure 1.13 Protease Inhibitors (PIs)(hydroxyethylene core/ dihydropyrone ring highlighted in blue)
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1.3.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Shortly after the approval of the first PI, non-nucleoside reverse transcriptase inhibitors
(NNRTIs) quickly followed (Figure 1.14). NNRTIs inhibit RT by binding in a reversible and
non-competitive manner to the enzyme in
a hydrophobic pocket located close to the
catalytic site. The interaction of the
compounds with RT induces
conformational changes that impact the
catalytic activities of the enzyme.132
Unlike the NRTIs, NNRTIs are active as
such, and do not need metabolized intracellularly

Figure 1.14 Non-Nucleotide Reverse
Transcriptase Inhibitors (NNRTIs)

to become active.103 NNRTIs are highly specific for HIV-1 and are not active against other
retroviruses.
The first generation of NNRTIs were approved in 1996 (nevirapine, NVP), 1997
(delavirdine, DLV), 1998 (efavirenz, EFV). Two NNRTIs, NVP and EFV are currently
cornerstones of first line HAART, whereas DLV is rarely used today.103 NVP is the drug of
choice in developing countries and due to its reduced teratogenesis and pediatric toxicity it is
also widely used in pregnant women and young children.133 NNRTIs are generally characterized
by a low genetic barrier to the development of resistance: they need to be combined with at least
two other fully active non-NNRTI ARV drugs, and resistance to one of them precludes
subsequent use of other first generation NNRTIs. They are generally well-tolerated and safe;
however, hepatotoxicity and severe hash are associated with NVP134 and central nervous system
(CNS) side effects are associated with EFV that are sometimes difficult to overcome.135 An
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important consideration with the first generation NNRTIs is that they are metabolized by
CYP450 and although the isoenzymes involved vary for each compound, there is a potential for
drug-drug interactions with drugs that are also metabolized via the CYP450 pathway.
The success of the first-generation class of compounds prompted research for the discovery and
development of the next generation of NNRTIs that would have a better resistance profile, in
order to offer treatment experienced patients the option to benefit from the convenience and good
safety profile of the NNRTI class of compounds. Etravirine was the first of the second generation
class of compounds to be approved by the FDA. Etravirine and rilpivirine belong to the family of
di-aryl-pyrimidine (DAPY) compounds and are reported to be clinically effective in HIV-1
strains that are resistant to other NNRTIs. They have a higher genetic barrier to resistance than
the first generation NNRTI compounds.133
Trade Name
Viramune (Immediate Release)
Rescriptor
Sustiva
Intelence
Viramune XR (Extended Release)
Edurant

Generic Name
NVP, nevirapine
DLV, delavirdine
EFV, efavirenz
etravirine
NVP, nevirapine
rilpivirine

Manufacturer

Boehringer Ingelheim
Pfizer
Bristol-Myers Squibb
Tibotec Therapeutics
Boehringer Ingelheim
Tibotec Therapeutics

Approval Date
21-Jun-96
4-Apr-97
17-Sep-98
18-Jan-08
25-Mar-11
20-May-11

Table 1.9 Clinically Approved Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs)

1.3.4. Highly Active Antiretroviral Therapy (HAART)
The combination of several classes of multiple classes of compounds, referred to as
Highly Active Antiretroviral Therapy (HAART) or, more recently, as combined Antiretroviral
Therapy (cART), reduces the viral load by sufficiently slowing the rate of viral replication, thus
by restoring the immune system by increasing circulating levels of CD4+ T cells.133 As a result,
HAART has changed the prognosis for patients with HIV-1 infection from that of high
morbidity and rapid mortality to, for many at least, a chronic, manageable, but still complicated
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disease.136 The key components of HAART are the RT inhibitors (NRTI or NNRTI) and PI,
which target different stages of the viral replication cycle. The combination therapy optimizes
the ARV effect of each drug and avoids genetic resistance.133 There are several HAART
strategies, which vary with the status of infection and/or patient characteristics, and are
frequently updated. According to the current guidelines, initial regimens should be composed of
two NRTIs with either a NNRTI or boosted PI.137
Over the past decade HAART has gradually evolved from drug regimens with more than 20 pills
daily (i.e., stavudine plus lamivudine plus indinavir) in 1996 to 3 pills daily (i.e., zidovudine
(Combivir®) twice daily and efavirenz once daily) in 2003 to 2 pills daily (i.e.,
emtricitabine/tenofovir disoproxil fumarate (Truvada®) and efavirenz) in 2004 and finally to one
pill daily in 2006 (Atripla) and in 2011 (Complera®) (Table 1.10).138
Trade Name
Atripla
Complera

Generic Name
Manufacturer
efavirenz + emtricitabine + tenofovir disoproxil fumarate Bristol-Myers Squibb & Gilead Sciences
emtricitabine + rilpivirine + tenofovir disoproxil fumarate Gilead Sciences

Approval Date
12-Jul-06
10-Aug-11

Table 1.10 Multi-Class HIV-1 Combination Drugs

1.3.5. Fusion inhibitors
Viral entry is a particularly attractive target for drug intervention since it involves the
exposure of highly conserved domains in Env and depends on the cell surface receptors that can
be targets for orally available small molecule inhibitors.71 Enfuvirtide (Fuzeon®, DP-178,
pentafuside, or T-20) is the first ARV fusion inhibitor approved for the treatment of HIV-1
infected patients. This new family of ARVs was eagerly awaited by the growing number of
patients carrying drug-resistant viruses to RT and PR inhibitors.139 Since the early 1990s it has
been known that peptides synthesized on the basis of the amino acid sequence of heptad repeat 1
(HR1) and heptad repeat 2 (HR2) of gp41 may show antiviral properties against HIV-1.140-142 In
1993, the in vivo potency of a peptide, D-178, which was synthesized on the basis of the amino
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acid sequence of HR2, was demonstrated.139 This molecule, enfuvirtide, is a synthetic peptide of
36 amino acids, which mimics the HR2 region of gp41 (Figure 1.15).143, 144 It is homologous to
the heptad repeat HR2 region of gp41 glycoprotein and, while T-20 will itself engage in a coiledcoil interaction with the heptad HR2 region of gp41, it prevents the six-helical bundle formation
required to initiate the fusion process.72 Enfuvirtide, the only HIV-1 drug injected
subcutaneously, is generally used in combination with HAART regimens for the treatment of
patients suffering failure to prior therapies. Although enfuvirtide is active in patients whose virus
is resistant to other classes of ARVs, as in the case of all other ARVs, continued exposure,
especially if the virus is not completely suppressed, can lead to emergence of viral resistance to
enfuvirtide. It is by far the most complex ARV ever manufactured at such a large scale, which
provides both production and economic challenges.145
Trade Name
Fuzeon

Generic Name

Manufacturer

T-20, enfuvirtide

Hoffmann-La Roche & Trimeris

Approval Date
13-Mar-03

Table 1.11 Clinically Approved HIV-1 Fusion Inhibitor

Figure 1.15 Linear schematic of the HIV gp41. Four regions of functional importance are depicted: fusion peptide (FP), heptad repeat 1 (HR1),
the cysteineresidues (cc) that form disulphide bridges, heptad repeat 2 (HR2) and the transmembrane region (tm). The amino acid sequences of
the HR1 and HR2 regionsare shown in detail. Amino acids involved in the interaction between HR1 and HR2 are shown in bold, including those
thought to be involved in resistance to enfuvirtide. The 36 amino acid region in HR2 corresponding to enfuvirtide indicated by a bold arrow.146
(Reprinted with permission from Oxford Journals: License)
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1.3.6. Chemokine Receptor Antagonists
The coincidental use of CXCR4 and CCR5 by HIV-1 as coreceptors to enter cells has
prompted the search for CXCR4 and CCR5 antagonists (Figure 1.16), through blockade of the
corresponding receptor, might be able to inhibit HIV entry into the cells.72
The most characterized of the CXCR4 antagonists is AMD3100 (JM3100, mozobil™). It was
originally discovered as an anti-HIV agent with
strong inhibitory effect on the replication of X4 HIV1 strains147 and was later found to inhibit X4 HIV-1
replication as a selective antagonist of CXCR4148 then
found to specifically mobilize hematopoietic stem
Figure 1.16 CXCR4 and CCR5 Antagonists

CD34+ cells from bone marrow into the
bloodstream.

Although several CCR5 antagonists have been evaluated in clinical trials only maraviroc
has been approved for clinical use in the treatment of HIV-1 infected patients (Table 1.12).149
Maraviroc binds to CCR5, thereby blocking the HIV-1 protein gp120 from associating with the
receptor and HIV-1 is unable to enter the host cell.150 Since HIV-1 can also use other
coreceptors, such as CXCR4, and HIV-1 tropism test such as a trofile assay must be performed
to determine if the drug will be effective.151 Maraviroc has an extremely safe and tolerability
profile, however, the long-term safety of blocking CCR5 is not fully understood.152 Despite
being approved in 2007, the optimal use of maraviroc has yet to be defined in HIV-1 therapy.
Unfortunately, one limitation to the clinical use of maraviroc is that it is only effective against
CCR5-using R5 HIV-1 strains. From dual (CCR5 and CXCR4)-tropic or mixed HIV-1
populations that use both CCR5 and CXCR4 (which are commonly used among highly treatment
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experienced patients), maraviroc may select for the outgrowth of pure CXCR4-tropic X4
strains.153 In addition, R5 HIV-1 strains may develop resistance to maraviroc while still utilizing
the inhibitor-bound receptor for entry.154 Evidently, to cope with dual-tropic or mixed X4/R5
HIV-1 populations, a combination of CXCR4inhibitors with CCR5 inhibitors will be needed.72
Trade Name
Generic Name
Manufacturer
Approval Date
Mechanism of Action
Selzentry
maraviroc
Pfizer
6-Aug-07
Non-competitive Inhibitor
Table 1.12 Clinically Approved CCR5 Antagonist

1.3.7. Integrase Inhibitors
Among the furthest advanced IN inhibitors in clinical development are raltegravir
(Isentress®, MK-0518) and elvitegravir (GS-9137) (Figure 1.17). Raltegravir was approved by
the FDA in 2007 and elvitegravir’s approval is
currently pending (Table 1.13).72 Both
compounds inhibit the strand transfer reaction
in the integration process and were validated as
genuine HIV-1 IN inhibitors is cell culture
Figure 1.17 HIV-1 Integrase Inhibitors

assays.155 When added onto an optimized

background regimen, raltegravir, offered better viral suppression than placebo over a 24-week
treatment period.156 Undoubtedly, the IN inhibitors may be welcomed (following NRTIs,
NNRTIS, PIs, and virus entry inhibitors) as the next new class of anti-HIV drugs. However, just
like all other classes of HIV-1 inhibitors, IN inhibitors should be carefully monitored for the
emergence of drug-resistant virus strains.72
Trade Name
Generic Name
Isentress
raltegravir

Manufacturer
Merck

Approval Date
12-Oct-07

Table 1.13 Clinically Approved HIV-1 Integrase Inhibitor
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1.3.8. Vaccines
There is currently little prospect of an effective vaccine for HIV-1 on the horizon. An
HIV-1 and AIDS vaccine does not yet exist, but efforts to develop a vaccine against HIV-1, have
been underway for many years. Since 1987, more than 30 vaccine candidates have been tested.157
The development of an HIV-1 vaccine faces formidable scientific challenges related to high
genetic variability in the virus, the lack of immune correlates of protection, lack of animal
models and logistical problems associated with the conduct of multiple clinical trials.158

1.4. ANTIRETROVIRAL DRUGS AND LABORATORY MONITORING
Antiretroviral drugs development was substantially accelerated by the development of
accurate, reproducible, and inexpensive laboratory tests. These laboratory tests are used today to
help individuals decide when to start ARV and continue to monitor the success of their anti-HIV
therapy.

1.4.1. CD4 Testing
The average CD4 T cell count of an uninfected adult is typically more than 500 cells per
µL, Most OIs occur as the CD4 T cell counts fall below 200 cells per µL. Recent guidelines
suggest the threshold of 350 cells per µL as a strong indicator for starting ARV.137 Once
treatment begins CD4 T cells typically increase rapidly for the first 3 months of treatment and
then slowly increase by roughly 50-75 cells per µL per year, with rates declining CD4 T cell
count reaches normal.159 The biological and assay variability of the peripheral CD4 cell count is
high, making it difficult to rely on one measurement.72

37

1.4.2. Quantitative Viral Load Testing
Quantitative viral load, or concentrations of plasma HIV-1 RNA, is measured with PCR
or related methods. Chronic established HIV-1 infection is often associated with a stable set
point, which varies widely among individual patients. The viral set point is associated with the
rate of CD4 T cell decline and the risk of AIDS and death.160, 161 Viral load is measured before
ARV therapy begins, but its primary value is monitoring treatment response or failure. The
immediate goal of therapy is to reduce HIV-1 replication threshold below which the virus does
not evolve and drug resistance does not emerge.8
1.4.3. Drug Resistance Testing
Antiretroviral drug-resistance mutations will almost inevitably emerge if HIV-1 is
allowed to replicate in the presence of ARV drug concentrations insufficient to exert complete
suppression. The common resistance mutations for all drugs have been well characterized and
their detection with reproducible commercial assays is straightforward, as long as the plasma
viral load is at least 500-1000 copies per mL.162

1.4.4. Chemokine Receptor Tropism and HLA-B* Testing
HIV-1 enters the preferred target cells by binding to one of both of the chemokine
receptors CXCR4 and CCR5. Nearly all patients with primary HIV-1 infection harbor a virus
that binds to CCR5 (R5 virus). For unclear reasons, as the disease progresses overtime, many
individuals develop a virus that also binds to CXCR4 (X4 virus).163 Since one therapeutic drug
specifically targets CCR5, testing is needed to define which tropism of the virus (CCR5 or
CXCR4) is present.137 The only validated tropism assay is an expensive phenotypic test that
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takes 2-4 weeks and is only completed in a few specialized laboratories.164 In view of these
limitations, genotypic tropism assays are being developed and might gain widespread use.72

1.5. COMPLICATIONS OF CURRENT ANTIRETROVIRAL THERAPIES
Considering the low fidelity of HIV-1 RT coupled with the high replication of the virus,
it is not surprising that even triple-class HAART therapy eventually fails in the majority of
patients and is typically associated with the emergence of drug resistance. The success of
HAART relies on a concerted multipoint attack that shuts down HIV replication so effectively
that it reduces the likelihood that drug-resistant viral mutants will emerge. But if a patient
doesn’t follow the demanding regimen and concentrations of anti-HIV drugs in the blood taper
off gradually, pressure on the virus is reduced, giving resistant strains a chance to emerge and
crowd out “wild-type” virus.165 Patients therefore need to be treated with sequential HAART
regimens progressively, using up the diminishing pool of active drugs that are left available.145
The combination of toxicity, “pill fatigue” and frequent changes in drug regimens has created the
perfect conditions for the worst of all limitations: drug resistance.
The cost for most combination regimens approaches $12,000 yearly. Despite the expense,
ART is generally seen as cost effective, at least compared with other therapeutic strategies
generally used.166 In many resource-rich regions, treatment is often subsidized by public funding.
There is a concern, however, in these countries, full and continuous access to ART could be
threatened by a weak economy. Long waiting lists for access to publically supported treatment
programs exist in many states within the US, and the lists seem to be getting longer. 72
The impact of the newly developed compounds incorporated in the HAART regimen remains to
be seen. However, the fact that HIV-1 is now a chronic illness implies that therapies are
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administered for life; therefore, their selection should be based not only on their efficacy but also
on their toxicological profile.133
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II. HIV-1 INTEGRASE INHIBITOR DEVELOPMENT

Extensive reviews of HIV-1 integrase (IN) inhibitor design, development and mechanism
of action have been previously published (Table 2.1). For the sake of brevity, a summary of
significant contributions and discoveries that outline and provide a historical perspective as to
the progression of the field of HIV-1 IN inhibition will be discussed.
Title
Design and Discovery of HIV-1 integrase inhibitors
HIV-1 integrase as a target for antiviral drugs
Retroviral integrase inhibitors year 2000: update and perspectives
HIV-1 integrase inhibitors: past, present, and future
Patented small molecule inhibitors of HIV-1 integrase: a ten year saga
Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update
Integrase inhibitors to treat HIV/AIDS
HIV-1 integrase inhibitors: 2003-2004 update
HIV-1 integrase inhibitors: 2005-2006 update
HIV-1 IN inhibitors: 2010 update and perspectives
HIV-1 integrase inhibitors: 2007-2008 update
HIV-1 integrase mechanism and inhibitor design

Reference
Drug Discovery Today 1997, 2, (11), 487-498.
Antiviral chemistry & chemotherapy 1997, 8, 463-483.
Antiviral Research 2000, 47, (3), 139-148.
Advances in Pharmacology 2000,49, 147-165.
Expert Opinion on Therapeutic Patents 2002, 12, (5), 709-724.
Current Pharmaceutical Design 2003, 9, (22), 1789.
Nature Reviews Drug Discovery 2005, 4, (3), 236-248.
Medicinal Research Reviews 2006, 26, (3), 271-309.
Medicinal Research Reviews 2008, 28, (1), 118-154.
Current Topics in Medicinal Chemistry 2009, 9, (11), 1016-1037.
Medicinal Research Reviews 2010, 30, (6), 890-954.
Mechanism and Inhibitor Design. 1 ed.; Wiley: 2011; p 528

Table 2.1 Review Articles Detailing HIV-1 Integrase Inhibitors (1992-2011)

2.1. HIV-1 INTEGRASE: A TARGET FOR DRUG DISCOVERY
HIV-1 integrase (IN) was initially considered to be a difficult and “undruggable” target
for antiretroviral (ARV) drug discovery and design. In comparison to HIV reverse transcriptase
(RT) and protease (PR) inhibitors, where lead compounds were abundant in chemical
repositories of major pharmaceutical companies, there were no authentic leads for IN inhibitors.
The first decade of development in the field of HIV-1 IN inhibitor design was slow. The early
lead IN inhibitors were not selective and in most cases were either inactive in blocking viral
replication or too cytotoxic for further development.
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2.1.1. Challenges of HIV-1 IN as a Target
The long process of HIV-1 IN inhibitor discovery and development can be attributed to
the complexity of the IN and the integration reaction itself. Many copies of IN (50-100 copies)
enter the cell with the infecting virus and only two integration events are required to produce the
functional provirus.167 Unlike RT, where several thousand enzymatic turnovers by RT are needed
to complete the synthesis of viral RNA, providing numerous opportunities for NRTIs and
NNRTIs to block RT, the relatively small number of events needed to complete integration
potentially makes IN difficult to inhibit. Secondly, the absence of the crystal structure of the full
length HIV-1 IN with viral or host DNA and its inhibitors has been an significant obstacle to the
rational design of specific IN inhibitors.168 Other challenges also include a shallow surface
substrate binding site located on the surface of IN169, 170 and its formation of a multimeric
complex in preintegration complexes.171 Finally, there were several initial technological
complications that researchers encountered in respect to designing inhibitors of IN. Many of the
early IN inhibitors were neither confirmed as antiviral nor specific inhibitors. Integrase can use
either Mn2+ or Mg2+ as a metal cofactor to catalyze integration. It has always been a challenge to
obtain good activity in the presence of Mg2+ and, therefore, most of the early inhibitors were
reported using Mn2+ as cofactor.168 It is now commonly acknowledged that Mg2+ is probably the
biological cofactor of IN.86, 172 Many of the early inhibitors screened in Mn2+ assays may have
been responsible for a large number of false positives.
Collectively, the challenges were so significant that many in the field questioned the
rationality of IN as a “druggable” target. Several recent studies predicting druggability still
characterize the binding site of HIV-1 IN as not druggable. 1, 169, 170 In 2007, Cheng et al. used a
model-based approach based on basic biophysical principles to predict the druggability of several
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targets using the crystal structure of the target protein binding site.1 They calculated values of the
maximal affinity achievable by a drug-like molecule and correlated these values with expected
drug-discovery outcomes. The group validated their theoretical data with experimental results
against two targets using high-throughput screening of a diverse compound collection. They
calculated druggability for a set of 27 protein target binding sites and remarkably HIV-1 IN was
determined to be the most challenging and fundamentally “undruggable” target (Figure 2.1).1

2.1.2. HIV-1 IN as a Valid and Attractive Target
With the long-term commitment of researchers dedicating time and resources to HIV-1
IN research, although once considered an invalid target, IN is now considered to be one of the
promising new targets in preclinical and early clinical trials. HIV-1 IN enzyme is an attractive
target for anti-HIV therapy for several reasons. First, IN specifically catalyzes the integration of
proviral DNA into the host cell genome, which is an early and crucial step in the HIV-1
retroviral life cycle, and represents a point of no return.173, 174 Upon inhibition of IN, the viral
DNA is converted into circular DNA unable to be integrated into the host genome.175 Moreover,
a key component of the catalytic core of HIV IN is the highly conserved DDE motif which is
composed of three amino acids: D64, D116 and E152.86 A mutation in any of these conserved
residues reduces the ability of the virus to replicate. Second, inhibitors of IN appear to be
particularly promising since, unlike PR and RT, this enzyme does not have direct human
homologs.176 Therefore drug selectively targeting IN are expected to show low toxicity in the
host. Third, reactions carried out by IN are unique, and sensitive assays exist for testing IN
enzymatic activity in vitro.177 In addition, crystal and nuclear magnetic resonance (NMR)
structures are available for use in rational structure-based drug design.172, 178 Lastly, combination
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therapy with IN inhibitors and drugs directed against PR and RT was shown to be synergistic in
several tested models.179

Figure 2.1 Calculated Druggability. Calculated druggability for a set of 27
target binding sites. Known druggable protein targets are shown on the left
vertical, whereas known difficult targets (prodrug and “undruggable”) are
shown in the right verticals. Difficult and druggable target binding sites
are effectively separated by the gray bar. The predicted druggability is the
MAPpod score calculated from the protein-ligand site structure. HMG-CoA,
3-hydroxy-3-methylglutaryl-CoA; EGFR, epidermal growth factor
receptor kinase; CDK, cyclin-dependent kinase 2; PDE,
phosphodiesterase; COX, cyclooxygenase; HIV RT, HIV reverse
transcriptase; PBP2x, penicillin binding protein 2x; IMPDH, inosine
monophosphate dehydrogenase; ACE-1, angiotensin-converting enzyme 1;
ICE1, interleukin-1β-converting enzyme 1; PTP1b, phosphotyrosine
phosphatase 1B.1

It is inconceivable to imagine that HIV-1 IN inhibitors were once considered an
unattainable option for HIV-1 therapy. The continuous research in the IN field is responsible for
the approval of the first marketed HIV-1 IN inhibitor and several other inhibitors emerging out
of late stage clinical development. The 20 year journey from hypothetical concept to a proof-ofconcept treatment option was not easy. The path was heavily laden with adversity and skepticism
but dedication to the field led to a realistic and “druggable” target.
44

2.2. THE EARLY YEARS OF DEVELOPMENT
Concisely, prior to 1992, inhibition of HIV-1 had been considered as a treatment
approach, but no specific IN inhibitor had been identified yet. Important biochemical studies on
HIV-1 life cycle conducted during this period were fundamental for future IN inhibitor
discovery.180-182 Topoisomerase inhibitors and DNA-binding drugs were among the first drugs
to be screened against IN (Figure 2.2).183 However, the approach of using the DNA-binding
drugs involved unfavorable risks and toxicity, and therefore, this route was quickly abandoned.
Interestingly, topoisomerase II inhibitors, doxorubicin and mitoxantrone, inhibited HIV-1 IN
catalytic activities but a topoisomerase I inhibitor, camptothecin, did not (Figure 2.2).183 From
these initial studies it was apparent that a common feature of the topoisomerase II inhibitors is
the 5,8-dihydroxynapthtalene-1,4-dione (Figure 2.2). This was the first piece of evidence that
compounds containing a keto-enol functionality (previously known to chelate divalent metal)
inhibited HIV-1 IN activities.

Figure 2.2 Select Examples of DNA Binders and Topoisomerase
Inhibitors
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2.2.1. The Development of an In Vitro Screening Assay
During the period of 1992-1996, NRTIs, NNRTIs and PIs were already undergoing
clinical testing or in an advanced phase of preclinical development and the discovery of IN
inhibitors was just beginning.184 These years would eventually lay the foundation for modern
small molecule IN inhibitor discovery. A crucial step in the advancement of HIV-1 IN inhibitors
was in 1992 with the development of an in vitro screening assay to identify inhibitors of IN.185
This assay was based on labeled short oligonucleotide duplexes mimicking U5 and U3 viral
DNA ends. These could act as mimics of both donor (e.g., viral) and target (e.g., cellular) DNA.
Together with these methods used for producing purified recombinant retroviral integrases, this
assay allowed to elucidate the first insights and several details regarding structure, catalytic
activities and inhibitors of IN.

2.2.2. Hydroxylated Aromatics and Catechol-Containing
Inhibitors
In the mid-1990s several classes of IN inhibitors
began to emerge and it became clear that a majority of

Figure 2.3 General Structure of
Catechol Containing Inhibitors

compounds contained one or more catechol moieties were active against purified IN. Although
the reported inhibitors are from unrelated structures, several of these compounds possessed
multiple aromatic rings, with poly(arylhydroxylation), frequently in the 1,2-catechol
arrangement. In many cases the aryl units of these compounds were separated by a variety of
aromatic or aliphatic central linkers (Figure 2.3). By systemic screening using purified IN-based
assays, several hydroxylated aromatic compounds (Figure 2.4) have been identified which
include flavones and flavonoids,186, 187 bis-catechols,188 caffeic acid phenethyl ester (CAPE), 189
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curcumin,186 arctigenins,190 tyrphostins,191 styrylquinolines (SQLs) and chicoric acid and its
derivatives.192, 193 Although catechols as a group exhibit favorable inhibitory profiles in cell-free
integrase assays, often these compounds have failed to have antiviral activity due to the doselimiting toxicities in in vitro assays. Many polyhydroxylated aromatics showed considerable
cytotoxicity, which obscures their potential antiviral activity.194 One potential in vivo limitation
is the cellular oxidation of the catechol to semiquinones or orthoquinones results in reactive

Figure 2.4 Select Examples of Polyhydroxylated Aromatic IN inhibitors

intermediates that tend to cross-link to various cellular-targets.195

2.2.3. Non-Catechol-Containing Aromatic Inhibitors
Several classes of compounds lacking hydroxyl groups were developed in attempt to
improve the toxicity and lack of antiviral activity of the catechol-containing compounds. These
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compounds were tested in an effort to distinguish between mechanism of cytotoxicity and IN
inhibition. In support of this endeavor, computer-assisted molecular modeling has been
employed to identify potential inhibitors from among 206,876 open compounds contained within
the National Cancer Institute (NCI) Drug Information System (DIS) database.196
An interesting detour in attempts to improve the profile and lack of antiviral activity of
the catechol containing compounds led to the discovery of hydrazides (Figure 2.5). The N, N’bis-salicylhydrazine (H1) generated fresh enthusiasm, albeit short lived, in synthetic exploration
of its analogues.197, 198 These hydrazide compounds are potent IN inhibitors, however, they do

Figure 2.5 Select Examples of Hydrazide-Based Inhibitors of IN

not show selectivity for 3’-P or ST. These compounds have been reported to inhibit IN through
metal chelation but were only effective in assays using Mn2+ and not Mg2+ cofactors and lacked
antiviral efficacy in HIV-1 infected cells.199, 200
The search for IN inhibitors that are superior to hydroxylated aromatics led to the
discovery of several sulfones. Unfortunately, highly potent and selective inhibitors did not
emerge from early structure-activity relationship studies of several screened sulfone analogues.
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However, the search continued with other variations of sulfones such as sulfonates, sulfonamides
and sulfides (Figure 2.6).194 Among these, the mercaptobenzenesulfonamides and benzothiazines
were shown to be promising for further optimization. In contrast to previously reported
catechols, several of the sulfone analogues inhibited HIV-1 replication at a concentration below
their cytotoxic concentrations. Futhermore, studies indicated that disulfones target an early-stage

Figure 2.6 Select Examples of Sulfone-Based Inhibitors of IN

HIV-1 replication event as well as a later step in virus replication, with IN as a possible target.201
Although, several compounds were found to inhibit IN function at low µM concentrations this
endeavor was unsuccessful in yielding a selective bona fide lead.

2.2.4. An Assay to Identify Strand Transfer Inhibitors of HIV-1 IN
Much of the earlier IN inhibition work led to the identification of compounds that interfered with
the assembly and processing activities of IN in biochemical assays but did not show antiviral
activity in cells.202 In 1994, Merck researchers developed a novel rapid assay for the DNA
strand–transfer activity of HIV-1 IN. This biochemical assay was able to separate the final strand
transfer step from the earlier assembly and processing steps allowing high-throughput screening
of compound libraries.175, 203 This was achieved by allowing isolated IN enzyme to form an in
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vitro IN-DNA-metal complex, also known as the preintegrase complex (PIC).204-206 This assay
allowed compounds to inhibit PIC-catalyzed strand transfer to a labeled “target” piece of DNA to
be evaluated and ultimately evaluated for their ability to act exclusively as strand transfer
inhibitors.207, 208
After about a decade of searching for a bona fide lead IN inhibitor it was apparent that
there was an overwhelming sense of frustration among researchers. It had become apparent that
the identification of a clinical candidate was noticeable more difficult than for other antiretroviral
drug classes. In 1996, IN inhibitor research was overshadowed by the enthusiasm of the
scientific community for the initial success of highly active antiretroviral treatment (HAART).
The potential of HAART was initially overestimated due to the calculations forecasting the
prolonged periods of HAART might lead to HIV eradication; therefore it was inevitable that
main interest in drug companies was NRTIs, NNTIs and PIs. Merck was one of the few large
pharmaceutical companies continuing huge efforts in IN research. 209 Despite the decay of
interest in IN inhibitors, the assays optimized in the previous years allowed the screening of large
numbers of molecules.209

2.3. The β-DIKETO ACID CLASS OF INHIBITORS
The β- diketo acid (DKA) class of compounds represents one of the most promising
classes of IN inhibitors and opened up a new frontier of IN antiviral drug discovery. A previous
large-scale random screening of over 250,000 compounds yielded potent inhibitors, and the most
active compounds proved to be 4-aryl-2,4-diketobutanoic acids, containing a distinct DKA
functionality that was capable of coordinating metal ions in the active site of IN.175 The DKA or
keto-enol acid family of inhibitors were the first IN inhibitors reported with selectivity for the
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strand transfer step of the integration reaction (STI),86 high specificity for IN, and antiviral
activity that could be related to IN inhibition.175 During the time that the DKAs were first
recognized, the hopes for HIV-1 eradication through HAART were definitively abandoned. Side
effects became a serious problem affecting a large number of people. Thus, the interest in IN
inhibitors in the scientific community was recharged.
The first small molecules (MW <500 Da) independently identified as potential HIV-1 IN STIs
were L-731,988 (2.1) and L-708,906 (2.2) from Merck Research Laboratories, 175, 210 and 1-(5chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone (5-CITEP, 2.3) from Shionogi &
Co. Ltd.211 It was immediately clear that both the Merck and Shionogi compounds could be
functionally classified together as DKAs.

Figure 2.7 First Lead DKA IN Inhibitors with Selectivity for ST

The DKAs from Merck (L-731,988 and L-708,906) were shown to selectively and
potently inhibit both IN catalyzed ST and HIV-1 replication in vitro. Further studies of 2.1 and
2.2 showed that these compounds had no effect on viral entry, reverse transcription, PIC
assembly, or 3’ processing.175 Additionally, upon serial passage of the HIV virus in cell culture
in the presence of the two inhibitors, mutations that confer resistance to inhibition arose in the
integrase active-site region (T66I/S153Y for L-731,988 , T661/M154I for L-708,906). These
mutations are very near to the active-site amino acid residues D64 and E152, two of the three
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amino acids critical for catalysis.175, 212 This data was evidence that 2.1 and 2.2 were preventing
integration by binding at the catalytic site.
The selectivity of these DKA containing compounds for ST inhibition over 3’P was
greatly increased compared to previously reported IN inhibitors. For example, 5-CITEP
presented and IC50 value of 35 µM for 3’P and 0.65 µM for ST.211, 213 Compound 5-CITEP (2.3)
is a DKA bioisostere where the carboxylic acid group is replaced with its well-known isostere
the tetrazole group. 214 The compound 5-CITEP was a breakthrough in the field of IN inhibitor
research because it was co-crystallized with the catalytic core domain (CCD).211 The electron
density map clearly revealed the inhibitor bound in the center of the active site of the enzyme,
lying between the three catalytic acidic residues D64, D166 and E152, suggesting that this
binding mode might mimic interactions with the DNA substrate.211 Of note, 5-CITEP was found
to assume a planar conformation within the active site (Figure 2.8, panel A).211
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Figure 2.8. 5-CITEP Complexed with Crystal Structure. Panels A, B and C are derived from the crystal structure of the IN core domain
complexed with 5-CITEP.211, 215 The catalytic amino acids are shown in red, the magnesium ion is colored in magenta and the four coordinating
water molecules are yellow. A: 5-CITEP interactions within the HIV-1 IN active site. Amino acids with direct interactions with 5-CITEP.211 are
highlighted in green. The view angle is the same in panel C. B: Crystal structure of the IN core domain dimer.216 Alpha helices targeted by
peptide inhibitors are colored and labeled. Helices 1 (cyan) and 5 (magenta) from the dimerization interface between two IN monomers. Helix 4
(green) is proximal to the active site and includes the catalytic amino acid E152. The three catalytic residues, D64, D116, and E152 are shown in
red. C and D: Illustration of the amino acids that are mutated in the DKA resistant viruses. The side chains of the amino acids conferring
resistance to DKA are highlighted in gold. Panel C is a view of the same orientation as in panel A. In panel D, the IN is rotated horizontally 90°.

The DKA derivatives mediate their antiviral activity through metal chelation.213, 217, 218 It
has been postulated that the integration mechanism involves two divalent metals (magnesium) in
the catalytic site of the enzyme. The first magnesium atom, as observed in the different crystal
structures, is coordinated by the two catalytic residues D64 and D116 (Figure 2.8) and the
second would be coordinated either by D116 and E152.213, 217, 218
Extensive SAR of the DKA series of compounds would eventually lead to some most
successful classes of IN inhibitors. The DKA integrase inhibitors 2.1-2.3 display a template of
two carbonyl groups flanking a central enol moiety.175, 210, 212 The DKA moiety was quickly
recognized as important for activity, but it offered several liabilities as a drug candidate. The
dicarbonyl portion was found to react reversibly with glutathione and the DKA was observed to
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be unstable in the presence of aqueous base. Under these conditions the inactive methyl ketone

Figure 2.9 Instability of DKA in Aqueous Base

was observed to form, as the result of loss of oxalate (Figure 2.9).219 The terminal carboxyl
group appears to act as a Lewis base rather than a Lewis acid, as has been confirmed by
replacement by heterocyclic aromatic rings that have Lewis basic but not Lewis acid character
(Figure 2.10).220

Figure 2.10 Replacement of DKA with Diaryl Diketones

The discovery of compounds L-731,988 (2.1), L-708,906 (2.2) and 5-CITEP(2.3)
represented a turning point in the IN inhibitor development because of their potent antiviral
activity and well-characterized selectivity targeting integrase in HIV-infected cells.175 From
these initial series of DKAs several DKA derivatives advanced to clinical trials and ultimately
the field of IN drug discovery started to gain momentum.

2.3.1. HIV-1 Integrase Inhibitors Enter Clinical Trials
The first IN inhibitor to enter clinical trials was S-1360 (2.10), a diaryl diketone
derivative of 5-CITEP, developed by Shionogi & Co. Ltd in partnership with GlaxoSmithKline
(GSK) (Figure 2.11).221, 222 S-1360 proved that IN is indeed a “druggable” target, and results
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Figure 2.11 Examples of Clinically Tested DKA IN inhibitors

with this drug in phase I clinical trials was very encouraging. Unfortunately, S-1360 failed phase
II clinical trials due to lack of efficacy and pharmacokinetic problems.222 It turned out that the
DKA portion of the molecule, important for IN inhibition, was also a good substrate for aldoketo reductase.223Although S-1360 did not proceed successfully through clinical trials it served
as a good lead for structural optimization studies to identify more potent IN inhibitors.
Further optimization of the DKA series of compounds led to another class of IN inhibitors, the
napthyridine carboxamides (2.11) and (2.12) by Merck. In this series of compounds the
carboxylate group was replaced with an appropriate heterocycle, which contained a lone pair
donor atom such as an 8-hydroxy-1, 6-napthyridine linked to a benzoyl substituent (Figure 2.11).
Representative compounds from this class, L-870, 810 (2.11) and L-870-812 (2.12) show potent
inhibition of the ST reaction with good antiviral potency.224, 225 Most importantly these
compounds provided the first proof-of-concept that IN inhibitors could prevent viral replication
in vivo.226 Unfortunately, following preliminary success in L-870, 810 (2.11) short-term
monotherapy in both naïve and treatment experienced HIV-1 infected patients, the clinical
development of this drug was terminated due to an observed long-term dosing toxicity in the
liver and kidneys of dogs.227 Additionally, L-870, 810 (2.11) exhibits a high affinity for serum
protein binding, which may result in a lower effective plasma drug concentration. Although L870, 812 (2.12) was one of the most extensively studied compounds of this series, the clinical
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status has not been made public. Considering the structural similarity to L-870, 810 (2.11) it is
assumed to display the same in vivo characteristics.

2.4. HIV-1 IN INHIBITORS: FROM CLINCAL TRIALS TO MARKET

2.4.1. Raltegravir
In October 2007, raltegravir (Isentress®, RAL, also known as MK-0518, 2.20) was the
first U. S. Food and Drug Administration (FDA) approved IN inhibitor to be used in combination
with other ARV agents for the treatment of HIV-1 in treatment-experiences adults.228 Raltegravir
is the result of a long-term commitment by Merck Research Laboratories, West Point USA, and
Istituto Ricerca Biologia Molecolare (IRBM) Italy in the development of IN inhibitors.229 The
medicinal chemistry behind the discovery of RAL by Merck Research Laboratories Rome
(known as IRBM) relies on the understanding of the similarities of the mechanism of action of
HIV-1 IN and another polynucleotidyl transferase, the NS5b RNA-dependent RNA polymerase
of hepatitis C virus (HC V).230 HIV-1 IN and HCV share the common feature of using two Mg2+
ions in the active site as a key constituent of the catalytic mechanism. The two enzymes catalyze
two different types of reactions, however, the amino acids within the catalytic site and the
geometry of the catalytic metals are conserved. This observation was the basis of the integrated
drug discovery program, where compounds designed as inhibitors for one viral target using the
catalytic machinery, were screened across enzymes belonging to the same superfamily from
other viruses.231
The research group working on hepatitis C virus polymerase discovered a simple DKA
(2.13) and meconic acid (2.14) derivative as inhibitors of active site HCV NS5b RNA-
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polymerase by random
screeening.232, 233 Both
classes (2.13) and
(2.14) were liable to
problems such as
chemical instability,
irreversible covalent

Figure 2.12 Discovery of Dihydroxypyrimidine Carboxamide (2.17) as an
HIV-1 IN Inhibitor

binding to protein, and poor stability in plasma. The constraint of the six member ring was an
attractive template and a third class, dihydroxypyrimidine carboxylic acids (2.15) and N-alkyl
hydroxypyrimidinone carboxylic acids (2.16), were designed to have more drug-like properties
and maintain the correct geometry to bind the Mg2+ ions in the active site of HCV
polymerase.232. The mechanism of action of inhibition is likely due to the interaction with metals
in the active site, resulting in a functional impairment by chelation of the critical metal
cofactors.217 Unfortunately, most of these inhibitors showed a suboptimal activity in the HCV
cell assay resulting from compounds containing a free carboxylic acid.234 Several carboxylic acid
isostere derivatives, including amides (2.17), were synthesized to circumvent this problem. The
dihydroxypyrimidine carboxamide that evolved from DKA in the HCV polymerase program232
was a potent, reversible and selective HIV-1 INSTI while being completely inactive on the HCV
polymerase.231
RAL was a result of continuous efforts to optimize these inhibitors, addressing pharmacokinetic,
metabolic and antiviral activity issues presented by previously reported DKA inhibitors. RAL is
an orally administrated (400 mg twice daily), well-tolerated, highly potent, and with an excellent
pharmacokinetic profile.228 In July 2009, RAL was also approved by the FDA for use in first-line
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antiretroviral (ARV) therapy and is undergoing Phase III studies in ARV treatment-naïve
subjects including investigation of once daily dosing.104

2.4.2. Elvitegravir
A second compound, elvitegravir (EVG, GS-9137 also known as JTK-303, 2.19) is the
next most advanced IN inhibitor in clinical development. EVG is a quinolone carboxylic acid
derivative originally discovered by Japan Tobacco, Inc. that was subsequently licensed to Gilead
Sciences for development outside of Japan. The 4-quinoline-3-glyoxlic acid scaffold was based
on the idea that IN inhibitors with this scaffold maintain the co-planarity of DKA functional
groups. Interestingly, the original developed scaffold (2.18) did not show activity, however, its
precursor 4-quinoline-3-carboxylic acid (2.19) had IN inhibitory activity. This eventually led to
the discovery of EVG. It is a potent, boosted, once-daily HIV-1 IN inhibitor with ARV activity

Figure 2.13 Discovery of 4-quinolone-3-carboxylic acid as an IN inhibitor

against wild-type and drug-resistant strains on HIV-1. EVG is not yet approved by the FDA
however; it is currently in Phase III clinical trials.235 Unlike, RAL, EVG is primarily metabolized
by cytochrome P450 3A4 isozyme and significant increases (boosts) in plasma exposure have
been achieved by co-administering it with CYP3A4 inhibitors (e.g., ritonavir or cobicistat).236
Boosting also results in a prolonged elimination half-life to ~9.5 hours, allowing once daily
administration of a low 150 mg dose.236 Structural modeling studies indicate that the efficient
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binding of EVG to IN results from the β–ketone and carboxylic acid functional groups that have
coplanar conformation similar to DKA derivatives.235 RAL and EVG share the same mechanism
of inhibitory action against IN.228, 237

2.4.3. GSK-364735
Several studies to develop follow-on analogs of S-1360, the two groups involved jointly
discovered a novel lead napthyridinone-based inhibitor, GSK-364735 (2.21). This compound
contains hydrophobic fluorobenzyl substituent flexibly linked to a chelatable quinolone
region.238 GSK-364735 exhibited ST inhibition comparable to RAL and EVG and demonstrated
satisfactory results in a phase I clinical trial, 239, 240 but its clinical development was halted in a
phase II clinical trial because of an unfavorable long-term safety profile.

2.4.4. Dolutegravir (S/GSK1349572)
The collaborative effort between Shionogi and GSK has advanced a Tricyclic hydroxypyridone carboxamide, S/GSK1349572 (2.22), into Phase IIb clinical trials. S/GSK1349572 is
considered a second-generation HIV-1 IN inhibitor with demonstrates pharmacokinetic
properties in humans consistent with once-daily unboosted dosing. Resistance data suggests that
this compound may have an improved resistance profile on RAL and EVG selected mutations,
which offers a potential therapeutic opportunity for patients suffering from RAL resistance.
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Compound

Structural
Class

IN
inhibition
profile

Anti-HIV
activity

Pharmacokinetic
Profile

Status

Pyrimidione
carboxamide

IC50 a= 2-7
nM

CIC95 b= 19 nM
(10% FBS)
CIC95= 33 nM
(50 % NHS)

Rat: Fabsolute= 62%
T1/2= <1 h
Cl= 46 mL/min/kg
Dog: Fabsolute= 62%
T1/2= <1 h
Cl= 46 mL/min/kg
Human: Fabsolute= 32%
T1/2 (i.v.)= 1.4 h

Market

4-Quinolone-3carboxylic acid

IC50= 7 nM

EC50 c= 0.7 nM
EC90 d= 1.7 nM
(serumadjusted)

Rat: Fabsolute= 34%
T1/2= 2.3 h
Cl= 8.3 mL/min/kg
Dog: Fabsolute= 29.6%
T1/2= 5.2 h
Cl= 17 mL/min/kg

Phase
III

1, 6Naphthyridinone
carboxamide

IC50= 8 nM

EC50 = 1.2 nM
EC90 = 42 nM
(serumadjusted)

Rat: Fabsolute= 42%
T1/2= 1.5 h
Cl= 3.2 mL/min/kg
Dog: Fabsolute= 12%
T1/2= 1.6 h
Cl= 8.6 mL/min/kg
Rhesus: Fabsolute= 32%
T1/2= 3.9 h
Cl= 2 mL/min/kg

Halted
Phase II

Tricyclic
hydroxypyridone
carboxamide

IC50= 2.7
nM

EC50 = 0.51
nM
EC90 = 2 nM

Human: Frelative= 70%
T1/2= 15 h

Phase
IIb

a

IC50—Concentration of compound that results in 50% inhibition of in vitro integrase assay
CIC95—Concentration of compound that results in 95% inhibition of the spread of HIV-1 infection in cell culture
c
EC50—Concentration of compound that results in 50% inhibition of in vivo viral replication
d
EC90—Concentration of compound that results in 90% inhibition of in vivo viral replication
b

Table 2.2 IN inhibitors in Clinic and Clinical Development223

2.5. PERSPECTIVE
Despite the clear successes of selective strand transfer IN inhibitors, the need for secondgeneration and new classes of inhibitors remains. Emergence of resistance leading to the
treatment failure has already been reported for RAL and EVG.229, 241 Consistent with selective
targeting of IN by RAL and EVG, resistance pathways have been described in relationship with
point mutations of IN residues surrounding the IN catalytic core site.215 Three main resistance
pathways involving the primary mutations Q148R/H/K, N155H and Y143R/C,241-243 are
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responsible for virological failure.244-248 These pathways seem to be associated with secondary
mutations that appear to rescue the viral fitness of those primary mutants for example G140S is
observed together with Q148H, or G140A with Q148R.244, 248 Several studies have shown the
presence of significant genotypic and phenotypic cross-resistance between RAL and EVG,
including mutations E92Q, Q148R/K/H, and N155H, suggesting that a common mechanism is
involved in a resistance and potential cross-resistance of both IN inhibitors.249 It is clear from the
emergence of resistance from RAL and EVG in the clinic that second-generation HIV-1 IN
inhibitors are needed.
After 20 years (Figure 2.14) IN is now a validated target for the development of anti-HIV
therapies. However, our knowledge about its structure and function is still lacking. After the
DKA series of compounds were discovered as STIs of IN and assay methods were refined, a
plethora of compounds were revealed. These efforts have produced one marketed IN inhibitor
(RAL) and several in late-stage clinical development, which validates IN as an effective target
for the treatment of HIV/AIDS. Several companies, academic institutions and agencies continue
to pursue novel scaffolds and inhibitors of HIV-1 IN.
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Figure 2.14 Timeline of IN Inhibitor Milestones
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III. DESIGN AND SYNTHETIC APPROACHES TOWARDS THE DEVELOPMENT
OF NOVEL HIV-1 INTEGRASE INHIBITORS

Despite the lack of valid structural information, several IN inhibitors have been
discovered using in vitro assays specific to IN. The clinical success of selective ST inhibitors
such as marketed raltegravir and the drug candidate elvitegravir, DKA-derived compounds, has
validated IN as a rational ARV target. However, the exact mechanism of action of the DKA class
of IN inhibitors has not yet been completely elucidated.250, 251 Insights derived from studies in the
field indicate several proposed mechanism of actions of IN inhibition by the DKA class of
compounds. Several questions concerning the interactions of IN inhibitors with IN have
remained unanswered86, 184 and include: the docking site, possible interactions with metal ion(s)
and viral DNA, the amino acids involved in IN binding, the role of drug resistance mutations,
and the conformations assumed by the inhibitors in complex with the enzyme.252 Clarification of
these issues is critical, given the strict requirement of IN for insertion of proviral DNA into the
host cell genome, leading to retroviral latency and persistence during therapy.253

3.1. HIV-1 IN STRUCTURE AND FUNCTION
HIV-1 IN enzyme belongs to the DNA processing polynucleotide transferase
superfamily, enzymes that cleave and join DNA by trans-esterfication and is the key viral
enzyme for catalyzing DNA integration.104 HIV-1 IN is a 32 KDa enzyme that contains 288
amino acids, divided into three structural and functional domains. The three functional domains
consist of the N-terminal domain (NTD), the catalytic core domain (CCD) and the C-terminal
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domain (CTD).211, 254, 255 Each IN monomer associates with another IN monomer to form a
homo-dimer and these have been proposed to further associate into functional tetrameric or
higher order IN complexes.254, 255

Figure 3.1 Structural Domains of HIV-1 Integrase104
Reprinted with permission from Elsevier 2866750655927

Each of the three IN functional domains contains recognizable functional motifs (Figure
3.1). The NTD is composed of residues 1-50 and contains two histidine residues (His12 and
His16) and two cysteine residues (Cys40 and Cys43), all of which are conserved and form a
HHCC zinc finger motif that chelates one zinc atom per IN monomer.256, 257 The NTD is
essential for higher order multimer formation, a process which requires zinc. The zinc atom acts
to stabilize the fold of the NTD and is necessary for the activity of IN.258 The CCD is composed
of residues 51-212 and contains three conserved negatively charged amino acids (residues Asp64
(D), Asp116 (D) and Glu152 (E), DDE motif). Mutation of any one of these three residues is
sufficient to inactivate IN. These key catalytic residues are involved in coordinating divalent
metal ions (Mg2+ or Mn2+) for catalysis of the chemical steps of DNA integration (Figure 3.2).259
The crystal structure of the CCD shows that it consists of 5 β-sheets and six α-helices that are
linked by flexible loops.211, 260, 261 The CCD is essential for two key steps of the integration
reaction, 3’ processing (3’-P) of the viral DNA and the strand transfer (ST) reaction, in which it
cleaves the phosphodiester bond of the host genomic DNA and subsequently joins the 3’processed viral DNA ends to the host genomic DNA (Figure 3.3.). The CCD forms a dimer in
solution and is a dimer in the functional IN enzyme.211, 260, 261 The CTD is composed of residues
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213-288 and has some structural homology
with SH3 DNA binding domains and binds
DNA nonspecifically.262 The CTD is less
conserved than the other two domains and
has positively charged regions on its surface
that are capable of binding DNA
nonspecifically.255 Coordinated action

Figure 3.2 Role of Divalent Metal Ions in
Catalysis. This figure represents the catalytic
pocket containing the pentacoordinated
phosphate in the (hypothetical) transition state.
One of the Mg2+ ions is proposed to act as a
Lewis acid is shown to be coordinated with
two aspartic acid residues and the oxyanion of
the leaving group (R1 of nonbridging oxygen.
The second Mg2+ is also shown to complex
with the nonbridging oxygen and to act as a
base for the deprotonization of the incoming
nucleophile. The substrate is 3’R1-R25’, and
the product is 3’R3-R25’.

between the three domains is, however,
necessary for the 3’-P and ST reactions to be
catalyzed efficiently. Even though all three
domains are required for full catalytic
activity, site-directed mutagenesis studies
have shown that the CCD is sufficient to

promote a reverse integration in vitro, disintegration, indicating that this region contains the
enzymatic catalytic center.263, 264 The structures of the individual domains of IN have been
determined but there still are no structures of the full-length protein and importantly, no
structures with DNA substrate bound.265
The DNA product formed after RT is a double-stranded linear DNA with LTR sequences
at each end. This molecule is the substrate for integration and is acted upon in several
biochemical and temporally discrete steps, before being co-linearly integrated in a host cell’s
chromosome. As soon as RT synthesizes double-stranded DNA, IN multimers will bind to DNA.
IN will exert its catalytic activity when it recognizes an intact LTR end.266 In the cytoplasm,
HIV-1 IN recognizes and binds to a specific, imperfect, and inverted sequence in the LTR of the
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reverse-transcribed DNA.86, 267 IN then catalyzes the removal of a GT dinucleotide immediately
3’ to the conserved CA dinucleotide at the 3’ end of both strands of the viral cDNA (donor
DNA) by a nucleophilic attack on the phosphodiester bond between deoxyguanosine and
deoxyadenosine.181, 268, 269 This initial step is called 3’-P and the IN remains bound to the LTR,
forming a preintegration complex (PIC). The PIC containing viral proteins is then transported to
the nucleus, where second reaction called 3’-end joining or ST occurs.
The ST reaction consists of a direct nucleophilic attack on the host chromosome
(acceptor DNA) by the 3’-hydroxy recessed viral DNA, which are kept in close proximity,
integrate at the 5’-ends of the host chromosomal DNA with a 5-base pair stagger.86, 269-271 The
two unpaired nucleotides at the 5’-ends of the viral DNA are removed, and the gaps at the
integration site on both termini are
likely filled by host cellular repair
enzymes.249, 272 The ST reaction
completes the viral DNA
integration into the host genome.
The intergrated viral DNA (proviral
DNA becomes a template for virion
synthesis, a process completed by
host cellular machinery.249
Figure 3.3 The Mechanism of the 3’Processing and ST Reactions269

In general, IN inhibitors can be divided into dual inhibitors of 3’-P and ST (referred to as
3’P inhibitors), and selective strand transfer inhibitors (INSTIs). Based on several structural
activity relationship studies, it was established that IN inhibitors bind to distinct regions of the IN
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enzyme following conformational change induced under donor DNA binding, and then impair
IN enzyme function by interaction with the catalytic triad.249 The 3’-P inhibitors may contact
both the donor and target DNA binding sites, whereas the ST inhibitors may bind selectivity to
the target DNA binding site.86, 273 IN inhibitors on the market and in advanced clinical trials are
members of the INSTI class of compounds. Chemically, they possess a β-hydroxy carbonyl,
thought to bind the two metal ions coordinating the three catalytic residues D64, D116 and
E152.184, 225

3.2. PROPOSED MECHANISMS OF ST INHIBITION
Interactions between HIV-1 IN and the HIV LTR are critical for IN-DNA binding, 3’-P,
ST, and inhibitor interactions. Studies analyzing mutations in the IN amino acid or the LTR
DNA base sequence provides insights into the structural requirements for IN 3’-P and ST.
Collectively, understanding these IN-DNA interactions can provide useful information to aid in
elucidating the interactions of IN inhibitors with IN. Although several synthetic and biological
studies for DKA compounds have been reported, the mechanism by which they bind IN has not
been well understood.
In order to increase the understanding of IN interactions with DNA, IN catalysis with
oligonucleotides containing DNA backbone, base, and groove modifications were placed at
unique positions surrounding the 3’-P site. IN sequence specifically recognizes the conserved 5’CA in HIV LTR (Figure 3.4). Interactions between IN and the backbone of viral DNA have been
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Figure 3.4 Role of Major and Minor Grooves in IN Reactions. (a) Sequences of U3 and U5 LTRs. Nucleotide positions
are indicated by numbers above the U5 LTR sequence. The 3’-P cleavage sites are indicated by vertical arrows, the
conserved 5’-CA dinucleotides are underlined and the AT stretches are boxed. (b) Diagram of IN 3’-P and ST reactions.

examined by substituting conformationally constrained sugars into the 3’-P cleavage site.274 The
conformationally constrained sugar modifications prevented IN 3’-P, demonstrating that
conformational restrictions at the 3’-P site block cleavage and suggesting DNA flexibility is
required for 3’-P. From this study it was determined that IN has an open catalytic site that
requires a flexible DNA backbone for 3’-P and ST.274, 275 Several oligonucleotides were
synthesized containing benzo[a]pyrene 7,8-diol 9,10-epoxide (BaP DE) adducts were tested to
probe the effects of DNA groove occupancy on IN catalysis.274-276 Only the adduct in the minor
groove at the 3’-P site inhibited 3’-P, suggesting that the DNA minor groove surrounding the 3’P site is important for IN-DNA interactions are important during 3’P.274 The guanine/cytosine
(GC) base-pair at the 3’-P site was replaced by the other 15 base-pair combinations to examine
the importance of the base-pair sequence for IN reactions.274 From this exercise it was
determined that the interaction between cytosine (L2 cytosine or 5’-C) and Gln148 is critical for
IN ST and plausible partners for hydrogen bonding.275 From these studies several structural
features of the viral cDNA that were found important for IN binding and reactions obtained from
are summarized in Figure 3.5.274-278
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Figure 3.5 Important Components of IN/DNA
Interactions. The components that are critical to
IN reactions are noted. A base is required at U3
adenine and U5 guanine positions. The L4 N2
guanine is required for 3’-P; the L2 cytosine N-3
group is required for ST. Interaction between IN
and the cDNA minor groove is required for both
3’-P and ST.

Several IN amino acids have been identified to interact with specific viral cDNA bases
(Figure 3.6).275 The catalytic amino acids Glu152 and Asp64 interact with the U3 adenine and L3
thymine, respectively.279 Lys159 interacts with the conserved U3 adenine280 and the scissile
phosphate.281 The C-terminal domain residue Glu246 forms a disulfide cross-link with L7
adenine, and the IN monomer containing the active-site residues.282 Gln148 interacts with the N3 group of the L2 cytosine,277 and Tyr143 forms a photo-cross-link with the terminal L1
adenine.280 A specific viral LTR contact for the catalytic amino acid Asp116 has not been
identified.283
Integrase strand transfer inhibitors define a
functionally distinct mechanistic class of compounds
that selectively inhibit strand transfer in vitro and in
Figure 3.6 IN amino acids interacting
with viral cDNA bases.

infected cells.175 The opinions on the mechanism of IN

inhibition by the β-DK class of compounds are divided. Previous studies have suggested that the
binding of DKA inhibitors require that IN be assembled into a nucleoprotein complex competent
to catalyze ST and that binding of the inhibitor and the target DNA are mutually exclusive.252, 284
These studies suggest a biochemical basis for ST selectivity of these inhibitors. Alternative
studies suggest a molecular basis of inhibition where there is interaction between IN inhibitor
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and metal ion(s) in the IN active site, resulting in a functional sequestration of the critical
cofactor(s).86, 217, 218, 275
3.2.1. Biochemical Mechanisms
In 1999, Goldgur et al. reported that the IN inhibitor, 5-CITEP (Figure 3.1, bound to the
crystal structure of the CCD seems to mimic the DNA substrate/IN
interaction.211 The stereo view of 5-CITEP bound at the active site
represented in Figure 3.8, and a schematic of the contacting
residues are shown in Figure 3.9. These figures depict the

Figure 3.7 Structure
of 5-CITEP

inhibitor/active site interactions implicating several residues of importance for catalysis or DNA
binding.211 Gln148 forms a hydrogen bond to the nitrogen of the indole ring; Glu152 is within
hydrogen-bonding distance of the enol hydroxyl. All four nitrogen atoms of the tetrazole ring are
hydrogen bonded to Asn155, Thr66, Lys159 and Lys156. Although no direct contacts

Figure 3.8 Stereo Image of 5-CITEP Inhibitor/Protein Contacts. Contacting protein side chains are shown
in cyan, with magnesium in purple and the catalytic residues Asp-64 and Asp-116 in pink.211

with the two catalytically essential aspartates are observed, one of the four water molecules
coordinating the magnesium ion is close enough to the plane of the indole ring to be regarded as
van der Waals interaction. Based on electron density mapping 5-CITEP is bound in the middle of
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the active site between two aspartates, D64 and D116, and the glutamate E152, all three which
are required for IN catalysis. This study also
revealed that the inhibitor does not displace the
bound magnesium ion, which remains complexed
to the two aspartic acid residues.211
It was speculated that the interactions between 5CITEP and IN partially mimic the normal
interactions with viral DNA substrate during the
Figure 3.9 Schematic of 5-CITEP and Interacting
Residues. The contacting distances corresponding to
the potential hydrogen bonds are shown. Note that for
this subunit the inhibitor makes two hydrogen bonds
with its symmetry-related neighbor. Also, one of the
oxygens of Glu-152 is within contact distance of both
inhibitors.

3’processing reaction. The distance between the
indole and tetrazole ring systems on the inhibitor
is approximately 8 Å, a distance that could easily
be spanned by two nucleotides, with the sugar

phosphate backbone containing the scissile bond passing between the active site carboxylates in
close proximity to the bound magnesium ion. In this model the two bases adjacent to the scissile
phosphate potentially would overlap the pockets in which the indole and tetrazole rings of the
inhibitor are buried. It is postulated from this study that this DKA IN inhibitor, 5-CITEP, mimics
the DNA substrate of the integration reaction and also interacts with unstacked DNA bases at the
catalytic site.211
In 2000, Espeseth et al. developed a scintillation proximity assay
(SPA) that allows analysis of radiolabeled IN inhibitor binding and IN
function.284 Investigations to aid in understanding the unique ability of
DKA inhibitors to selectively inhibit the ST activity of IN in the
absence of an effect on 3’end processing were investigated.
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Figure 3.10 Structure
of L-731,988

Specifically, the mechanism of action of DKA, L-731,988 (Figure 3.10) and interactions of this
inhibitor with IN were elucidated from this study. 175, 284 This study determined that L-731,988
binds within the IN active site and inhibits ST by competing with target DNA substrate. Highaffinity binding of L-731,988 is shown to require the assembly of a specific complex on HIV-1
LTR. The interaction of L-731,988 with the complex and the efficacy of L-731,988 in ST can be
abolished by the interaction with target substrates, suggesting competition between the inhibitor
and target DNA. Although distinct from that of the viral donor substrate, the binding site for the
DKA inhibitors is within the active site.284 Given the results presented in this study it is
surprising that 5-CITEP binds in the absence of donor substrate and that substantial
conformational changes in the protein were not observed in the 5-CITEP complex.211 Although it
is not known if the mechanism of inhibition for 5-CITEP and L-731,988 is analogous, it is
possible that the 5-CITEP represents the less interesting weak micromolar binding mode
observed for the DKAs in the absence of substrate. Whether this interaction is predictive of the
high-affinity DKA inhibited complex is therefore unclear.284

3.2.2. Molecular Mechanism
It is believed that the β-DKA
pharmacophoric motif could be involved in
a functional sequestration of one or both
divalent metal ions (Figure 3.11) in the
enzyme catalytic site86, 217 to form a ligandFigure 3.11 Complexing motifs for DKAs. (a) bidentate
ligand (DKA-a and DKA-b), tridentate ligand (DKA-c),
and (b) general scheme of two-metal-chelating state for
DKA-type compounds. Dashed lines are the interactions
with the metal ions (spheres).

M2+-IN complex. This would subsequently
block the transition state of the IN-DNA
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complex by competing with the target DNA substrate.86, 284, 285
In 2002, Grobler et al. characterized the molecular basis of IN inhibition by using
functional and binding assays to evaluate a series of DKA inhibitors.217 Binding and mechanistic
studies suggest that the DKAs and 5-CITEP are structural homologs.217, 250 To explore the
common functionalities in these compounds, carboxylate and tetrazole (isosteric replacement of
carboxylate) containing compounds were synthesized and evaluated for binding and inhibition of
IN. As shown in Table 3.1, both hybrid molecules were active; however, in the context of either
template, the carboxylate (L731,988 and 3.2, respectively)
was more potent. The choice of
metal did not affect the affinity
or potency of the carboxylate
analogues. However, the
tetrazole derivatives (3.1 and 5CITEP) exhibited reduced
binding and inhibition in Mg2+
Table 3.1 Binding and Inhibition by Hybrid Integrase Inhibitors

relative to Mn2+. This

observation can also in part explain the lack of antiviral activity in cellular system for the
tetrazole containing DKAs, since Mg2+ is the plausible metal in vivo.250 The acidic
tetrazole/carboxylate moiety therefore is not required for binding but it is essential for inhibition.
It was demonstrated from this study that binding to IN is in part mediated by the interaction of
the acid functionality with metals in the active site.217 A model for the binding of the DKA
analogs to IN that is consistent with the requirement for the acid functionality and observed
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metal dependence of these inhibitors was developed (Figure 3.12). In this model, the inhibitor
coordinates two metals bound at the active site by the conserved DDE motif of IN.217 The bond
lengths and angles for the acidic functional group used were based on the crystal structure of 5CITEP.211 Binding requires divalent metal and
additionally, resistance is metal dependent with active
site mutants displaying resistance only when the
enzymes are evaluated in the context of Mg2+. The
mechanism of action of these inhibitors is therefore

Figure 3.12 Model for the Binding of
Two Divalent Metals by DKA Inhibitors

likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active
site, resulting in a functional sequestration of the critical metal cofactor(s).217

3.2.3. Proposed Mechanisms and Inhibitor Development
Even if the exact mechanism of action of IN inhibitors has not been completely
elucidated, it is generally more widely accepted that INSTIs bind to the host chromosomal DNA
site of the enzyme and act by sequestering the metal ion(s) bound in the IN active site to form a
ligand-M2+-IN complex.217, 286-288 Furthermore, it has been believed that the inhibitors bind at the
IN-DNA interface rather than to IN alone,243, 284 thus acting as interfacial inhibitors of proteinnucleic acid interactions.86, 289, 290 Almost all of the authentic HIV-1 IN inhibitors developed
share similar chemical structural features. All of these compounds possess at least two distinct
regions: an aromatic hydrophobic region and a metal chelating region.291 Except for elvitegravir
(GS-9137), the chelating region of all of these compounds is represented by a DKA motif or a
bioisostere of DKA. In structural terms, these molecules have essentially three functional groups
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in a coplanar conformation that are assumed to chelate two magnesium ions in the so-called twometal-ion mechianism.217, 291
Research has focused on the molecular binding of INSTIs to IN complexes because of the
increasing importance of selective INSTIs as ARV compounds and their unique mechanism of
action.86 Unfortunately, a full understanding of the inhibitor binding mode remains unclear.
Although the X-ray crystal structure of 5-CITEP bound to the HIV-1 CCD has been investigated,
the ligand forms a dimer with another molecule of 5-CITEP at a crystallographic dimer
interface.211 Therefore, the binding site of the inhibitor in the crystal is assumed rather unlikely
to resemble the physiologically relevant binding configuration, especially considering that no
DNA was observed in this structure.290

3.3. DISCOVERY OF THE AMINOCARBOXYALTE SYSTEM

3.3.1. Aromatic Substitutions of the DKAs
One interesting trend noted with the
β-DKA containing class of inhibitors is that
several distinct compounds, while
possessing various aromatic substitutions
with the DKA scaffold (Figure 3.13),
demonstrate potent ST inhibition and antiviral
activity with remarkable fidelity.

273, 288, 292

Figure 3.13 Potent DKA ST inhibitors with
Antiviral Activity. Aromatic substitutions
highlighted in blue.

For

example, the β-DKA (carboxylate or tetrazole)
compounds containing the aromatic groups diphenylmethane (3.3),293 benzyl furan (S-1360),294
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benzyl pyrrole (L-731,988)295 or benzyl quinolone (3.4)292, 296 demonstrate potent IN inhibition
(<50 nM) with antiviral activity. However, compounds lacking a bulky aromatic group (Table
3.2) such as the indole derivative 5-CITEP and phenyl containing DKA 3.5 did not show
antiviral activity in cells even though they demonstrated potent ST inhibition.
In 2000, Wai et al. investigated
the SAR of a series of DKAs
using L-731,988 (Figure 3.13) as
a lead molecule and replacing the
central pyrrole ring with a series
of aromatic systems.212 This SAR
study provided a series of potent
3-benzylphenyl DKA IN
inhibitors (Table 3.2, compounds
3.6-3.8) and revealed that by
replacing the aromatic benzyl
group with diphenylmethane or
substituted diphenylmethane
antiviral activity is significantly
increased. For example, benzyl
carboxylate 3.5 did not show any
antiviral activity; however, when

Table 3.2 SAR of Aromatic Substitution on β-DKA Scaffold

the aromatic group possesses an additional benzyl group (3.6) antiviral activity is observed.
Furthermore, these compounds also show an increased selectivity for inhibition of ST reaction as
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compared to 3’-P reaction and bind to IN only after viral DNA is bound.176, 284 Substitutions on
the phenyl and benzyl ring of diphenylmethane (3.7-3.9) further increase the antiviral activity of
compounds to nM activity (3.7-3.9).212 Compound 3.9 (2,4-difluoro-1-(4isopropoxybenzyl)benzene) was synthesized and tested previously by our collaborators,
Panvirex, LLC (unpublished results), lending a potent ST IN inhibitor that has better antiviral
potency compared to the previously studied aromatic substituted series.212 The mechanism of
action of this series of compounds remains unknown but collectively, these studies suggest that
the IN inhibitory potency is influenced by β-DKA motif of the molecule while the aryl
substituents provide antiviral potency and ST specificity.

3.3.2. Keto-Enol Tautomerism of DKA IN Inhibitors
Several of the authentic IN inhibitors derived from the β-DKA class of compounds have
multiple possible tautomers (Figure 3.14).297 It is generally accepted that the β-DKA compounds
exist most favorably in the tautomer-B form (Figure 3.14), which was noted as the most
favorable
thermodynamic
structure in the
inhibitor bound crystal
structure (PDB:1QS4).211 A lot of the early SAR work on the β-DKA compounds determined
that the terminal carboxylate is involved in inhibitor binding and IN inhibition.217 To date,
developmental strategies for alternative heterocyclic structures assume that the β-diketo
functional groups are essential in IN inhibitor design and functional groups of tautomer-B are
retained in an empirical manner. Previous studies investigated by our collaborators (Panvirex,
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LLC.) investigated the significance of the tautomeric state of the β-diketo functional groups. The
diol derivative (3.11) of 3-benzylphenyl DKA (3.6) was synthesized and evaluated for ST
inhibition. In the diol derivative (3.11) the carboxylate functional group involved in IN inhibition
was retained and the
diketo groups were
converted into diols.
The diol derivative
is similar to the β-diketo
compound 3.6 in the
sense that contains all of
the functional groups as
they would be present in
the tautomeric state. It
was anticipated that the
derivative would either
demonstrate potent or
moderate IN inhibition.
Surprisingly, diol (3.11)
was a poor inhibitor (IC50
>100 µM), although it

Table 3.3 SAR of β-Diketo Compounds Lacking the Terminal Carboxylate

contained all of the functional group requirements of the DKA 3.6 (Panvirex, unpublished data).
The lack of ST inhibition of 3.11 in conjunction with data from previously studied compounds
containing the β-diketo functional group devoid of a terminal carboxylate (Table 3.3)217
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collectively indicate that potent IN inhibition is influenced by the tautomeric state of β-diketo
groups together with the terminal functional group. One of the consequences in loss of the enolic
configuration of the β-diketo functional group is that the intermolecular interaction between the
keto groups is likely disrupted resulting in a non-planar configuration of the functional motif.
From this study, it was assumed that the planar geometry of the functional motif is essential in a
potent IN inhibitor.

3.3.3. Aminocarboxylate: Alternative Surrogate for the β-DK scaffold
Despite the success of selective ST inhibition, potency and antiviral activity of the βDKA class of IN inhibitors several serious limitations in regards to the development of drug
candidates exist. For example, the β-DKA class of compounds contains two reactive keto groups
that react irreversibly with plasma proteins. The
lead candidate S-1360 failed Phase II clinical
trials due to lack of efficacy resulting from 99%
of the drug being bound irreversibly to plasma
proteins.178 Thus, compounds containing
“druggable” characteristics while retaining the βDK motif functional groups were explored with
Figure 3.16 Potent DKA IN Inhibitors

heterocyclic systems using the geometry of the β-

DK motif. Using this approach, the β-DK characteristics were retained in the fused heterocyclic
structures and evolution of the naphthyridine carboxamides (L-870, 810 and L-870,812) led to
potent ST inhibition and good antiviral potency. However, development of these compounds
was suspended due to long-term cardiotoxicty in Phase II clinical trials.251 Alternative suitable
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surrogates to the reactive β-DKA functional group may overcome the pharmacological
limitations of these compounds. To date, there have been no reports of a functional domain that
can serve as a surrogate for the β-DKA motif of IN inhibitors.
The work described in this dissertation project is focused on the development novel HIV1 IN inhibitors that contain an aminocarboxylate functional group to serve as a surrogate for the
β-DKA functional motif. In the design towards a lead molecule several key findings discussed in
the preceding section were
considered. The planar
configuration of the functional
domain was given high priority
and less consideration was
given to retaining the β-DK
characteristics previously
retained in the development of
heterocyclic scaffolds (e.g.,
naphthyridine carboxamides, L870, 810 and L-870,812).
Compound L-708,810 (3.6) was
selected as the starting building
Table 3.4 SAR of Aminocarboxylate Scaffolds

block, since the aryl group, 3-

benzylphenyl, does not contain any additional substitutions. In this regard, it was anticipated that
the ST inhibition response would rely solely on the role of the aminocarboxylate functional
groups under evaluation. Several compounds containing the aminocarboxylate functional group
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(28 total compounds) were evaluated in an all or non-response ST inhibition assay by our
collaborators and the results of a few closely related compounds are summarized in Table 3.4
(Panvirex, unpublished results). Among the various compounds analyzed, only 3.16 containing
the oxalohydroxamate (OHA) motif showed potent ST inhibition, whereas all others were
negative. From this SAR data, it was noted that
the hydroxyl group of the terminal hydroxamic
3.16

acid is critical to obtain potent ST inhibition.
Interestingly, compounds containing a terminal
carboxylate (3.17-3.20), previously considered
3.6

to be essential for binding affinity and potent IN
inhibition,217 did not show IN inhibition (Table
3.4). In the serine amide derivative 3.18, the

Figure 3.17 Overlapping 3D Geometry of
Compounds 3.6 and 3.16. The compounds are
overlaid on their 3-benzylphenyl aryl groups.

assumed α-keto group of the β-diketo motif
hydroxyl (tautomer-B) is one carbon length

away from its normal position. In the glycine amide 3.19 and oxalamic acid containing
compound 3.20, all of the functional groups are present yet no IN inhibition was observed. It can
be considered that the lack of IN inhibition shown from these compounds is a result of deviation
of the functional motif from the planar configuration due to the free rotational bond (Table 3.4,
highlighted with blue arrows). Such assumption is further supported by the observation that diol
3.11 containing all of the groups of the functional motif also did not show inhibition of IN.
However, the requirement of the planar geometry of the functional group is not absolute as it is
previously assumed in the inhibitor. The 3-benzylphenyl aryl group of 3.16 distorts the
functional domain from the absolute planarity of the prototypical β-DKA inhibitor 3.6 or as in
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the naphthyridine carboxamides (L-870, 810 and L-870,812) as illustrated by the overlapping
geometry in Figure 3.17. The moderate deviation appears to be tolerable without losing the
potent IN inhibitor characteristics. Collectively, the structural observations of the OHA motif
containing compounds suggests that the isosteric functional group of the β-diketo motif in
moderate planar configuration (3.16) is sufficient for IN inhibition but significant deviation from
planar or near planar configuration abolishes IN inhibitory potency (Table 3.4).

3.3.4. Ligand Docking of Aminocarboxylate IN Inhibitors
Although the chelation model (Figure 3.12) of ST inhibition by the β-DKA class of
compounds has been widely accepted as a plausible mechanism of IN inhibition several studies
have surfaced, based largely on SAR and IN crystal structure studies, prompting investigators to
revisit the proposed mechanisms of inhibition. In previous studies, the β-DKA 3.6 has
demonstrated progressive drug resistant viral mutations beginning at T66I and it is followed with
concomitant mutations of either amino residues S153Y, M154I or N155S.175 The T66I mutation
alone is significant enough to render IN inhibitors less effective. Studies have also shown that the
tetrazole β-diketo isoster, 5-CITEP (Figure 3.7), and carboxylate β-DKA, L-731,988 (Figure
3.10), although having different aryl groups are ineffective to the same drug mutations
(T66I/M154I) in IN.211, 217 These findings suggest that regardless of the aryl and terminal
functional groups (tetrazole or carboxylate) present in the β-DKA molecule, the compounds
appear to bind at the same site. Interestingly, the drug resistant mutations described above are in
the vicinity of the tetrazole terminal functional group of 5-CITEP bound in the IN CCD and are
located 180° opposite to the Mg2+ ion bound to the catalytic residues D64 and D116.211 In the
chelation model, compound 5-CITEP should bind in an opposite orientation compared to the
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orientation observed when bound in the IN CCD crystal structure (PDB: 1QS4). Also, the aryl
group should contact the IN residues that undergo drug resistance mutations and the β-diketo
functional groups should interact with the Mg2+ metal ions. It was suggested that the drug
resistance mutations are capable of causing distortion of the molecule and result in loss of
interaction with the Mg2+ ions. The inhibitor binding site has adequate room and compounds can
be easily docked without steric hindrance in support of the chelation model and manual docking
is sometimes utilized to demonstrate the likely scenario of metal ion chelation.225 Alternatively,
since compounds containing both tetrazole and carboxylate terminal functional groups and are
resistant to the same mutations, it is also possible that the binding orientation is the same.
In collaboration with Panvirex, molecular docking studies were carried out to investigate the
mechanism of IN inhibition. Ultimately, clarity of the binding orientation of β-DKA class of
compounds is essential to aid in the elucidation of the role of the terminal functional groups of
the novel aminocarboxylate IN inhibitors and lead to the design of novel IN inhibitors.
The structural similarities between 5-CITEP and 3.5 (Table 3.2) and the availability of 5CITEP bound IN crystal structure provide an opportunity to understand the role of the terminal
functional group interactions. In collaboration with Panvirex, molecular docking experiments
were carried out in rigid ligand conformation since the planar or near planar configuration of the
inhibitors was discovered essential in our previous SAR studies (Table 3.4 and diol derivative
3.11). In all of the docking experiments, the 5-CITEP bound region was chosen as the inhibitor
binding site. The validity of the ligand docking was established by our collaborators by
comparing the orientation and geometry of our docking of 5-CITEP to the previously reported 5CITEP bound IN crystal structure. From this comparison it was determined that the structural
interactions are essentially the same as previously reported in the crystal structure.211 The major
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focus of our docking studies is the hydrogen bonding interactions of the terminal functional
group and the binding orientation of the inhibitors.
In the initial analysis of 5-CITEP bound IN
crystal structure all of the possible interactions of 5CITEP were mentioned. However, analysis of the
crystal structure in Ligand Explorer298 within the
hydrogen bonding threshold (3.3Å) with all of the
residues including the water molecules that are present
in the IN crystal structure suggest that the tetrazole
functional can only form two hydrogen bonds with
T66 and K159. The enolic α-keto group provides
hydrogen bond interactions with E-152 carbonyl and
K156 side chain nitrogen (Figure 3.18). The
Figure 3.18 Analysis of 5-CITEP
bound in IN Crystal Structure
(1QS4).

interaction of the α-keto group is not mentioned in the
initial docking studies of 5-CITEP. The only possible

interaction of the γ-keto group is with a water molecule which is about 5Å distance away. There

A

B
Carboxylate
3.5

Figure 3.19 Binding of the Carboxylate Derivative of 5-CITEP (3.5) (A) The flipped
orientation binding of 3.5 in ligand docking (B) The hydrogen bonding interactions of 3.5.
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were no hydrogen bond interactions noted with the nitrogen atoms of the tetrazole or indole
although they can interact electrostatically with the nearby N155 and Q148 (Figure 3.18). In
contrast, the carboxylate derivative of 5-CITEP (3.5) binds in a flipped orientation in the ligand
docking but the carboxylate terminal functional group interacts with the same IN amino acid
residues as that of the tetrazole (Figure 3.19A). The acid carbonyl oxygen of the carboxylate can
form two bonds between the side chains of K159 and T66. The carbonyl oxygen of the
carboxylate interacts with K156. In the flipped orientation the α-keto functional group of 3.5
interacts with N155 (Figure3.19B). The interaction between E152 and the α-keto functional
group of 3.5 is lost in the flipped configuration. However, the interaction of E152 is regained by
the hydrogen atom or nitrogen atom of the indole ring. The γ-keto group is within hydrogen
bonding distances with the D64 carbonyl but the carbonyl-carbonyl interactions are considered
unlikely. The aryl group is flanked by the region occupied by E152, D64, D116 and Q148 and is
within hydrogen bonding distances. In the ligand docking studies the compounds are in rigid
conformation but the aryl group is expected to undergo some degree of rotation following
enzyme binding as observed in the crystal structure bound 5-CITEP (Figure 3.20) and optimal
interactions with any one of the residues is possible.
The binding orientations of the tetrazole containing S1360 and the carboxylate containing compound L-731,
988 having different aryl groups were also compared
(Figure 3.21). These compounds bind essentially in the
same orientation as observed with 5-CITEP and the

Figure 3.20 The Overlapping
Geometry of Crystal Structure
Bound 5-CITEP (C) and Energy
Minimized Structure (E)

interactions with the functional motifs were essentially
identical. The tetrazole group of S-1360 interacts with T66, K156 and K159 (Figure 3.21B) as
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seen previously with 5-CITEP and L-731,988. The terminal functional group interactions of L731,988 is essentially the same with coordination to K159 and T66 with the acid carbonyl of the
carboxylate interacting with N155
(Figure 3.21D).
The potent ST inhibition
exhibited with hydroxamate containing
3.16 and complete loss of ST inhibition
with closely related 3.17 (Table 3.4),
lacking the hydroxamate terminal
functional group, provides an
opportunity to assess how the ST
inhibition potential of an IN inhibitor is
Figure 3.21 The Binding Orientation and Interactions of
S-1360 and L-731,988.

attained by docking the compounds in

the crystal structure and comparing the interactions. The compounds containing the OHA motif
bind in the 5-CITEP binding direction but in a flipped orientation similar to the carboxylate
derivative of 5-CITEP (3.5). In this configuration, the hydroxamate is centrally located between
K156, K159 and T66 but only K159 and T66 residues can interact with the hydroxyl group
(Figure 3.22B). The K156 is located 4.5Å from the nitrogen atom and 3.5Å from the hydrogen
atom of the hydroxamate. The oxamate carbonyl in the trans position can interact with N155 as
that of the carboxylate in the β-DK motif. The aryl group of 3.16 is in proximity of the D64,
D116, E152 and Q148 residues (Figure 3.22B).
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In this configuration it is easy to understand why 3.17,
A

a compound lacking a hydroxamic acid group, did not
show IN inhibition. Compound 3.17 binds in the
same configuration as that of 3.16 but the hydroxyl
group of 3.17 did not have any interactions with K159
or T66. Moreover, the hydroxyl group of
B

hydroxamate of 3.16 provides optimal hydrogen
bonding interactions with K159 and T66. Thus, it is
assumed that minimal terminal functional group
interactions with T66 and K159 may be considered as
the defining parameters of gain or loss of IN

Figure 3.22 Binding Orientation of
Hydroxamate Containing Compound 3.16.

inhibition. This observation is supported by the
consistent interactions of both the carboxylate and

tetrazole terminal functional group with K159 and T66. The interactions with K156 and N155
and all of the other interactions may be necessary for
inhibitor binding. The binding orientation of 3.21 containing
an aryl group with substitutions (2, 4-difluoro-1-(4isopropoxybenzyl) benzene, Figure 3.23) is comparable
to the orientation observed in the core compound 3.16.

Figure 3.23 Hydroxamate 3.21 with
Substituted Aryl Group.

The hydroxamate terminal group of 3.21 also interacts with K159 and T66 and the oxamate
carbonyl interacts with N155. The benzyl functional group occupies the position between D64
and D116 and the isopropoxy of the phenyl ring occupies the region surrounded by K156, E152
and Q158 (Figure 3.24).
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Ligand docking in the absence of DNA bound IN crystal structure has its limitations. However, it
can provide insight towards the preferred orientation
of compound binding. Although, the binding
configurations of various compounds are different,
the terminal functional group interactions with K159
and T66 are consistently noticed. Also, as previously
mentioned, several of the β-DKA inhibitors are
rendered ineffective when there is a mutation at T66I.

Figure 3.24 Binding Orientation of 3.21.
E152, Q148 and D116 are not shown for
clarity but locations are indicated.

The similarity of these compounds to interact with T66 suggests that the terminal functional
group interaction with T66 together with K159 prevents ST reactions. The progressive N155S
mutation encountered together with T66I as originally observed in the early carboxylate
containing compounds175 and the interactions of the functional domains with these residues
suggest selective evolutionary pressure to undergo drug resistance. Additional interactions
contributed by the diketo or oxamate functional domain with K156 or N155 along with E152 and
aryl group interactions with D64, D116 and Q148 can provide better binding affinity. These
ligand docking studies are more aligned with the proposed biochemical mechanism211 of IN
inhibition compared to the proposed chelation model217 of IN inhibition.
Studies indicate that the mutations of K156 or K159 impair DNA binding and mutation
of either of these amino acid residues is lethal to HIV-1 virus.280, 299 In the IN crystal structure
(PDB: 1K6Y) phosphate ion binding is observed between T66, H67 and C65 residues. The
preferential interactions of these amino acids with a phosphate ion led to the assumption that
these amino acid residues contact the phosphate backbone in DNA.281 The K156 and K159 bind
equally to both viral LTR end and host DNA. However, photo-cross-linking with the viral DNA
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end shows specific interaction of K159 and K156 with viral adenine280 adjacent to the scissile
phosphate of the CA dinucleotide at the 3’-end of the strand that undergoes 3’-processing
reaction. Based on this observation it was proposed that the K156 and K159 are involved in viral
DNA binding280 and the phosphate ion in the crystal structure (PDB: 1K6Y) could represent the
viral DNA.281 In this context, 5-CITEP inhibitor bound crystal structure (PDB:1QS4) was
superimposed with the phosphate ion bound IN structure (PDB: 1K6Y) to obtain a spatial
configuration of inhibitor interactions. Superimposed structures indicate juxtaposed position of
the inhibitor terminal residue with phosphate ion indicating that the site of viral DNA interaction
and inhibitor terminal functional group is the same (Figure 3.25). The superimposed crystal
structures docked with the 5-LTR end double-stranded DNA (dsDNA) phosphate backbone on
the phosphate ion of the phosphate ion bound IN structure (PDB: 1K6Y) suggests that the
inhibitor binding site spans between the binding sites of the two strands. Interestingly, the
terminal functional group of the inhibitor and the DNA phosphate backbone of 3’-P strand cross
at T66 and K159. The scissile phosphate 5’-to the GT dinucleotide that undergoes 3’-P is exactly

Figure 3.25 Supimposed 5-CITEP inhibitor
bound crystal structure (1QS4) and the
phosphate ion bound IN structure (1K6Y).

89

on the catalytic site at the Mg2+ ion (Figure 3.26 arrow). It is observed in the docking study that
the dsDNA confirmation is essential and it is consistent with the observation that single-stranded
DNA (ssDNA) fail to bind to IN. The DNA sugar residue of the strand that undergoes 3’-P
contact the K159 and its complementary strand sugar residues contact K156, E152, S157 and
Q148. Studies have shown that the CA dinucleotide overhang of the complementary strand of the
viral DNA that undergoes the 3’-P (T66 and K159 binding strand) forms a stable complex with
Q148204 and mutation of Q148I abolishes viral DNA binding.279 From this study, it is indicated
that the inhibitor terminal functional group interactions between T66, K156 and K159 and the
aryl moiety is likely to interact with the Q148 and the viral DNA bridges the viral LTR end and
prevents them from undergoing the ST reaction. Goldgur et al. proposed that the inhibitor may
bind between the unstacked bases mimicking DNA substrate interactions.211 This view is
consistent with the model (Figure 3.26) and the inhibitor functional motif is wedged between the
bases of the two strands and the aryl group occupies the position in which the viral DNA bases
undergo unstacking during the 3’-P reaction. It is apparent that the rigid conformation of the

Figure 3.26 Superimposed DNA Phosphate Backbone of dsDNA
(1K6Y) with 1QS4. The orientation of 3.16 docked in the 5-CITEP
binding site is shown. P:phosphate ion of 1K6Y and DNA; S: Sugar
Residue in DNA; Arrow: scissle phosphate; GT: nucleotides
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inhibitors is essential for wedging between the bases.
It has been reported in the literature that the β-DK inhibitors should be considered as
“interfacial inhibitors” because they interfere with host DNA binding.86 The structure based
analysis of SAR functions of various compounds is in agreement with the view of interfacial
inhibitors and provides a molecular mechanism of interaction. In comparing the interactions of
the terminal functional groups, only the carboxylate containing compounds additionally interacts
with N155 as compared to the tetrazole containing inhibitor (Table 3.5). In the OHA containing
inhibitors, the oxamate is shown to interact with residue N155; however, there is not a noticeable
interaction of the hydroxamate with K156. The interaction of the oxamate carbonyl with N155
suggests that the addition of a suitable terminal functional group can provide interaction with
K156 which is likely missing from the hydroxamate functional group.

β-DK carboxylate
β-DK tetrazole
OHA

T66
+
+
+

E152
+
+
+

K156 K159
+
+
+
+
+

N155
+
+

# of bonds
5
4
4

Table 3.5 Summary of Hydrogen Bond Interactions with β-BK and OHA Terminal Functional Groups

3.3.5. Design of the Oxalamate IN inhibitors: Isosteric Replacement of the Hydroxamate
Crystal structure based correlation of SAR studies indicate that the IN inhibitor
interactions are essentially acid-base interactions. One of the major focuses of this project is to
investigate the role of the terminal functional group interactions with the amino acid residues of
IN. The design of the target molecules is envisioned to contain three specific functional groups.
Each molecule is designed to contain the core functional motif (α, β-diketoamide), optimal aryl
groups (3-benzylphenyl or substituted 3-benzylphenyl) and a terminal group (proton donor or
acceptor or amphoteric functional groups) in a planar or near planar configuration (Figure 3.27).
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The molecular docking studies on the OHA motif completed in collaboration with Panvirex have
led to the identification of an oxamate serving
as a suitable surrogate for the β-DK functional
group. The tetrazole and pyridine were
identified as carboxylate isosters in the β-DK
class of compounds and the OHA motif studies
indicate that the hydroxamate can also serve as
an isosteric replacement. It is likely that the

Figure 3.27 General SAR of Designed Oxalamate
Scaffolds

tetrazole and pyridine can also function as a
hydroxamate isoster in the oxamate scaffold. In addition, various terminal functional groups will
be investigated for their potential to serve as isosteric replacements of the hydroxamate and the
interactions with the IN amino acids can be determined.

3.3.6. SAR of the Terminal Functional Groups of the Oxalamate Scaffolds
The oxalamate derivitates to be investigated and synthesized can be classified in three
groups (A-C) based upon the expected interactions of the terminal functional groups with the
HIV-1 IN binding site (Figure 3.28). The group A terminal functional groups are expected to

Figure 3.28 The interactions of β-DK class
of IN inhibitors with IN aminoacids and their
donor (D) and acceptor (A) functions.
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have the same interactions as the hydroxamate (Figure 3.29). While the position of the terminal
amine of A2 is similar to that of
hydroxamate 3.16, the terminal
amine of A3 is one carbon shorter.
Compound A3 is expected to have
potential electrostatic interactions
with T66 and K159. The group B
compounds B1 and B2 (Figure
3.30) contain a phosphate or sulfate functional group and due to the position of the terminal
functional group interaction is expected with the phosphate ion binding residue (Figure 3.25).
The interactions of B1-B5 are expected to be similar to the carboxylate or tetrazole interactions
with T66, K159 and K156. Additional interactions that are absent in the group A compounds are
expected from the imidazole derivatives (B6 and B7) and the pyrimindine derivative (B8). The
group C compounds (Figure 3.31) are of interest because the terminal functional groups cytosine
and uracil (C1-C3) of these compounds are expected to provide interactions. In biochemical
studies of viral LTR interaction uracil was found to interact with K156 and K159.280 The
carbonyl atom of the nucleotide and the phosphate or sulfate substituted in the pyrimidine (C4),
pyridine (C5), pyrazine (C6), triazole (C8) and imidazole (C9 and C10) can coordinate
additionally to the H67 and the amide nitrogen of the H67-T66 peptide bond. Ligand docking
with phosphate substituted imidazole in the oxamate motif of C9 containing the aryl group Ar-1
(Figure 3.33) shows interactions with H67, T66, K156, K159, N155, and E152 (Figure 3.32).
The phosphate of C9 interacts with backbone carbonyl of H67, the peptide bond nitrogen and
hydroxyl group of T66.
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The compounds from the three groups (A-C) will be synthesized in phases. For the initial
evaluation of the various terminal functional groups, the compounds that will be synthesized
will contain the Ar-1 aryl scaffold (Figure 3.33). The response of these compounds will be a
direct reflection of the terminal functional group under evaluation. The compounds that
demonstrate potent ST inhibition (<500 nM) will have the substituted aryl scaffold (Ar-2)
incorportated in place of Ar-1, which was determined to be necessary for potent antiviral activity
(Table 3.2, 3.9).
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Figure 3.32 The Ligand Docking Analysis of C9 (Ar-1 Aryl Group)

3.4 SYNTHETIC APPROACHES

3.4.1. Heteroaromatic α-Oxoacetic Acids: Cyanohydrin Chemistry
At the onset of this project we began to focus our attention on the synthesis of the several
of the heteroaromatic α-oxoacetic acids. It was envisioned that several of these compounds could
be obtained through cyanohydrin chemistry as proposed in Scheme 3.1. In general, commercially
available heteroaromatic aldehydes (3.22) could be synthesized into corresponding cyanohydrins
(3.23)300, 301 followed by hydrolysis of the cyanohydrin to obtain the α-hydroxy esters (3.24).302
The α-hydroxy esters could then be oxidized303 to obtain the α,β-diketo derivatives (3.25) that
could then undergo ester hydrolysis304, 305 to afford the desired α-oxoacetic acids (3.26). With
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access to the α-oxoacetic acids the final compounds (3.27) could easily be made utilizing amide
coupling conditions with desired aniline aryl scaffolds.306
Of particular interest was the synthesis of the 2-, 3-, and 4-pyridine heterocyclic
scaffolds. The availability of the pyridine carboxaldehydes and inexpensive reagents and
solvents made this an attractive route for synthesizing the pyridine series of compounds (Scheme
3.2). Sequential addition of potassium cyanide in water and acetic acid to the 2-, 3-, or 4pyridine carboxaldehyde (3.28, 3.29 or 3.30) afforded the corresponding racemic cyanohydrin
(3.31, 3.32 or 3.33).300 Cyanohydrins are well-documented as unstable and under basic
conditions they can be converted back to the carbonyl compound or racemize through reversible
loss of hydrogen cyanide (HCN).307 Therefore, it was necessary to proceed forward to the next
reaction step, hydrolysis of the cyanohydrins, immediately following cyanohydrin isolation. The
initial procedure (Scheme 3.2, method a) attempted for the hydrolysis of cyanohydrin derivatives
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(3.31-3.33) was a method reported for the acid-catalyzed hydrolysis of mandelonitrile, the
cyanohydrin of benzaldehyde, to obtain mandelic acid or the α-hydroxy ester (Scheme 3.3).302
Although, hydrolysis of the cyanohydrins (3.31-3.33) did occur there were several issues with
isolating the desired α-hydroxy acid and ester products (3.34-3.37) and yields were much lower
than anticipated (9-38% yield). This was due primarily as a consequence of working with a
heteroaromatic (pyridine) scaffold with acid/base properties and trying to adapt a procedure used
for the synthesis of an aryl aromatic scaffold. In order to move the synthesis forward with
optimal yields it was necessary to try and obtain a reaction procedure that included compounds
possessing similar chemical properties as to the heteroaromatic scaffolds. Also, any examples
found in the literature would allow us to gain an understanding on efficient work-up procedures
and product isolation techniques for our heteroaromatic scaffolds, which had previously been our
limiting factor. To our delight, a procedure from a 1986 patent was found for the synthesis of
pyrid-3-yl-hydroxyacetic acid (3.35) from the corresponding pyrid-3-yl cyanohydrin (3.32)
(Scheme 3.2, method b).308 The α-hydroxyacetic acids (3.34, 3.35 and 3.37) were obtained by
refluxing the corresponding cyanohydrin in concentrated hydrochloric acid (HCl). Instead of
isolating compounds using an acid/base work-up, as previously utilized,302 after reaction
completion (monitored by mass spectrometry (MS)) the HCl was removed and products were
simply obtained as pyridium chloride salts (3.34-3.37). Although, MS product peaks were
identified for all three isomers (3.34,
3.35 and 3.37) the NMR for the pyrid4-yl-hydroxyacetic acid (3.37)
remains unclear, possibly due to
impurities from the crude product, therefore, only the 2- and 3- derivatives (3.34 and 3.35) were
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carried forward in the synthesis. In addition to obtaining the α-hydroxyacetic acids (3.34 and
3.35), the procedure was easily modified by adding ethanol as a solvent and obtaining the ethyl
ester products. Only ethyl pyrid-3-ylhydroxyacetate (3.36) was successfully obtained using this
method. With the α-hydroxyacetic acids (3.34 and 3.35) or ester (3.37) in hand, the next logical
step in our linear sequence was to oxidize the α-hydroxy to the α-keto acid or ester (3.25).
Oxidative conditions using Collins reagent,303 Oxone,309 Fremy’s salt,310 and manganese
dioxide311 proved unsuccessful for the conversion of the α-hydroxyacetic acids (3.34, 3.35 and
3.36) to α, β-diketones. The unsuccessful attempts for this conversion is assumed to be a result
of reactivity issues with the pyridine series of compounds as well as solubility issues with the
starting α-hydroxy compounds.
An alternative route was required to obtain the desired oxoacetic acids. It was
hypothesized that a reasonable step to proceed forward was to first complete the amide coupling
reaction with α-hydroxyacetic 3.35 and aniline to obtain 3.43 (Scheme 3.3). Once 3.43 was
synthesized attempts to oxidize the α-hydroxy to ketone and provide 3.44 could be easily
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pursued. There were several advantages to using this route, the α-hydroxyacetic acids could be
used as their pyridium chloride salts and the terminal carboxylic acid functional group would be
removed and replaced by the amide bond and therefore solubility issues may be dealt with. Also,
unlike the α-hydroxyacetic acids, compounds 3.41 and 3.43 could be easily purified by column
chromatography. Initially, these reactions were rehearsed with aniline and once validated a
practical approach to the reaction was then performed with 3-benzylaniline, primarily due to cost
factors (3-benzylaniline 1g=$49.00; aniline 1g=$0.03). The reactions were conducted on both the
2- and 3-pyridine series of compounds; however, the 2-pyridine oxamide was not successfully
isolated from the reaction mixture. The amide coupling of pyrid-3-yl-hydroxyacetic acid (3.35)
and aniline or benzylaniline was completed with ease using standard amide coupling conditions
to obtain 3.41 and 3.43, respectively.306 To our delight, a recent publication utilizing MnO2 as the
oxidant for α-hydroxyacetic amides to oxamides was identified which led to the successful
synthesis of 3.42 and 3.44 (Scheme 3.3).312
Once this route was determined to be feasible to obtain the desired oxamide 3.44 for the
pyridine series of compounds it was of interest to explore other heteroaromatic scaffolds using
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the same methodology. Starting with 5-bromo-2-carbaldehyde we employed the same reaction
conditions as previously noted in Scheme 3.5. The reactions proceeded forward smoothly until
the amide bond formation between α-hydroxyacetic acid (3.47) and 3-benzylaniline.306 Although
it had appeared as if product had formed by monitoring the reaction with MS analysis, column
chromatography purification and isolation of all products from the reaction mixture
demonstrated that the production of 3.48 was unsuccessful. The reaction was repeated several
times with varying conditions but unfortunately, compound 3.48 was not isolated.
Similarly, the same cyanohydrin chemistries were employed with imidazole-2carboxaldehyde (3.50) and imidazole-4-carboxaldehyde (3.51) derivatives (Scheme 3.6).
Unfortunately, using the previously noted procedure for the pyridine series the conversion of
imidazole-2-carboxaldehyde 3.50 to desired imidazole-2-cyanohydrin 3.52 was not successful.
However, success was demonstrated with the conversion of imidazole-4-carboxaldehyde 3.51 to
imidazole-4-cyanohydrin 3.53 using this procedure.300, 301 The imidazole-4-cyanohydrin 3.53
was successively hydrolyzed to the α-hydroxyacetic acid 3.56 and also as the ethyl ester 3.55.308
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Analogous to problems faced with several of the other heteroaromatic derivatives previously
noted at this stage, the amide coupling of α-hydroxyacetic acid 3.56 with 3-benzylaniline was
unsuccessful and 3.58 was not isolated .306
The synthesis of the furan oxalamate derivative began with the coversion of furfural
(3.61) to the cyanohydrin 3.62 (Scheme 3.7).313, 314 An attempt to convert the cyanohydrin 3.62
to the methyl ester 3.63 via the corresponding imidate through a modified Pinner reaction315 was
unsuccessful and alternative routes to obtain 3.63 were explored.316 However, due to the
instability of the furan scaffold, especially under acidic conditions, this route was abandoned and
more favorable routes were pursued (Scheme 3.13 and 3.19, compound 3.98).
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3.4.2. Heteroaromatic α-Oxoacetic Acids: Activation of Pyridium Salts for Electrophilic
Acylation
At the same time that the cyanohydrin chemistries were underway, alternative routes to
obtain the pyridine derivatives were also being investigated. It is well-known that electrophilic
aromatic substitution reactions of pyridines are extraordinarily challenging. Instead of Csubstitution at the pyridine ring, the electrophile typically forms an adduct with the pyridine
nitrogen, which even further deactivates the already electron deficient pyridine ring toward
electrophilic substitution. For example, the direct nitration of pyridine requires a reaction
temperature of 330°C to provide only a 15% yield of 3-nitropyridine.317
To overcome the lack of reactivity of pyridines, pyridines can be converted into a
temporarily activated electron rich 1,4-dihydropyridine which features strongly enhanced
reactivity towards electrophiles at the 3-position.318-322 Klapars et al. recently reported an indirect
method for the 3-acylation
of pyridines by converting
recalcitrant pyridinium salts
into Reissert-type 4-cyano1,4-dihydropyridines in a
one-pot procedure. In
general, this method works
favorably if the equilibrium mixtures are treated with strong acylating agents such as ethyl oxalyl
choride. However, treatment with weaker acylating agents does not provide the desired
dihydropyridines. Instead, products resulting from the reaction of the cyanide ion, present in the
equilibrium mixture, can be observed (Scheme 3.8). This method was a good alternative to the
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cyanohydrin chemistry and was used to obtain ethyl 3-pyridineglyoxylate (3.67) which was used
for the synthesis of the 3-pyridine oxalamate derivative (3.68).323
The optimized procedure (Scheme 3.9) starting with pyridine (3.65) followed the
sequence of N-alkylation with methyl chloromethyl ether (MOMCl) and addition of the soluble
cyanide source benzyltrimethylammonium cyanide (BnMe3N+CN-) to generate the activated
dihydropyridine 3.66, and C-acylation with ethyl oxalyl chloride in the presence of Hünig’s base.
The aromatization of dihydropyridine 3.66 to the desired 3-acyl pyridine 3.67 was accomplished
with the help of zinc chloride (ZnCl2) as a mild cyanophile. Upon addition of ZnCl2 to 3.66, a
rapid decyanation to the pyridinium salt which activated the MOM group toward deprotection
via nucleophilic displacement. This was accomplished by refluxing the crude pyridinium salt
mixture in ethanol, resulting in the formation of ethyl 3-pyridineglyoxylate 3.67 in moderate
yields.
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Initial attempts of amide formation by heating ethyl ester 3.67 in the presence of 3benzylaniline in a CEM microwave synthesizer for 10 min at 65 °C and an initial power of 65 W
or refluxing the reaction mixture overnight did not give corresponding oxamide (3.44) and only
starting material (3.67) remained.324 The ethyl 3-pyridineglyoxylate 3.67 was then subjected to
amide coupling conditions using sodium hexamethyldisilazide (NaHMDS) to deprotect the
aniline and then to react with the ethyl ester to give the required amide 3.44. Although, the
desired amide was obtained, the product was contaminated with an undesired Schiff-base
product 3.68. The thin-layer chromatography (TLC) profile of the isolated product from the
reaction mixture appeared as one spot; however, NMR and HPLC analysis revealed both
products 3.44 and 3.68 (50:50 ratio).

3.4.3. Heteroaromatic α-Oxoacetic Acids: Heterocyclic α-Iminonitriles
There are several synthetic procedures for the preparation of α-Iminonitriles (Schiffbases), however, most of them are multistep processes and have a limited application scope.325337

Jursic et al. reported this procedure as for the conversion of heterocyclic aldehydes (3.28-

3.30) into heterocyclic methylidene-p-hydroxyanilines , heterocyclic α-iminonitriles (3.75-3.77),
and finally into heterocyclic α-oxoacetic acids (3.38, 3.39 and 3.78).338 Initially, this route was
anticipated as an efficient three-step route for the synthesis of heteroaromatic α-oxoacetic acids
(Scheme 3.10).338 A simple reaction of 2-, 3- and 4-pyridine carboxaldehydes (3.28-3.30) with
p-aminophenol in methanol resulted in the corresponding heterocyclic imines (3.69-3.71) in high
purity and yields. The heterocyclic imines were then treated with sodium cyanide and dimethyl
sulfoxide (DMSO) and subjected to air oxidation to yield the α-iminonitriles (3.75-3.77).
Following the reported procedure, preparation of 3.77 was straight-forward and product was
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identified with ease in high yield. Interestingly, it was extremely difficult to identify and purify
both of the 2- and 3- pyridine α-iminonitrile derivatives (3.75 and 3.76) following the reported
procedure. However, after carefully modifying the purification method both of the desired αiminonitriles (3.75 and 3.76) were identified successfully. With all three α-iminonitriles available
the next step invoked hydrolysis to the desired heterocyclic-α-oxoacetic acids (3.38, 3.39 and
3.78). The α-iminonitriles represent a class of compounds that should hydrolyze rather easily to
the desired heterocyclic-α-oxoacetic acids.338, 339 However, following the reported approach of
stirring an aqueous hydrochloric acid suspension of heterocyclic α-iminonitrile followed by
separation of the heterocyclic-α-oxoacetic acid (3.38, 3.39 and 3.78) from p-aminophenol (3.79)
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failed. Hydrolysis was attempted several times with varying reaction conditions, times and
temperatures.339-342 Collectively, the hydrolysis methods tested did not yield the desired
heterocyclic-α-oxoacetic acids (3.38, 3.39 and 3.78), and the products identified from the
hydrolysis reactions were nicotinic acid (3.80-3.82) and p-aminophenol (3.79) co-eluting as a
mixture (Scheme 3.10). After reviewing the literature it became apparent that mechanistically,
the hydrolysis of the α-imino functional group happens at a faster reaction rate compared to the
nitrile functional group and therefore lending to the formation of nicotinic acid instead to αoxoacetic acids (3.11).339-342 Although the published method reports the synthesis of α-oxoacetic
acids there is skeptism due to the lack of reproducibility. It is worth mentioning that since the
publication of this preliminary report there have been no other reports using this method to
obtain α-oxoacetic acids in the literature. Also, comparing the reported NMR values for 3.39 in
this paper338 to known and estimated values of 3.39 shows discrepancy (Figure 3.35).
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In order to elucidate a reason for this and potentially come to a more reliable reaction
protocol, we chose to investigate alternative reaction conditions. Additionally, when aniline 3.85
was used as an alternative to the p-aminophenol 3.79, containing an electron donating hydroxyl
group, the same reaction products were obtained (Scheme 3.10).We decided to use the lessons
learned from this chemistry to explore an alternative route to obtain the α-oxoacetic acids
(Scheme 3.12). It was evident that the major hurdle to overcome was the competing hydrolysis
reaction rate of the α-imino group compared to that of the nitrile functional group. We
envisioned that a more robust route would invoke an α-amino group in place of the α-imino
group. Therefore, a simple and efficient one-pot, three component method was used for the
synthesis of α-aminonitrile 3.88.343 The α-aminonitrile 3.88 was subjected to Pinner synthesis to
hydrolyze the nitrile and afford the amino ester 3.89.344 The next step towards the synthesis of
the α-oxoacetic acid 3.39 was to oxidize the α-amino to an α-imino functional group with 2, 3dichloro-5, 6-dicyano-1, 4-benzoquinone (DDQ)345, 346 to furnish 3.90, in preparation of
hydrolysis of both the ester and α-imino functional group to provide α-oxoacetic acid 3.39.338
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3.4.4. Aryl α-Keto Esters and Acids
In the past several decades, much attention focused on the synthesis of α-keto esters.
Several routes were reported including the oxidation of α-hydroxy esters with either pyridinium
chlorochromate (PCC) or Dess-Martin periodinane (DMP),347, 348 Friedel-Crafts acylation, 349
oxidative cleavage of cyano keto phosphoranes,350 hydrolysis and esterification of acyl
cyanides,351 the reaction of organometallic species with oxalic ester derivatives,352 and acylation
or alkylation of mono-substituted 1,3-dithianes.353 The most common route for the synthesis of
α-keto esters is the reaction of Grignard reagents with oxalyl chloride.354 However, all of these
methods involve either strict reaction conditions, complicated procedures, or in some instances
low yields. Collectively, all of the drawbacks associated with these procedures have limited the
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synthetic application of these methods to obtain α-keto esters. Recently, Zhaung et al. reported
an efficient one-pot synthesis of α-keto acids and α-keto esters by using selenium dioxide to
oxidize aryl ketones (Scheme 3.13).355 Although there are several routes for the synthesis of aryl
α-keto esters as noted above, this method provided a convenient and efficient route for the
synthesis of our aryl α-keto acids (Figure 3.34). With the synthesis outlined in Scheme 3.14,
numerous compounds could be effortlessly synthesized starting with readily available aryl
ketones 3.91 to obtain the α-ketoacids 3.92. The α-ketoacids produced could then be used in
subsequent amide coupling reactions306 with aniline or 3-benzylaniline to obtain target
compounds 3.93-3.105 (Figure 3.34).
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The brominated aryl
oxalamate compounds 3.95 and 3.96
were of particular interest because
they are viable precursors for the
palladium-catalyzed cross-coupling reaction with dialkyl phosphites (Scheme 3.15).356
Traditional synthetic methods for aryl- and vinylphosphonic acid class of compounds include
Friedel-Crafts reactions,357 Cu-catalyzed reactions of diazonium salts with PCl3,324, 358
nucleophilic substitution reactions of activated aryl halides and sodium dialkylphosphites,359 Nior Cu-mediated couplings between aryl halides and trialkyl phosphites,360-364 and reaction of
arylmetal derivatives and trialkyl phosphites.365-367 However, due to the aggressive and harsh
reaction conditions required, these transformations tend to be incompatible with sensitive
functionalities.356 A potentially more general access to dialkyl arylphosphonates based on
palladium-catalyzed reaction of aryl halides with dialkyl phosphite has been previously reported
by Hirao et al. (Scheme 3.15).368-372 Unfortunately, when Gooβen et al. employed these
previously published procedures for the preparation of various functionalized aryl phosphonates
the reactions provided unsatisfactory yields.356 Therefore it was necessary to explore alternative
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reaction conditions to develop an efficient and broadly applicable approach for the crosscoupling of aryl bromides with dialkyl phosphites. The best results were obtained using
Pd(OAc)2 as the Pd-source, triphenylphosphine as the phosphine source, a sterically demanding
tertiary amine as the base, and use of the protic solvent ethanol. Remarkably clean reactions were
observed even with functionalized molecules bearing keto, nitro, ester, thioether, nitrile and even
hydroxyl functional groups.356 Therefore, this method seemed reasonable to follow with the α, βdiketo containing oxoamide starting materials 3.95 or 3.96 (Scheme 3.16). After reaction
completion and subsequent purification by column chromatography, two products were isolated.
Unfortunately, neither product was the desired aryl phosphonate (3.111 or 3.112), as determined
by spectroscopic methods of analysis. The products isolated from both the 3- and 4-substituted
derivatives were 3.113 and 3.115 or 3.114 and 3.116, respectively (Scheme 3.16). It appears
from the reaction mechanism that products 3.113 and 3.114 are a result of nucleophilic addition
to the reactive α-keto carbonyl with diethyl phosphite, happening at a faster reaction rate than the
phosphorus-carbon bond coupling reaction. Products 3.115 and 3.116 are a result from the
diethyl phosphite acting as a hydride source and reducing the α-keto carbonyl group. Therefore,
it can be concluded that both products are a result from the reactivity of the α-carbonyl ketone. A
solution for this problem was to install the phosphonate ester first (3.119 or 3.120, Scheme 3.17)
and then oxidize the aryl ketone to obtain the α-hydroxyacetic acid (3.121 or 3.122).306, 355 Once
the phosphonate α-hydroxyacetic acid derivatives were available, amide bond formation with 3benzylamine (3.111 or 3.112) and deprotection of the phosphonates under mild conditions to
afford the phosphoric acid oxalamate derivatives 3.123 or 3.124.306, 373 Unexpectedly, the
reaction yielded a mixture of multiple products of mono-dealkylated, di-dealkylated instead of
the phosphonate ester α-keto acids (3.121 and 3.122). It was quickly apparent from the two
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methods employed that an alternative route was warranted for the synthesis of the phosphoric
acid oxalamate derivatives.

3.4.5. Negishi and Suzuki Cross-Coupling Reactions with Acid Chlorides
In 2011, Kim et al. published a procedure for a Ni-catalyzed cross-coupling reaction of
organozinc reagents with acid chlorides.374 From the series of compounds derived from this
study, of particular interest was the Negishi cross-coupling reaction between ethyl 2-oxalyl
chloride and an aryl zinc bromide (Scheme 3.18). This was of interest because the reaction
conditions reported were well-tolerated by the acid chloride which contained two ester
functionalities. This procedure seemed to be feasible method for the synthesis of the furan
oxalamate scaffold 3.107
(Scheme 3.19). The furan
zinc bromide 3.126 was
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synthesized375 and subjected to Ni-catalyzed cross-coupling conditions to afford 3.127 in
moderate yield. During the time that this synthetic route was being pursued an alternative route
to synthesize the furan oxalamate 3.107 (Scheme 3.14) was discovered and this route was
abandoned. However, the use of acid chlorides, specifically diketo acid chloride prompted us to
pursue alternative interesting and less exploited cross-coupling reactions (Scheme 3.21).

Currently, there is no procedure reported for the Suzuki cross-coupling of diketo acid
chlorides with arylboronic acids. In 1999, a procedure by Haddach et al. for the Pd-catalyzed
cross-coupling of acid chlorides with arylboronic acids was reported (Scheme 3.20).376 This
method provided a convenient route to ketones, since boronic acids and acid chlorides are
inexpensive commercially available starting reagents. The Suzuki coupling reaction is generally
carried out as a two-phase Pd-catalyzed reaction in ethanol, toluene and water.377 These
conditions are not suitable for the coupling of acid chlorides with boronic acids. However, this
procedure synthesis ketones from acid chlorides and boronic acids under anhydrous Suzuki
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cross-coupling reaction conditions with Pd-catalyst and cesium carbonate in toluene (Scheme
3.20).376
It was projected that Suzuki cross-coupling with diketo acid chlorides and boronic acids,
derived from this seminal paper,376 would offer the ability to synthesize a library of oxalamate
derivative scaffolds for this project. Several boronic acids with ethyl oxalyl chloride (Scheme
3.21, Table 3.6 ) were subjected to Pd-catalyzed cross-coupling conditions using similar reaction
conditions as reported in the literature. Both NMR and mass spectral analysis of the products
isolated from the performed reactions determined that although in several instances the desired
diketo ester product had formed it was in undesirable yields (0-28% yield). The anticipated
products in the crude reaction mixture were among several byproducts. One of the most
commonly observed byproducts formed from these reactions was the homocoupling of the
boronic acid to itself rather than boronic acid coupling to the acid chloride. An interesting
observation was noted when Tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) was used as
the catalyst for these Suzuki-cross coupling reactions. The (Pd2(dba)3) catalyzed reactions
provided some of the higher yields
compared to the reactions using
alternative palladium catalysts. However,
when the desired products were isolated
they were co-eluted as inseparable
mixtures with dibenzalacetone (dba) that
had been dissociated from the (Pd2(dba)3)
catalyst (Figure 3.35). Due to the
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undesirable yields and complicated reaction mixtures these chemistries were not continued as a
method for obtaining the oxalamate scaffolds.

Figure 3.36 TLC of Desired Product B co-eluting with dba A

Reference

Boronic Acid

Boronic
Acid Eq

Cs2CO3

Catalyst

Catalyst
Eq

Results

NB11P53

1

2

2.5

Pd(PPh3)4

2.57 mol%

Several products
(homocoupling)

NB11P57

1

3

2.5

Pd(PPh3)4

1.61 mol%

Isolated major product
(byproduct)

NB11P60

1

3

2.5

Pd(PPh3)4

1.04 mol%

Several products

NB11P66

1

2

2.5

Pd(PPh3)4

4 mol%

Several products

NB11P83

1

2

5

Pd(PPh3)4

5 mol%

homocoupling

NB11P86

1

2

5

Pd(PPh3)4

5 mol%

Several products
(could not isolate prod)

NB11P87

1

2

5

Pd(PPh3)4

5 mol%

Several products
(could not isolate prod)

NB11P93

1

2

2.62

Pd(PPh3)4

5 mol%

Several products
Mass spec shows
product

NB11P97

1

3

3

Pd(PPh3)4

5 mol%

homocoupling

NB12P03

1

3

3

Pd2(dba)3

5 mol%

TLC matches Negishi
NMR-shows but w/dba

NB12P05

1

3

3

Pd(OAc)2

5 mol%

homocoupling

NB12P07

1

3

3

Pd2(dba)3

5 mol%

TLC-one bright spot
NMR-mixture w/dba

NB12P15

1

3

3

Pd2(dba)3

5 mol%

NB12P17

1

3

3

Pd2(dba)3

5 mol%

TLC-one bright spot
NMR-mixture w/dba
TLC-one bright spot
NMR-mixture w/dba

Table 3.6 Suzuki Methodology Summary of Coupling with Acid Chlorides and Aryl Boronic Acids
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3.4.6. Friedel-Crafts Acylation
In the early 2000s, with the emergence of resistance from the commonly prescribed
marketed HIV therapeutics, Bristol-Myers Squibb (BMS) implemented a screening program to
identify new classes of HIV-1 inhibitors that acted against novel drug targets without bias for a
particular mechanism of action.378 This initiative produced a number of compounds that
interfered with HIV-1 replication in cell culture without overt cytotoxicity. Most of the
compounds discovered were characterized as NNRTIs. However, one compound, the simple
indole glyoxamide (A, Figure 3.36), emerged as a molecule with a unique mechanistic profile.379,
380

Time-of-addition experiments eventually elucidated that the indole glyoxamides (Figure 3.36)

inhibited an early event in HIV infection that was subsequently determined to be interference
with the binding of HIV-1 gp120 to the host-cell receptor CD4.380

The ease of the synthesis for the indole glyoxamide class of compounds using FriedelCrafts acylation chemistry, their advent as HIV-1 entry inhibitors with similar structural features
to our proposed molecules made these scaffolds interesting molecules to pursue and test as HIV1 IN inhibitors. Moreover, considering the analogous structural features of the library of
synthesized molecules from this dissertation project it may be worthwhile to also evaluate our
compounds as HIV-1 entry inhibitors.
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As shown in Scheme 3.22 and 3.23, Friedel-Crafts acylation of substituted indoles led to
the synthesis of several indole glyoxamides. Due to the high nucleophilic character at the 3position of indole, the treatment with oxalyl chloride of appropriate indoles 3.138 produced the
corresponding 2-(1H-indol-3-yl)-2-oxoacetyl chloride intermediates 3.139 which were then
coupled with aniline or 3-benzylaniline in alkaline medium in a one-pot procedure to give the
desired indole oxalamate derivatives 3.140-3.144 (Scheme 3.22).381, 382 The synthesis of
azaindole (3.148) is depicted in Scheme 3.23 and is initiated by acylating 7-azaindole (3.145)
with ethyl chlorooxoacetate in the presence of AlCl3 to afford 3.146.383 Hydrolysis of the
resulting ester, using K2CO3 in aqueous MeOH,305 followed by coupling with 3-benzylaniline
afforded the azaindole glyoxamide 3.148.306
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3.5. BIOLOGICAL EVALUATION

The compounds designed and synthesized from this dissertation project were completed
with an agreement between the University of Mississippi and Panvirex, LLC. In summary,
several of the compounds (3.41-3.44, 3.95-3.107, 3.113-3.115, 3.140-3.144 and 3.148) that were
synthesized during the course of this project have been submitted to our collaborators at
Panvirex, LLC. and the biological data is currently pending at the time of writing this
dissertation. The synthetic analogues will undergo biological screening to determine the IN
inhibitory activity, the sensitivity to known IN inhibitor mutations and analyzed for their
antiviral efficacy.

3.5.1. Determination of IN inhibition
The selectivity of β-DKA class of IN inhibitors towards the inhibition of the ST-reaction
provides specificity to the viral enzyme mediated reaction. Several types of assays to determine
IN inhibition have been previously described in the literature.203, 384-389 The high-throughput
electrochemiluminescent (ECL) based determination of the ST inhibition reaction and the solid
phase ELISA assay (Biomek® robotic system) will be used for the evaluation of the synthesized
chemical scaffolds (Figure 3.37). The principles of the ECL and ELISA assays are essentially the
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same, however, in the solid-phase ELISA assay either biotin or fluorescent FTC (fluorescein-5thiosemicarbazide) labeled DNA is used and in the ECL assay the DNA label is a
chemiluminescence molecule. The high-throughput ECL assay (BioVeris Inc., Gaithersburg,
MD) is commercially available and will be used in routine analysis of IC50 potency of the
synthesized compounds.
Both the solid-phas ELISA assay and high-throughput ECL can only determine the
inhibition of the ST reaction, which is important from a drug development perspective. However,
it is important to also determine the inhibitor selectivity of the ST-reaction over the 3’-P reaction.
The traditional gel-based assay containing the labeled 21-mer duplex oligonucleotide
corresponding to the U5 end of the HIV LTR sequence can determine both ST-inhibition and 3’P inhibition. Although this assay is cumbersome and tedious, it will be of great importance from
a mechanistic perspective. The evaluated compounds that show ST inhibition from the highthroughput ECL assay will be evaluated using this gel-based assay to determine if any inhibition
of the 3’-P
reaction is
also seen.

Figure 3.37 Standard ELISA ST IN Assay251

3.5.2. Determination of Sensitivity to Known IN Inhibitor Mutations
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It has been previously reported that the β-DKA class of compounds induce progressive
drug resistance mutations of T66I/S153Y, T66I/M154I or T66I/SI53Y/N155S. These mutations
in the enzyme do not alter the enzyme efficiency as observed with the emergence of drug
resistant viruses and also established by in vitro studies. In this regard, compounds synthesized
will be evaluated against the IN enzyme containing either an individual mutation or a
combination of mutations. Analysis of ST inhibition in IN mutations of K156 and K159 or Q148
are not meaningful because these residues are involved in host and viral DNA binding and ST
inhibition is lost if these residues are mutated. Similarly, mutations of the residues in the
catalytic triad, E152, D64 and D116, are not possible. The histidine (His) Tag-recombinant
cDNA clones of the IN enzyme containing T66I, S153Y and M154I are readily available at
Panvirex, LLC and the combination of mutants were obtained as a gift from Dr. Vinay Pathak, at
the National Cancer Institute (NCI).

3.5.3 Determination of Antiviral Efficacy
The antiviral activity of the compounds determined to have IC50 values of <500 nM will
be determined in multiple rounds of replication inhibition assays comparable to a Phase I clinical
study. The cytotoxicity of the newly synthesized molecules will also be evaluated prior to being
subjected to the antiviral inhibition assay. Briefly, cells infected with HXB-2 or CEM-TART
cells infected with HIV-1 MC99IIIB∆Tat-Rev viral strains390 will be added to uninfected cells
and the extent of viral replication will be determined using commercially available ELISA kits .
The EC50 will be determined by comparing the viral replication of cells exposed to synthesized
inhibitors to no inhibitor control.

120

3.6 CONCLUSIONS AND FUTURE DIRECTIONS
The identification and characterization of HIV-1 as the causative pathogen of AIDS in
1984 triggered an enthusiastic effort to identify antiviral drugs capable of interrupting replication
of the virus that in absence of therapeutic intervention represents a death sentence.391, 392
HIV-1 encodes three enzymes that are required for viral replication: reverse transcriptase (RT),
protease (PR) and integrase (IN). To date, there are 25 ARV drugs approved for the treatment of
HIV-1 infection and AIDS. FDA-approved therapies target three steps of the HIV life cycle:
reverse transcription, proteolytic maturation and fusion. Triple therapy, commonly referred to as
highly active antiretroviral therapy (HAART) is the standard treatment for HIV. HAART
consists of a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI)
in combination with two nucleoside reverse transcriptase inhibitors (NRTI.)86 HAART, however,
is often not well tolerated by patients, requires discipline, is expensive and leads to multidrug
resistance and cross-resistance.86, 165, 393 Despite the quantity of marketed antiretroviral HIV-1
drugs, there are only a limited number of mechanistic drug classes to build combinations from.
HIV-1 exhibits poor fidelity of replication which eventually leads to the emergence of resistance
viruses and treatment failure making the development of new inhibitors essential for continued
therapy.
The third viral enzyme, IN, has emerged as an attractive target because it is necessary for
stable infection and has no cellular human equivalent.86 Substantial progress has been achieved
since IN was first recognized as an important antiretroviral drug target. In October 2007, the
FDA approved raltegravir, the first example of a drug active against IN, validated the enzyme as
a new target in the field of anti-HIV drug research.227, 228, 394 Over the last decade, a number of
IN inhibitors have been discovered but many of these compounds are toxic, do not show antiviral
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activity or display decreased potency. Therefore, new classes of potent IN inhibitors are
desperately needed. The β-diketo (β-DK) class of compounds has emerged as one of the most
successful classes of IN inhibitors. Although several β-DK inhibitors with potent antiviral
activity are known, compounds containing β-DK motifs have limitations in drug development.
The overall objective of this dissertation was to design and synthesize a novel series of
IN inhibitors that retain the favorable characteristics of the β-DK scaffolds but are devoid the
“undruggable” properties. Several analogs proposed from crystal structure-based correlation and
structure-activity relationship studies were synthesized during the course of this dissertation
project. Many of the originally projected synthetic pathways to obtain these inhibitors, although
initially appearing as reasonable routes, failed in the practical setting. These challenges led to the
exploration of alternative chemistries and allowed us to gain new insight into alternative
chemistries as a mechanism to synthesize several of the oxalamate scaffolds.

3.6.1. Alternative Strategy for the Synthesis of α, β-diketo Amides
A common strategy employed for the synthesis of the majority of desired α, β-diketo
amide desired compounds was to establish the α-hydroxy or α-carbonyl in the early stages of
compound synthesis (Scheme 3.24). Although these routes seemed feasible originally, and
several compounds were obtained through these methods, there were also several problems
encountered when exploiting these synthetic routes. For example, the initial attempts to oxidize
the α-hydroxy functional group of α-hydroxy acetic acids were not straightforward (Scheme 3.2),
the anticipated Pd-catalyzed coupling of aryl bromides with diethyl phosphite failed due to the
reactivity of the electrophilic α-carbonyl functional group (Scheme 3.16), and hydrolysis of the
α-iminonitriles to provide diketo acids was unsuccessful because the hydrolysis reaction rate of
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the α-imino functional group was faster than that of the nitrile functional group (Scheme 3.11). A
common theme observed with these unexpected difficulties was the involvement of the αhydroxy or α-carbonyl functional group. In terms of optimizing and planning a more efficient
synthetic route to obtain α, β-diketo amide derivatives the reactivity of the α-functional groups
was considered. An alternative synthetic route the observed byproduct (compounds 3.115 and
3.116) isolated from the phosphonate coupling reaction and the challenges associated with the
chemistries described above was to begin the synthesis without the α-hydroxy or α-carbonyl
functional group in place and then oxidize to the α-keto amides at a later step in the linear
synthesis (Scheme 3.25 and 3.26).

After reviewing the literature for chemistries that are concurrent with the new synthetic
approach a few appealing synthetic opportunities were discovered. One option for the new
synthetic route is to do a direct α-oxidation of amides or esters using SeO2 as a metal oxidant.395399

This oxidation of the methylene group adjacent to the carbonyl using SeO2 is generally

referred to as a Riley oxidation and this method has been reported previously with a variety of
aromatic and heterocyclic scaffolds.395-399 It would be beneficial to employ this reaction using
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commercially available or easily synthesized aryl- or heteroarylacetamides or esters (Scheme
3.25).

In 2012, Shao et al.400 reported a simple synthetic route using a sodium bicarbonate
promoted aerobic oxidation reaction to prepare α-keto amides from easily available aryl- or
heteroarylacetamides (Scheme 3.26). This method was explored on a variety of functionalized
molecules that were tolerated and readily to give the corresponding α-keto amides in good yields.
The oxidation reaction was not limited to simple benzene-containing aromatics, substrates
containing the substructure of naphthalene, pyrimidine, pyridine, and aliphatic chains also gave
good yields. This route would potentially offer the ability to synthesize several structurally
diverse compounds conviently without the use of toxic reagents and harsh conditions.
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3.6.2. Synthetic Strategies for Alternative Aryl Scaffolds
The main focus of the compounds synthesized to date was to determine the SAR and role
of the terminal functional group in regards to IN inhibition. Almost all of the compounds
developed contained either an aniline or diphenylmethane as the aromatic functional group. One
of the long term goals of this project is to develop analogues with “decorated” aromatic
substituted scaffolds in place of the diphenylmethane scaffold (Figure 3.33). Preliminary data
showed that substitutions on the phenyl and benzyl ring of diphenylmethane further increase the
antiviral activity of compounds to nM activity (3.7-3.9, Table 3.2).
It was originally proposed that (2,4-difluoro-1-(4-isopropoxybenzyl)benzene) could be
synthesized using a three-step protocol (Scheme 3.27). Initially, a Kumada coupling of 1-chloro2,4-difluorobenzene (3.155) and the appropriate Grignard reagent using Ni/C catalyst to afford
diaryl methane (3.156).401, 402 Electrophilic nitration of 3.156 with ammonium nitrate/TFAA
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utilizing the ionic liquid 3-methylimidazolium (emim) to produce the nitration product, and
subsequent catalytic hydrogenation will afford aniline 3.157.403 However, initial attempts by the
Rimoldi research group to synthesize 3.157 using this method were unsuccessful. Therefore,
alternative routes to obtain substituted aryl scaffolds were considered.

In 2010, Fan et al.404 published an efficient and practical method to a wide range of
perfluorinated unsymmetrical diarylmethanes with good to excellent yields and high
regioselectivity using a direct Pd-catalyzed benzylation (Scheme 3.28). The most widely used
approaches to this functional group array rely on cross-couplings of a stoichiometric amount of
organometallic aryl with electrophiles.405 However, this “prefunctionalization” process suffers
from the requirement of additional steps for the preparation of organometallic reagents and the
incompatibility of functional groups.404 In this regard, direct benzylation of arenes and
heteroarenes has been successfully discovered recently and this current method provides a
method for the direct benzylation of highly electron-deficient perfluorenes with various
functional groups.404, 406-408 Collectively, these methods may provide access to a variety of
substituted aromatic scaffolds.
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3.6.3. Opportunities for Alternative Biological Targets
3.6.3.1 p38α Mitogen-Activated Protein Kinase Inhibitors
The p38α mitogen-activated protein kinase (MAPK) is a serine-theonine protein kinase
and is recognized as a highly attractive target for therapeutic intervention. It is well established
the proinflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-β), play
an important role in the pathogenesis of various inflammatory diseases and that the stressactivated signal transduction pathway leading to these cytokines is in part regulated by p38α
MAPK.
Recent publications like that of Mavunkel
et al. 409 report the design and synthesis of MAPK
inhibitors based on 4-fluorobenzylpiperdine
heterocyclic oxalyl amides (Figure 3.38). In 2008,
Montalban et al.410 identified a novel series of p38α
MAPK inhibitors through structure-based design and
interestingly the α-ketoamide series of compounds were
examined for p38α MAPK inhibition. Although, the
representative molecule (Figure 3.39) only showed
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moderate TNF-α inhibition it may eventually be used as a lead molecule towards the
development of more potent p38α MAPK inhibitors. Although the synthesized α-ketoamides
from this dissertation project were designed as HIV-1 IN inhibitors it would be interesting to
examine the activity of the molecules as MAPK inhibitors, considering the similar structural
features of the compound. Additionally, numerous studies have shown that the MAPK signal
pathway can regulate the replication of HIV-1, but exactly how each MAPK pathway affects
HIV-1 infection and replication is not fully understood.411
3.6.3.2 Inhibitors of HIV-1 Attachment
The interaction of HIV-1 surface glycoprotein gp120 with CD4, a glycoprotein receptor
expressed in mammalian cells, is the critical first step of a series of several events that allows
virus access to the host cells.71 As mentioned previously in this dissertation with the synthesis of
the indole glyoxamide derivatives, several structurally similar indole glyoxamides (A, Figure
3.36) were determined previously to inhibit an early event in HIV infection. These inhibitors
were subsequently shown to be interfering with the binding of HIV-1 gp120 to the host-cell
receptor CD4. 379, 380 With the apparent similarities of the indole glyoxamide HIV-1 attachment
inhibitors and the α, β-diketo amides class of compounds, it is likely that the synthetic analogs of
this dissertation project may possess inhibitory activity against HIV-1 attachment.
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IV. EXPERIMENTAL

General Methods:
Moisture and oxygen sensitive reactions were carried out in flame-dried glassware under
an inert argon atmosphere. Anhydrous tetrahydrofuran (THF), diethyl ether (Et2O), and 1,4dioxane were distilled over sodium metal in the presence of benzophenone indicator. Anhydrous
dichloromethane (DCM, CH2Cl2), acetonitrile (AcN) and toluene were distilled over calcium
hydride (CaH2). All commercially available starting materials and reagents were purchased at the
highest commercial quality and used without further purification, unless otherwise noted.
Reactions were monitored by thin-layer chromatography (TLC) carried out on 225 µm aluminum
backed TLC sheets coated with silica gel 60 F254 (EMD Chemicals Inc. Gibbstown, NJ, USA).
TLCs were visualized under UV (254 nm) and by staining with either p-anisaldehyde,
phosphomolybdic acid (PMA), iodine, or Dragendorff’s reagent. NMR spectra were recorded at
room temperature on Bruker Avance DRX 400 (400 MHz) and DRX 500 (400 MHz)
spectrometers. The following abbreviations were used to explain the multiplicities: s = singlet, d
= doublet, t = triplet, q = quartet and m = multiplet. Infrared (IR) spectra were recorded on
Bruker Vector 33 FT-IR spectrometer. Electrospray ionization (ESI) mass spectrometry (MS)
experiments were performed on a Waters Micromass ZQ single quadrupole mass spectrometer.
High-resolution mass spectra (HR-MS) were recorded using a Waters Micromass quadrupole
time of flight (Q-TOF) micro mass spectrometer. High-performance liquid chromatography
liquid chromatography (HPLC) analysis was conducted using a Waters Delta Prep 4000 System
with a 77725I Rheodyne injector, a Waters 2487 Dual Wavelength Absorbance Detector, and an
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XTerraTM MS C18 5 µm 4.6 x 100 mm column. Elemental Analysis was obtained using a
PerkinElmer 2400 Series II CHNS/O Analyzer.

General Procedure for the Synthesis of 2-, 3- and 4-pyridineacetonitriles (S2):
Using an adapted procedure from Sauerberg et al.,300 to
a solution of potassium cyanide (KCN) (1.33 g, 0.0205
mol, 1.10 eq) in water (8.39 mL) was added
pyridinecarboxaldehyde S1 (2.0 g, 0.0187 mol, 1.0 eq )
over 30 minutes at 5-10 °C. To the reaction mixture was added AcOH (1.17 mL, 0.0205 mol,
1.10 eq) over 30 minutes at 5-10 °C. The reaction mixture was stirred at room temperature for 16
hours and then cooled to 0 °C. The precipitate was filtered using a Buchner funnel and the 2-, 3and 4-pyridineacetonitriles (S2) solid products were collected, washed with cold water and used
immediately. CAUTION: potassium cyanide is highly toxic. Care should be taken when
handling this reagent.412

2-Pyridineacetonitrile, α-hydroxy- (3.31)
Synthesized using the general procedure described for S2. Light yellow solid
(41% crude yield); Rf = 0.30 (50:50 EtOAc: hexanes); 1H NMR (400 MHz,
DMSO) δ 8.59 (d, J = 3.2 Hz, 1H), 7.90 (t, J = 7.7 Hz, 1H), 7.58 (d, J = 7.8 Hz,
1H), 7.45 – 7.39 (m, 1H), 5.81 (s, 1H); 13C NMR (101 MHz, DMSO) δ 156.39, 149.35, 137.60,
123.93, 120.72, 120.38, 63.74; DEPT-135 101 MHz, DMSO) δ 149.54, 138.09, 124.39, 121.02,
64.12; ESI+ MS: m/z 134 [MH]+.
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3-Pyridineacetonitrile, α-hydroxy- (3.32)
Synthesized using the general procedure described for S2. Pale yellow
crystalline solid (67 % crude yield); Rf = 0.30 (50:50 EtOAc: hexanes); 1H
NMR (400 MHz, DMSO) δ 8.72 (s, 1H), 8.63 (s, 1H), 7.93 (d, J = 5.2 Hz,
1H), 7.51 (s, 1H), 7.30 (s, 1H), 5.90 (s, 1H); 13C NMR (101 MHz, DMSO) δ 150.54, 148.12,
134.77, 133.42, 124.33, 120.41, 60.45; DEPT-135 (101 MHz, DMSO) δ 150.55, 148.13, 134.79,
124.34, 60.45; ESI+ MS: m/z 134 [MH]+.

4-Pyridineacetonitrile, α-hydroxy- (3.33)
Synthesized using the general procedure described for S2. Light orange-pink
clay-like solid (81% crude yield); Rf = 0.30 (50:50 EtOAc: hexanes); 1H NMR
(400 MHz, DMSO) δ 8.65 (d, J = 4.9 Hz, 2H), 8.53 (d, J = 4.9 Hz, 1H), 7.53 (d,
J = 5.0 Hz, 2H), 7.39 (d, J = 4.9 Hz, 2H), 5.48 (s, 1H), 4.79 (s, 1H); 13C NMR (101 MHz,
DMSO) δ 150.92, 150.62, 150.04, 149.19, 148.45, 123.68, 123.25, 121.72, 121.37, 119.75,
76.92, 76.66; DEPT-135 (101 MHz, DMSO) δ 150.91, 150.60, 150.03, 149.54, 149.18, 149.01,
123.67, 123.24, 123.17, 122.47, 121.76, 121.71, 121.36, 76.66, 76.30; ESI+ MS: m/z 135
[MH]+.

2-Pyridineacetic acid, α-hydroxy-, hydrochloride (3.34)
Using an adapted procedure from Ward et al.,308 a suspension of crude
cyanohydrin 3.31 (500 mg, 3.73 mmol) in 5 mL of concentrated HCl was
refluxed for 15 hours. The concentrated HCl was removed under reduced pressure (0.03 mmHg)
with slight heating (60 °C). The residue was washed with water and the water was removed
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under reduced pressure (0.03 mmHg) with slight heating (60 °C) to yield 3.34 as an orangebrown solid powder (96% crude yield). No further purification was used; ESI+ MS: m/z 153
[MH]+; ESI- MS: m/z 151 [M-H]-.

3-Pyridineacetic acid, α-hydroxy-, hydrochloride (3.35)
Using an adapted procedure from Ward et al.,308 a suspension of crude
cyanohydrin 3.32 (500 mg, 3.73 mmol) in 5 mL of concentrated HCl was
refluxed for 15 hours. The concentrated HCl was removed under reduced
pressure (0.03 mmHg) with slight heating (60 °C). The residue was washed with water and the
water was removed under reduced pressure (0.03 mmHg) with slight heating (60 °C) to yield
3.35 as a pale yellow solid (63% crude yield). No further purification was used.; 1H NMR (400
MHz, D2O) δ 8.94 (s, 1H), 8.79 (d, J = 5.6 Hz, 1H), 8.74 (d, J = 8.2 Hz, 1H), 8.12 (dd, J = 7.9,
6.1 Hz, 1H), 5.65 (s, 1H); 13C NMR (101 MHz, D2O) δ 173.46, 145.03, 140.83, 139.43, 139.07,
127.34, 69.33; DEPT-135 (101 MHz, D2O) δ 145.03, 140.84, 139.43, 127.34, 69.33. ESI+ MS:
m/z 154[MH]+; ESI- MS: m/z 151 [M-H]-.

3-Pyridineacetic acid, α-hydroxy-, ethyl ester, hydrochloride (3.36)
Using an adapted procedure from Ward et al.,308 and Baeza et al.,302 to a
solution of crude cyanohydrin 3.32 (500 mg, 3.73 mmol) in ethanol (11 mL)
and water (11 mL) was slowly added concentrated HCl (22 mL). The reaction
flask was fitted with a reflux condenser and refluxed for 15 hours. The solvents
were removed under reduced pressure (0.03 mmHg) with slight heating (50-60 °C) to yield 3.36
as a white solid (91% crude yield). No further purification was used; ESI+ MS: m/z 181 [MH]+.
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2-hydroxy-N-phenyl-2-(pyridin-3-yl) acetamide (3.41)
Using a modified procedure from Martyn et al.,306 to a mixture of
crude 3.35 (250 mg, 1.33 mmol, 1.0 eq) and freshly distilled aniline
(0.134 mL, 1.47 mmol, 1.1 eq) in anhydrous DCM (14 mL) was added
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (331.80 mg, 1.73 mmol, 1.3eq)
and 1-hydroxybenzotriazole hydrate (HOBT) (269.6 mg, 1.96 mmol, 1.5 eq) at room
temperature. The reaction mixture was yellow and cloudy in appearance. N, NDiisopropylethylamine (0.256 mL, 1.47 mmol, 1.1 eq) was added dropwise and the reaction
mixture stirred at room temperature for 18 hours. The reaction was quenched with H2O (5 mL)
and stirred for 30 minutes at room temperature. The solution was diluted with DCM (10 mL),
washed with 1N HCl (3 x 10 mL), water (3 x 10 mL), and the combined aqueous washings were
back-extracted with fresh DCM (3 x10 mL). The combined organic fractions were dried over
Na2SO4 and the solvent was removed in vacuo to afford crude product. Flash-column
chromatography on silica using a gradient of 10:90 EtOAc:Hexanes to 100% EtOAc followed by
10:90 MeOH:EtOAc afforded 3.41 as a brown “caramel-color” sticky oil (110.3 mg, 36%); Rf =
0.34 (10:90 MeOH:EtOAc; stains white with anisaldehyde/orange spot with Dragendorf
reagent);1H NMR (400 MHz, CDCl3); 13C NMR (101 MHz, CDCl3); DEPT-135 (101 MHz,
CDCl3); ESI+ MS: m/z 229 [MH]+; ESI- MS: m/z 227 [M-H]-.

2-oxo-N-phenyl-2-(pyridin-3-yl) acetamide (3.42)
Using a modified procedure from Bou-Hamdan et al.,312 to a solution
of 3.41 (24.3 mg, 0.107 mmol, 1.0 eq) in anhydrous DCM (1 mL) was
added MnO2 (93.03 mg, 1.07 mmol, 10 eq) and the mixture was stirred
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at room temperature for 1 hour. The mixture was filtered through a short pad of silica gel and the
silica layer was washed with fresh DCM (20 mL). Concentration of the filtrate afforded 24 mg
(quant. yield) of 3.42 as a solid; ESI+ MS: m/z 227 [MH]+.

N-(3-benzylphenyl)-2-hydroxy-2-(pyridin-3-yl) acetamide (3.43)
Using a modified procedure from Martyn et al.,306 to a
mixture of crude 3.35 (132.9 mg, 0.703 mmol, 1.0 eq) and 3benzylaniline (141.66 mg, 0.773, 1.1 eq) in anhydrous DCM
(9.52 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (175.29
mg, 0.914 mmol, 1.3eq) and 1-hydroxybenzotriazole hydrate (HOBT) (142.43 mg, 1.054 mmol,
1.5 eq) at room temperature. The reaction mixture was an orange-pink color. N, NDiisopropylethylamine (0.202 mL, 1.15 mmol, 1.65 eq) was added dropwise (reaction mixture
became yellow in color) and the reaction mixture stirred at room temperature for 24 hours. The
reaction was quenched with H2O (5 mL) and stirred for 30 minutes at room temperature. The
solution was diluted with DCM (10 mL), washed with 1N HCl (3 x 10 mL), water (3 x 10 mL),
and the combined aqueous washings were back-extracted with fresh DCM (3 x 10 mL). The
combined organic fractions were dried over Na2SO4 and the solvent was removed in vacuo to
afford crude product. Flash-column chromatography on silica using a gradient of 10:90
EtOAc:Hexanes to 100% EtOAc afforded 3.43 as a pale yellow sticky oil (54 mg, 24%); Rf =
0.53 (100% EtOAc; stains white with anisaldehyde/orange spot with Dragendorf reagent); 1H
NMR (400 MHz, CDCl3) δ 8.92 (s, 1H), 8.49 (s, 1H), 8.33 (d, J = 3.6 Hz, 1H), 7.87 (d, J = 7.8
Hz, 1H), 7.47 – 7.35 (m, 3H), 7.30 – 7.13 (m, 5H), 6.95 (d, J = 7.4 Hz, 1H), 5.15 (s, 1H), 3.92 (s,
2H); 13C NMR (101 MHz, CDCl3) δ 169.64, 148.23, 147.15, 142.29, 140.72, 137.16, 136.37,
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135.56, 129.19, 128.91, 128.53, 126.22, 125.44, 124.00, 120.25, 117.62, 71.76, 41.86; DEPT135 (101 MHz, CDCl3) δ 148.23, 147.15, 135.56, 129.19, 128.91, 128.53, 126.22, 125.44,
123.99, 120.25, 117.62, 71.76, 41.86; ESI- MS: m/z 317 [M-H]-.

N-(3-benzylphenyl)-2-oxo-2-(pyridin-3-yl) acetamide (3.44)
Using a modified procedure from Bou-Hamdan et al.,312 to a
solution of 3.43 (17.5 mg, 1.0 eq, 0.0550) in anhydrous DCM
(1 mL) was added freshly prepared MnO2 (119 mg, 25 eq,
1.375 mmol) and the mixture was stirred at room temperature for 16 hours. The mixture was
filtered through a short pad of silica gel and the silica layer was washed with fresh DCM.
Concentration of the filtrate afforded 17 mg ( quant yield) of 3.42 as a yellow solid residue; Rf =
0.75 (100% EtOAc); 1H NMR (400 MHz, DMSO) δ 10.90 (s, 1H), 9.22 (s, 1H), 8.88 (s, 1H),
8.43 (d, J = 7.2 Hz, 1H), 7.38 – 7.14 (m, 10H), 3.97 (s, J = 22.7 Hz, 2H).;ESI- MS: m/z 315 [MH]-.

2-(5-bromopyridin-2-yl)-2-hydroxyacetonitrile (3.46)
Using an adapted procedure from Sauerberg et al.,300 to a solution of KCN
(192.34 mg, 2.959 mmol, 1.10 eq) in water (2.08 mL) was added 5bromopyridine-2-carboxaldehyde (500 mg, 2.69 mmol, 1.0 eq) over 30
minutes at 5-10 °C. To the reaction mixture was added AcOH (0.169 mL, 2.959 mmol, 1.10 eq)
over 30 minutes at 5-10 °C. The reaction mixture was stirred at room temperature for 16 hours.
After 16 hours, the reaction mixture was cooled to 0°C and the solids were collected via vacuum
filtration in a Buchner funnel to afford 3.46 as a yellow-brown golden solid (575 mg,
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quantitative crude yield) Compound 3.46 was used immediately without any additional
purification. ESI- MS: m/z 124 [M-H]-.

2-Pyridineacetic acid, 5-bromo-α-hydroxy-, hydrochloride (3.47)
Using a modified procedure from Baeza et al.,302 compound 3.46 (515 mg,
2.417 mmol) was dissolved in a 1.5:1 mixture of EtOH:H20 (5 mL) at
room temperature. To this mixture was slowly added concentrated HCl (5
mL). The reaction flask was fitted with a reflux condenser and refluxed for 24 hours. The
reaction was cooled to room temperature and neutralized with saturated NaHCO3 (pH ~6). The
aqueous mixture was extracted with EtOAc (3 x 20 mL) and the organic layers were combined,
dried over Na2SO4 and concentrated in vacuo to afford crude 3.47 as a red-brown solid (253.1
mg, 45% crude yield). No further purification was used. ESI+ MS: m/z 253, 252 [MH]+.

1H-Imidazole-4-acetonitrile, α-hydroxy- (3.53)
Using an adapted procedure from Sauerberg et al.,300 to a solution of KCN
(372.74 mg, 5.724 mmol, 1.10 eq) in water (2.094 mL) was added imidazole4-carboxaldehyde (500 mg, 5.203 mmol, 1.0 eq ) over 30 minutes at 5-10 °C.
To the reaction mixture was added AcOH (0.327 mL, 5.724 mmol, 1.10 eq) over 30 minutes at
5-10 °C. The reaction mixture was stirred at 0 °C for 18 hours. After 18 hours, the solvents were
removed under reduced pressure (0.03 mmHg) with slight heating (45 °C) to afford 3.53 as
orange-yellow solid (598 mg, 85% crude yield). Compound 3.53 was used immediately without
any additional purification. ESI- MS: m/z 124 [M-H]-.
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1H-Imidazole-4-acetic acid, α-hydroxy-(3.56)
Using an adapted procedure from Ward et al.,308 to a suspension of crude
cyanohydrin 3.53 (540 mg, 4.38 mmol) in 10 mL of EtOH: H2O
(5mL:5mL) was slowly added 10 mL of concentrated HCl. The reaction
flask was fitted with a reflux condenser and refluxed for 16 hours. The concentrated HCl was
removed under reduced pressure (0.03 mmHg) with slight heating (50 °C). The residue was
washed with water and the water was removed under reduced pressure (0.03 mmHg) with slight
heating (50 °C) to yield 3.56 as a pale yellow solid (600.4 mg, 79% crude yield). No further
purification was used. 1H NMR (400 MHz, MeOD) δ 8.91 (d, J = 1.4 Hz, 1H), 7.55 (s, 2H), 5.42
(d, J = 0.8 Hz, 2H); 1H NMR (400 MHz, DMSO) δ 9.12 (s, 1H), 7.64 (s, 1H), 5.32 (s, 1H); 13C
NMR (101 MHz, DMSO) δ 171.80, 134.60, 132.42, 116.93, 64.76; DEPT-135 (101 MHz,
DMSO) δ 134.59, 116.92, 64.75; ESI- MS: m/z 140 [M-H]-.

2-Furanacetonitrile, α-hydroxy-(3.62)
Using an adapted procedure from Felfer et al.,314 trimethylsilyl cyanide
(TMSCN) (0.333 mL, 2.496 mmol, 1.2 eq) was added to freshly distilled
furfural (0.172 mL, 2.08 mmol, 1.0 eq) in anhydrous DCM at 0 °C. After the
addition of a few crystals of ZnBr the reaction was stirred at 0 °C for 15 minutes before it was
allowed to warm to room temperature. The reaction stirred for 45 minutes at room temperature.
The TMS protected cyanohydrin was subjected to acid-hydrolysis by the addition of 3N HCl
(3.75 g) at 0 °C. The mixture was stirred for 1 hour at room temperature. The crude reaction
mixture was extracted with ether (3 x 20 mL), combined, dried over Na2SO4 and concentrated in
vacuo to afford crude product as an orange yellow oil (307.1 mg, quantitative crude yield); Rf =
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0.71 (50:50 EtOAc: hexanes); 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.39 (m, 1H), 6.59 (d, J =
3.3 Hz, 1H), 6.42 (dd, J = 3.3, 1.9 Hz, 1H), 5.55 (s, 1H), 3.80 (s, 1H).

Ethyl 4-cyano-1-methoxymethyl-1, 4-dihydro-3-pyridineglyoxylate (3.66)
Preparation of Benzyltrimethylammonium Cyanide (BnMe3N+CN-):
was prepared according to a procedure by Vedejs and Monahan413 with
modification. Benzyltrimethylammonium chloride (1.33 grams, 7.18 mmol)
was dried at 0.5 mmHg vacuum and dissolved in anhydrous MeOH (1.67
mL). The resulting solution was transferred via syringe into a stirring
solution of NaCN (525 mg, 10.71 mmol) in 10 mL of anhydrous MeOH. After stirring for 30
minutes at room temperature, the white suspension was carefully concentrated by rotary
evaporation with minimal exposure to atmospheric moisture. The white residue was treated with
10 mL of hot anhydrous AcN and the resulting suspension was filtered hot through a fritted glass
filter under argon. The filtrate was carefully concentrated by rotary evaporation at room
temperature to dryness and collected and dried under reduced pressure (0.03 mmHg) to yield
white hygroscopic crystals (373.10 mg, 29%).
Using an adapted procedure from Klapars and Vedejs, 323 to a solution of anhydrous pyridine
(0.33 mL, 4.08 mmol) in 10 mL of anhydrous CHCl3 at room temperature was added
methoxymethyl chloride (0.34 mL, 4.48 mmol). After stirring at room temperature for 1 hour,
the colorless solution was transferred via syringe into a 50 mL flame-dried round bottom flask
charged with BnMe3N+CN- (660 mg, 3.74 mmol). The resulting clear solution was cooled in an
ice-bath to 0 °C, and diisopropylethylamine (0.80 mL, 4.59 mmol) was added followed by ethyl
oxalyl chloride (0.48 mL, 4.30 mmol). After stirring at 0 °C for 1 hour, the orange solution was
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poured into 50 mL of ether and washed with 2 x 20 mL of H2O. The bright yellow organic layer
was dried over Na2SO4 and concentrated by rotary evaporation to give crude dihydropyridine
3.66, which was used immediately in the next step without further purification. Yellow-orange
oil; Rf = 0.47 (50:50 acetone:hexanes); 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 6.26 (d, J =
7.9 Hz, 1H), 5.20 (dd, J = 7.9, 4.5 Hz, 1H), 4.64 (s, 2H), 4.60 (d, J = 4.5 Hz, 1H), 4.35 (d, J = 7.1
Hz, 2H), 3.36 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H); ESI+ MS: m/z 251 [MH]+.

3-Pyridineacetic acid, α-oxo-, ethyl ester (3.67)
The crude dihydropyridine 3.66 was dissolved in anhydrous AcN (5 mL,
including syringe washings), and the solution was transferred via syringe
into a 25 mL round bottom flask charged with ZnCl2 (1.05g, 7.70 mmol).
After stirring at room temperature for 5 hours, the yellow suspension was filtered through Celite
eluting 2 x 2 mL of anhydrous AcN. Anhydrous EtOH (10 mL) was added to the filtrate, the
resulting tan solution was refluxed for 15 hours, cooled to room temperature, and poured into
10% aqueous solution of NaHCO3 (20 mL) at 0°C (ice-bath). The resulting suspension was
filtered through Celite eluting with 2 x 10 mL of EtOH. The tan filtrate was extracted with DCM
(3 x 30 mL). The combined organic phase was dried over Na2SO4, concentrated by rotary
evaporation, and the orange-red residue was purified by flash chromatography on silica gel using
4:1 hexanes:acetone to yield 3.67 yellow solid (147.2 mg, 82%); 1H NMR (400 MHz, CDCl3) δ
9.26 (d, J = 1.7 Hz, 1H), 8.86 (dd, J = 4.8, 1.6 Hz, 1H), 8.37 (d, J = 8.0 Hz, 1H), 7.61 – 7.37 (m,
1H), 4.48 (q, J = 7.1 Hz, 2H), 1.43 (dd, J = 23.4, 16.3 Hz, 3H); ESI+ MS: m/z 359 [M+MH]+.
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Phenol, 4-[(2-pyridinylmethylene) amino] - (3.69)
Using an adapted procedure from Jursic et al.,338 a mixture of 2pyridine-carboxaldehyde (0.446 mL, 500 mg, 4.66 mmol) and 4aminophenol (509 mg, 4.66 mmol) in methanol (93 mL) was refluxed
for 2 hours. The solvent was reduced to 1/10 of its original volume (~10
mL). The resulting suspension was cooled in an ice-water bath. The bright yellow crystalline
solid was separated by filtration, washed with cold methanol (3x10 mL) and dried under highvacuum to afford 3.69 (687.2 mg, 74 %). No further purification was needed for the next step. Rf
= 0.30 (50:50 EtOAc: hexanes); 1H NMR (400 MHz, DMSO) δ 9.67 (s, 1H), 8.70 (d, J = 4.6 Hz,
1H), 8.62 (s, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.92 (dd, J = 11.0, 4.2 Hz, 1H), 7.49 (dd, J = 6.8, 5.4
Hz, 1H), 7.32 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H); 13C NMR (101 MHz, DMSO) δ
157.53, 157.40, 155.02, 149.99, 141.97, 137.32, 125.50, 123.40, 121.14, 116.29; DEPT-135
(101 MHz, DMSO) δ 157.40, 149.99, 137.32, 125.51, 123.40, 121.14, 116.29; ESI+ MS: m/z
199 [MH]+.

Phenol, 4-[(3-pyridinylmethylene) amino] - (3.70)
Prepared by the procedure described for 3.69. Pale yellow fluffy solid
(8.55 g, 92 %) Rf = 0.37 (70:30 EtOAc: hexanes); 1H NMR (400 MHz,
DMSO) δ 9.59 (s, 1H), 9.03 (d, J = 1.5 Hz, 1H), 8.70 (s, 1H), 8.67 (dd, J
= 4.7, 1.5 Hz, 1H), 8.27 (dd, J = 7.9, 1.7 Hz, 1H), 7.52 (dd, J = 7.8, 4.8 Hz, 1H), 7.26 (d, J = 8.7
Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H); 13C NMR (101 MHz, DMSO) δ 157.14, 155.14, 151.79,
150.48, 142.64, 134.95, 132.41, 124.42, 123.14, 116.18; DEPT-135 (101 MHz, DMSO) δ
155.15, 151.80, 150.50, 134.96, 124.43, 123.16, 116.20; ESI+ MS: m/z 199 [MH]+.
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Phenol, 4-[(4-pyridinylmethylene) amino] - (3.71)
Prepared by the procedure described for 3.69.Gold-yellow solid (7.11 g,
76%) Rf = 0.28 (70:30 EtOAc: Hexanes); 1H NMR (400 MHz, DMSO)
δ 9.69 (s, 1H), 8.72 (d, J = 5.7 Hz, 2H), 8.68 (s, 1H), 7.81 (d, J = 5.8 Hz,
2H), 7.31 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H); 13C NMR (101
MHz, DMSO) δ 157.68, 155.55, 150.80, 143.45, 142.04, 123.53, 122.32, 116.26; DEPT-135
(101 MHz, DMSO) δ 155.55, 150.80, 123.53, 122.32, 116.26; ; ESI+ MS: m/z 199 [MH]+.

4-Pyridineacetonitrile, α-[(4-hydroxyphenyl) imino] - (3.77)
Using an adapted procedure from Jursic et al.,338 a DMSO (20 mL)
solution of 3.71 (600 mg, 3.02 mmol) and sodium cyanide (162.8 mg,
3.32 mmol) stirred at room temperature for 24 hours. In the first 5
minutes, the solution went from yellow to orange then to deep red. After 24 hours at room
temperature, the DMSO was evaporated at reduced pressure (0.03 mmHg) with slight heating
(60 °C). A dark burgundy residue remained which was then dissolved in THF (slight heating 4050 °C was needed). The solution was immediately filtered through a pad of silica gel in a fritted
Buchner funnel and washed with fresh THF (6 x 50 mL). Immediately it was noted that a bright
orange solid was crashing out of the THF solution. The combined THF filtrates were evaporated
to a solid. The solid residue was slurred in MeOH (50 mL) and the resulting suspension was
heated at 50 °C for 10 minutes, cooled down in an ice-water bath and the fluorescent-orange
solid was collected by vacuum filtration and washed with ice-cold MeOH (3x20 mL) and dried
under high-vacuum to afford 3.77 (381 mg, 56 %). No further purification was needed for the
next step.; Rf = 0.60 (70:30 EtOAc: hexanes; stains bright yellow with p-anisaldehyde); 1H
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NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 8.94 – 8.68 (m, 2H), 8.12 – 7.69 (m, 2H), 7.43 (d, J =
8.8 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H); 13C NMR (101 MHz, DMSO) δ 159.37, 151.18, 141.20,
139.68, 133.65, 124.75, 121.21, 116.41, 112.10; DEPT-135 (101 MHz, DMSO) δ 151.18,
124.75, 121.21, 116.42. ESI+ MS: m/z 224 [MH]+.

2-Pyridineacetonitrile, α-[(4-hydroxyphenyl) imino] - (3.75)
Prepared by the procedure described for 3.77, with modification of the
purification method. Unlike previously reported, no solid residue formed
to be filtered and collected as product. Therefore, the MeOH solution
was concentrated in vacuo to afford crude product. Purification was
achievable via flash-column chromatography (20:80 to 50:50 EtOAc: Hexanes) to yield bright
yellow solid “saw dust” (95.4 mg, 42 %) Rf = 0.77 (70:30 EtOAc: hexanes; stains bright yellow
with p-anisaldehyde); 1H NMR (400 MHz, DMSO) δ 10.08 (s, 1H), 8.79 (d, J = 4.3 Hz, 1H),
8.20 (d, J = 7.9 Hz, 1H), 8.02 (t, J = 7.7 Hz, 1H), 7.71 – 7.56 (m, 1H), 7.42 (d, J = 8.7 Hz, 2H),
6.94 (d, J = 8.7 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 158.96, 152.50, 149.95, 139.52,
138.03, 136.53, 126.83, 124.52, 121.63, 116.33, 112.49; DEPT-135 (101 MHz, DMSO) δ
149.95, 138.03, 126.82, 124.52, 121.63, 116.33; ESI+ MS: m/z 224 [MH]+.

3-Pyridineacetonitrile, α-[(4-hydroxyphenyl) imino] - (3.76)
Prepared by same procedure described for 3.75. Burnt orange solid
(88.9 mg, 13%); Rf = 0.71 (70:30 EtOAc: hexanes; stains bright yellow
with p-anisaldehyde);1H NMR (400 MHz, DMSO) δ 10.07 (s, 1H),
9.16 (s, 1H), 8.80 (d, J = 3.8 Hz, 1H), 8.36 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 7.9, 4.8 Hz, 1H),
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7.37 (d, J = 8.6 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H); 13C NMR (101 MHz, DMSO) δ 158.70,
152.96, 148.75, 140.15, 135.25, 133.87, 130.27, 124.57, 124.20, 116.31, 111.97; DEPT-135
(101 MHz, DMSO) δ 152.96, 148.75, 135.25, 124.57, 124.21, 116.31; ESI+ MS: m/z 224
[MH]+.

Benzenamine, N-(3-pyridinylmethylene) - (3.83)
Using an adapted procedure from Dickson et al.,414 freshly distilled aniline
(0.294 mL, 300 mg, 3.22 mmol) and freshly distilled 3-pyridine
carboxaldehyde (0.324 mL, 369.7 mg, 3.38 mmol) were dissolved in
anhydrous 1, 2-dichloroethane (38.34 mL), and magnesium sulfate (461.4
mg, 3.83 mmol) was added. The reaction flask was fitted with a reflux condenser and refluxed
for 18 hours. The solution was filtered to remove the magnesium sulfate and the solvents were
concentrated under reduced pressure to yield crude product as a viscous dark orange oil. Flashcolumn chromatography on silica using a gradient of 20:80 EtOAc:hexanes to 30:70
EtOAc:hexanes afforded 3.83 as a bright orange oil (498 mg, 84%); ( Rf = 0.38 (50:50 EtOAc:
Hexanes; stains bright yellow with p-anisaldehyde) 1H NMR (400 MHz, CDCl3) δ 9.01 (d, J =
1.2 Hz, 1H), 8.70 (d, J = 3.5 Hz, 1H), 8.49 (s, 1H), 8.29 (d, J = 7.9 Hz, 1H), 7.47 – 7.36 (m, 3H),
7.30 – 7.19 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 157.18, 151.99, 151.43, 150.94, 134.89,
131.82, 129.25, 126.55, 123.80, 120.85; DEPT-135 (101 MHz, CDCl3) δ 157.18, 151.99,
151.43, 150.94, 134.89, 131.82, 129.25, 126.55, 123.80, 120.85; ESI+ MS: m/z 183 [MH]+.
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3-Pyridineacetonitrile, α-(phenylimino) - (3.84)
Using an adapted procedure from Surya K. De.,415 a mixture of freshly
distilled 3-pyridinecarboxaldehye (0.103 mL, 1.073 mmol, 1.0 eq), freshly
distilled aniline (1.022 mL, 1.073 mmol, 1.0 eq), KCN (104.9 mg, 1.609
mmol, 1.5 eq) and CoCl2 (14.36 mg, 10 mol%) in anhydrous AcN (20 mL) was stirred at room
temperature for 3 hours. After reaction completion, the reaction mixture was extracted with
EtOAc (2 x 20 mL). The organic layers were washed with water (20 mL), brine (20 mL), dried
over Na2SO4, and concentrated by rotary evaporation to yield crude yellow-orange oil. The
residue was purified by flash-column chromatography on silica using a gradient of 10:90
EtOAc:hexanes to 100% EtOAc to afford 3.84 as an orange-yellow waxy residue (36.4 mg, 16
%); Rf = 0.58 (50:50 EtOAc: hexanes; stains light yellow with p-anisaldehyde); 1H NMR (400
MHz, CDCl3) δ 9.36 (s, 1H), 8.82 (d, J = 3.7 Hz, 1H), 8.41 (dd, J = 6.2, 1.9 Hz, 1H), 7.55 – 7.44
(m, 3H), 7.36 (t, J = 7.4 Hz, 1H), 7.29 – 7.21 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 153.19,
149.53, 148.47, 137.09, 135.22, 129.53, 129.41, 128.09, 123.71, 120.59, 110.32; DEPT-135
(101 MHz, CDCl3) δ 153.20, 149.53, 135.22, 129.41, 128.09, 123.71, 120.59. ESI+ MS: m/z 210
[MH]+; ESI- MS: m/z 208 [MH]-.

3-Pyridineacetonitrile, α-(phenylamino) - (3.88)
Using a modified procedure from Jarusiewicz et al.,343, 414 to a mixture of
PdCl2 (14.89 mg, 3 mol%), freshly distilled 3-pyridinecarboxaldehyde
(0.268 mL, 2.80 mmol, 1.0 eq), freshly distilled aniline (0.255 mL, 2.80
mmol, 1.0 eq), and Na2SO4 (1.39 g, 9.80 mmol, 3.5 eq) in anhydrous DCM
(4 mL) was added dropwise TMSCN (0.700 mL, 5.60 mmol, 2.0 eq). The reaction was stirred at
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room temperature for 24 hours. After completion the mixture was filtered and the filtrate was
concentrated under reduced pressure to yield a pale yellow solid (712.8 mg, 60%). Product was
used in the subsequent reaction without further purification; Rf = 0.35 (50:50 EtOAc: hexanes;
stains bright yellow with p-anisaldehyde); 1H NMR (400 MHz, CDCl3) δ 8.82 (d, J = 1.7 Hz,
1H), 8.66 (d, J = 4.6 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.38 (dd, J = 7.9, 4.9 Hz, 1H), 7.28 (t, J =
7.9 Hz, 2H), 6.93 (t, J = 7.4 Hz, 1H), 6.82 – 6.76 (m, 2H), 5.49 (s, 1H), 4.34 (s, 1H); 13C NMR
(400 MHz, CDCl3) δ 150.63 , 148.58, 144.26, 135.03, 130.08, 129.67, 123.97, 120.78, 117.32,
114.46, 48.19; DEPT-135 13C NMR (101 MHz, CDCl3) δ 150.63, 148.58, 135.03, 129.67,
123.97, 120.78, 114.46, 48.19; ESI+ MS: m/z 210 [MH]+; ESI- MS: m/z 209 [M-H]-.

3-Pyridineacetic acid, α-(phenylamino)-, methyl ester (3.89)
Using a modified procedure from Burkhart et al.,344 the α-amino nitrile 3.88
(199.5 mg, 0.953 mmol) was dissolved in anhydrous MeOH (5 mL) and
cooled to 0°C with an ice-bath. Anhydrous HCl gas was bubbled into the
solution for 30 minutes until the solution was completely saturated. The reaction was warmed to
room temperature and stirred for 12 hours. After completion the reaction was neutralized with
saturated NaHCO3 and the extracted with EtOAc (3 x 20 mL). The organic layers were collected,
dried over Na2SO4 and evaporated under reduced pressure. The caramel-colored crude residue
was purified by flash-column chromatography on silica using a gradient of 10:90 EtOAc:hexanes
to 100% EtOAc to yield 3.89 as a yellow-orange oil (65.0 mg, 54%); Rf = 0.54 (70:30 EtOAc:
hexanes, stains pink with p-anisaldehyde); 1H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H), 8.58 (d, J
= 3.9 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.31 (dd, J = 7.8, 4.9 Hz, 1H), 7.12 (t, J = 7.9 Hz, 2H),
6.72 (t, J = 7.3 Hz, 1H), 6.54 (d, J = 7.7 Hz, 2H), 5.14 (s, 1H), 3.75 (s, 3H); 13C NMR (101
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MHz, CDCl3) δ 171.29, 148.85, 148.60, 145.31, 135.21, 134.00, 129.36, 124.07, 118.64, 113.51,
58.47, 53.18; DEPT-135 (101 MHz, CDCl3) δ 148.85, 148.60, 135.21, 129.36, 124.08, 118.64,
113.51, 58.47, 53.18; ESI+ MS: m/z 243 [MH]+.

3-Pyridineacetic acid, α-(phenylimino)-, methyl ester (3.90)
Using a modified procedure from Vu et al.,416 a mixture of 3.89 (25.0 mg,
0.103 mmol, 1.0 eq) and DDQ (25.71mg, 0.113 mmol, 1.1 eq) in anhydrous
benzene (3 mL) was stirred at room temperature for 24 hours. Initially, the
reaction mixture was yellow then went to green followed by a dark maroon
color. After reaction completion the solvent was removed by rotary evaporation and immediately
purified using flash-column chromatography on basic alumina using a gradient of 100% hexanes
to 10:90 EtOAc:hexanes to yield 3.90 as a yellow oil (2.0 mg, 8%); Rf = 0.62 (50:50 EtOAc:
hexanes; stains yellow with p-anisaldehyde); 1H NMR (400 MHz, CDCl3) δ 9.09 (s, 1H), 8.79 (s,
1H), 8.25 (d, J = 8.0 Hz, 1H), 7.56 – 7.42 (m, 1H), 7.36 (t, J = 7.9 Hz, 2H), 7.19 (dd, J = 14.0,
6.6 Hz, 1H), 6.99 – 6.94 (m, 2H), 3.67 (s, 3H).; ESI+ MS: m/z 241 [MH]+.

General Procedure A for the Synthesis of Aryl α-Keto Acids (S4-S13):
Using an adapted procedure from Zhuang et al.,355 in a
15 mL oven-dried pressure tube was added aryl ketone
S3 (1.0 eq), selenium dioxide (2.0 eq) and anhydrous
pyridine (6.25 eq) under argon. The reaction was heated between 110°C-120°C for 15 hours. The
reaction was cooled and filtered through a pad of Celite eluting 2 x 2 mL of EtOAc and the
filtrate was concentrated by rotary evaporation. The crude residue was dissolved in EtOAc,
transferred into a separatory funnel and washed with 2 M NaOH (3 x 10 mL). The aqueous
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layers were combined, cooled to 0°C and acidified with concentrated HCl (pH 1-2) and backextracted with fresh EtOAc (3 x 20 mL). The organic layers were combined dried over Na2SO4
and concentrated in vacuo to afford crude product S4-S13 which were used without any
additional purification.

General Procedure B for the Synthesis of Aryl Oxalamate Scaffolds (3.95-3.107)
Using an adapted procedure from Martyn
et al.,306 to a mixture of crude S14 (1.0 eq)
and 3-benzylaniline or aniline(1.1 eq) in
anhydrous DCM (213 eq) was added 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.3eq) and 1-hydroxybenzotriazole
hydrate (HOBT) (1.5 eq) at room temperature. N, N-Diisopropylethylamine (1.1 eq) was added
dropwise and the reaction mixture stirred at room temperature for 24 hours. The reaction was
quenched with H2O (5 mL) and stirred for 30 minutes at room temperature. The solution was
diluted with DCM (10 mL), washed with 1N HCl (3 x 10 mL), water (3 x 10 mL), and the
combined aqueous washings were back-extracted with fresh DCM (3 x 10 mL). The combined
organic fractions were dried over Na2SO4 and the solvent was removed in vacuo to afford crude
product. Flash-column chromatography on silica using a gradient of 10:90 EtOAc:hexanes to
100% EtOAc afforded 3.95-3.107 as pure oxalamates.
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2-(4-bromophenyl)-2-oxoacetic acid (S4)
Synthesized using the general procedure A described for aryl α-keto acids. Salmon-pink solid
(1.48 g, quantitative crude yield ); Rf = 0.17 (20:80 EtOAc: hexanes);
1

H NMR (400 MHz, CDCl3) δ 9.81 (s, 1H), 8.17 (d, J = 8.6 Hz, 2H),

7.66 (dd, J = 17.9, 8.5 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ
183.56, 162.35, 132.47, 132.44, 131.63, 130.47; DEPT-135 (101 MHz, CDCl3) δ 132.47,
132.44; ESI- MS: m/z 227, 229[M-H]-; ESI+ MS: m/z 456, 458 [MNa]+.

N-(3-benzylphenyl)-2-(4-bromophenyl)-2-oxoacetamide (3.95)
Synthesized using the general procedure B described for
aryl oxalamate scaffolds with modification. Flashcolumn chromatography on silica using a gradient of
50:50 CHCl3:hexanes to 100% CHCl3 afforded 3.95 as a pale yellow solid (192 mg, 54%); Rf =
0.50 (50:50 CHCl3: hexanes, stains yellow with p-anisaldehyde);1H NMR (400 MHz, CDCl3) δ
8.88 (s, 1H), 8.30 (d, J = 8.6 Hz, 2H), 7.64 (d, J = 8.6 Hz, 2H), 7.56 (d, J = 8.0 Hz, 1H), 7.48 (s,
1H), 7.30 (td, J = 7.4, 3.9 Hz, 3H), 7.21 (t, J = 7.1 Hz, 3H), 7.03 (d, J = 7.5 Hz, 1H), 4.00 (s,
2H); 13C NMR (101 MHz, CDCl3) δ 186.29, 158.46, 142.56, 140.54, 136.60, 132.97, 131.96,
131.82, 130.45, 129.36, 128.94, 128.58, 126.30, 126.11, 120.40, 117.78, 41.87; DEPT-135 (101
MHz, CDCl3) δ 132.97, 131.96, 129.36, 128.93, 128.58, 126.30, 126.11, 120.40, 117.78, 41.87;
ESI- MS: m/z 392, 394 [M-H]-; Elemental Analysis: Calc. for C21H16BrNO2: C, 63.97; H, 4.09;
N, 3.55. Found: C, 63.75; H, 3.91; N, 3.49; melting point: 110-112 °C.
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2-(3-bromophenyl)-2-oxoacetic acid (S5)
Synthesized using the general procedure A described for aryl α-keto
acids. Yellow solid (844.8 mg, 64% crude yield); Rf = 0.17 (20:80
EtOAc: hexanes); 1H NMR (400 MHz, CDCl3) δ 9.30 (s, 1H), 8.51 –
8.31 (m, 1H), 8.22 (d, J = 7.9 Hz, 1H), 7.82 (dd, J = 8.0, 0.9 Hz, 1H), 7.52 – 7.37 (m, 1H). 13C
NMR (101 MHz, CDCl3) δ 183.63, 162.59, 138.30, 133.57, 130.50, 129.64, 123.20; DEPT-135
(101 MHz, CDCl3) δ 138.30, 133.57, 130.50, 129.64; ESI- MS: m/z 226, 228 [M-H]-.

N-(3-benzylphenyl)-2-(3-bromophenyl)-2-oxoacetamide (3.96)
Synthesized using the general procedure B described for
aryl oxalamate scaffolds with modification. Flashcolumn chromatography on silica using a gradient of
50:50 CHCl3:hexanes to 100% CHCl3 afforded 3.96 as a pale yellow crystalline solid (302.2 mg,
71%); Rf = 0.50 (50:50 CHCl3: hexanes; stains yellow with p-anisaldehyde);1H NMR (400
MHz, CDCl3) δ 8.89 (s, 1H), 8.56 (s, 1H), 8.39 (d, J = 7.9 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.60
(d, J = 7.9 Hz, 1H), 7.51 (s, 1H), 7.42 – 7.20 (m, 8H), 4.02 (s, 2H); 13C NMR (101 MHz, CDCl3)
δ 186.01, 158.20, 142.56, 140.52, 137.41, 136.54, 134.73, 134.15, 130.09, 129.36, 128.93,
128.58, 126.30, 126.15, 122.71, 120.41, 117.80, 41.87; DEPT-135 (101 MHz, CDCl3) δ 137.42,
134.16, 130.11, 129.37, 128.94, 128.59, 126.31, 126.16, 120.42, 117.81, 41.87. ESI- MS: m/z
391, 393 [M-H]-; Elemental Analysis: Calc. for C21H16BrNO2: C, 63.97; H, 4.09; N, 3.55.
Found: C, 63.27; H, 3.86; N, 3.46; melting point: 103-105°C.
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2-oxo-2-(2,3,4-trimethoxyphenyl)acetic acid (S6)
Synthesized using the general procedure A described for aryl α-keto
acids. Yellow solid (240.2 mg, quantitative crude yield); Rf = 0.10
(50:50 EtOAc: hexanes); 1H NMR (400 MHz, CDCl3) δ 10.97 (s, 3H), 7.73 (d, J = 8.9 Hz, 1H),
6.80 (d, J = 8.9 Hz, 1H), 3.99 (s, 3H), 3.96 (s, 2H), 3.87 (s, 3H); 13C NMR (101 MHz, CDCl3) δ
184.50, 169.85, 160.22, 155.48, 141.18, 126.44, 119.66, 107.84, 61.52, 60.85, 56.35; DEPT-135
(101 MHz, CDCl3) δ 126.43, 107.83, 61.51, 60.85, 56.34; ESI- MS: m/z 239 [M-H]-.

2-oxo-N-phenyl-2-(2,3,4-trimethoxyphenyl)acetamide (3.97)
Synthesized using the general procedure B described for aryl
oxalamate scaffolds. Orange-brown oil (45 mg, 34%); Rf = 0.68
(50:50 EtOAc: hexanes);1H NMR (400 MHz, CDCl3) δ 8.46 (s,
1H), 7.70 – 7.66 (m, 2H), 7.58 (d, J = 8.8 Hz, 1H), 7.38 (t, J = 7.9 Hz, 2H), 7.17 (t, J = 7.4 Hz,
1H), 6.75 (d, J = 8.8 Hz, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.85 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ 189.78, 161.00, 158.79, 154.68, 141.67, 137.02, 129.17, 127.05, 124.95, 121.55,
119.80, 106.99, 61.79, 60.76, 56.24; DEPT-135 (101 MHz, CDCl3) δ 129.17, 127.06, 124.95,
120.16, 119.80, 106.99, 61.78, 60.76, 56.24. ESI+ MS: m/z 316 [MH]+; Elemental Analysis:
Calc. for C17H17NO5: C, 64.75; H, 5.43; N, 4.44. Found: C, 64.22; H, 5.81; N, 4.06.

2-(3,4-dimethoxyphenyl)-2-oxoacetic acid (S7)
Synthesized using the general procedure A described for aryl α-keto
acids. Off-white powder (466.5 mg, quantitative crude yield); Rf = 0.11
(50:50 EtOAc: hexanes); 1H NMR (400 MHz, CDCl3) δ 9.15 (s, 1H), 8.19 (dd, J = 8.5, 1.9 Hz,
1H), 7.79 (d, J = 1.8 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 3.98 (d, J = 15.7 Hz, 6H); 13C NMR (101
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MHz, CDCl3) δ 182.32, 162.12, 155.82, 149.29, 128.08, 124.80, 112.11, 110.48, 99.99, 56.30,
56.07; DEPT-135 (101 MHz, CDCl3) δ 128.08, 112.10, 110.48, 56.30, 56.07; ESI+ MS: ESIMS: m/z 209 [M-H]-.

N-(3-benzylphenyl)-2-(3,4-dimethoxyphenyl)-2-oxoacetamide (3.98)
Synthesized using the general procedure B described for
aryl oxalamate scaffolds. Brown-orange sticky residue
(42.5 mg, 79%); Rf = 0.603 (50:50 EtOAc: hexanes;
stains orange-yellow with p-anisaldehyde); 1H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H), 8.33 (dd,
J = 8.6, 1.9 Hz, 1H), 7.92 (d, J = 1.8 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.35 – 7.26
(m, 3H), 7.21 (t, J = 5.5 Hz, 3H), 7.02 (d, J = 7.5 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 4.00 (s, 2H),
3.97 (s, 3H), 3.95 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 185.07, 159.48, 154.92, 148.88,
142.44, 140.62, 136.89, 129.30, 128.93, 128.56, 127.72, 126.26, 126.16, 125.87, 120.44, 117.82,
112.92, 110.25, 56.18, 56.03, 41.87; DEPT-135 (101 MHz, CDCl3) δ 129.28, 128.92, 128.54,
127.71, 126.24, 125.86, 120.43, 117.80, 112.91, 110.24, 56.17, 56.03, 41.86; Elemental
Analysis: Calc. for C23H21NO4: C, 73.58; H, 5.64; N, 3.73. Found: C, 71.86 H, 6.37 N, 3.15.

2-(3-chlorophenyl)-2-oxoacetic acid (S8)
Synthesized using the general procedure A described for aryl α-keto
acids. Light tan solid (240.1 mg, quantitative crude yield); Rf = 0.10
(30:70 EtOAc: hexanes);1H NMR (400 MHz, CDCl3) δ 10.57 (s, 1H),
8.32 – 7.98 (m, 2H), 7.63 (dd, J = 21.0, 7.7 Hz, 1H), 7.56 – 7.38 (m, 1H); 13C NMR (101 MHz,
CDCl3) δ 183.42, 163.33, 135.40, 135.32, 133.29, 130.52, 130.30, 129.04; DEPT-135 (101
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MHz, CDCl3) δ 135.40, 134.22, 130.52, 130.31, 129.93, 129.04, 128.41 ESI- MS: m/z 182, 184
[M-H]-.

N-(3-benzylphenyl)-2-(3-chlorophenyl)-2-oxoacetamide (3.99)
Using an adapted procedure from Kumar et al.,417
carbonyldiimidazole (CDI) (66.32 mg, 0.409 mmol, 1.5
eq) was dissolved in anhydrous THF (3 mL) and stirred
at room temperature. To this mixture was slowly added S8 (75.54 mg, 0.409 mmol, 1.5 eq). The
reaction mixture was further stirred for 10 minutes at room temperature and then after the
evolution of CO2 ceased, 3-benzylaniline (50 mg, 0.273 mmol, 1.0 eq) was added. The stirring
was continued for an additional 10 minutes at room temperature and then refluxed for 16 hours.
After completion of the reaction, monitored by TLC, reaction mixture was concentrated in vacuo
to obtain crude product as orange-brown oil. The crude product was immediately purified by
flash-column chromatography using a gradient of 10:90 EtOAc: hexanes to 30:70
EtOAc:hexanes to afford 3.99 (54.6 mg, 38%) as a yellow oil. Rf = 0.89 (30:70 EtOAc: hexanes;
stains yellow eith p-anisaldehyde); 1H NMR (400 MHz, CDCl3) δ 8.87 (s, 1H), 8.39 (d, J = 1.6
Hz, 1H), 8.32 (d, J = 7.8 Hz, 1H), 7.65 – 7.54 (m, 2H), 7.49 (s, 1H), 7.43 (t, J = 7.9 Hz, 1H),
7.30 (dd, J = 12.8, 7.4 Hz, 3H), 7.21 (t, J = 6.8 Hz, 3H), 7.04 (d, J = 7.5 Hz, 1H), 4.00 (s, 2H);
13

C NMR (101 MHz, CDCl3) δ 186.12, 158.24, 142.56, 140.52, 136.54, 134.80, 134.51, 131.27,

129.86, 129.63, 129.36, 128.93, 128.57, 126.29, 126.15, 120.41, 117.80, 41.86; DEPT-135 (101
MHz, CDCl3) δ 134.51, 131.27, 129.86, 129.64, 129.36, 128.93, 128.57, 126.29, 126.15, 120.41,
117.80, 41.86; ESI- MS: m/z 209 [M-H].

152

2-(3,4-dimethoxyphenyl)-2-oxo-N-phenylacetamide (3.100)
Synthesized using the general procedure B described for aryl
oxalamate scaffolds. Yellow crystalline solid (51 mg, 53%); Rf =
0.72 (50:50 EtOAc: hexanes); 1H NMR (400 MHz, CDCl3) δ 9.05
(s, 1H), 8.33 (dd, J = 8.6, 1.9 Hz, 1H), 7.93 (d, J = 1.8 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.39 (t,
J = 7.9 Hz, 2H), 7.18 (t, J = 7.4 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 3.97 (s, 3H), 3.95 (s, 3H); 13C
NMR (101 MHz, CDCl3) δ 185.09, 159.56, 154.91, 148.86, 136.76, 129.19, 127.70, 126.15,
125.19, 120.00, 112.91, 110.26, 56.16, 56.00; DEPT-135 (101 MHz, CDCl3) δ 129.19, 127.70,
125.19, 120.00, 112.91, 110.26, 56.16, 56.00; Elemental Analysis: Calc. for C16H15NO4: C,
67.36; H, 5.30; N, 4.91. Found: C, 66.85; H, 5.0; N, 4.90.

N-(3-benzylphenyl)-2-oxo-2-(2,3,4-trimethoxyphenyl)acetamide (3.101)
Synthesized using the general procedure B described for
aryl oxalamate scaffolds. Pale yellow oil (15.3 mg, 18
%); Rf = 0.85 (50:50EtOAc: hexanes);1H NMR (400
MHz, CDCl3) δ 8.37 (s, 1H), 7.57 (t, J = 7.1 Hz, 2H), 7.45 (s, 1H), 7.25 (dt, J = 24.6, 7.7 Hz,
5H), 7.01 (d, J = 7.5 Hz, 1H), 6.73 (d, J = 8.8 Hz, 1H), 3.99 (s, 2H), 3.93 (d, J = 4.4 Hz, 6H),
3.84 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 189.71, 160.84, 158.76, 142.44, 140.60, 137.14,
129.27, 128.96, 128.54, 127.03, 126.24, 125.58, 121.61, 120.25, 117.62, 106.99, 61.77, 60.76,
56.23, 41.85; DEPT-135 (101 MHz, CDCl3) δ 129.26, 128.95, 128.53, 127.02, 126.23, 125.57,
120.24, 117.61, 106.98, 61.76, 60.75, 56.23, 41.85; Elemental Analysis: Calc. for C24H23NO5:
C, 71.10; H, 5.72; N, 3.45. Found: C, 70.38 H, 5.87 N, 3.30.
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2-(4-methoxyphenyl)-2-oxoacetic acid (S9)
Synthesized using the general procedure A described for aryl α-keto
acids. Pale pink-orange oil (479 mg, quantitative crude yield); Rf = 0.106
(50:50 EtOAc: hexanes);1H NMR (400 MHz, CDCl3) δ 12.56 (s, 1H),
8.07 (d, J = 8.9 Hz, 2H), 6.93 (d, J = 8.9 Hz, 2H), 3.86 (s, 3H); 13C NMR (101 MHz, CDCl3) δ
188.68, 168.43, 164.57, 132.70, 114.01, 55.54; DEPT-135 (101 MHz, CDCl3) δ 132.70, 114.01,
55.54; ESI- MS: m/z 179 [M-H]-.

N-(3-benzylphenyl)-2-(4-methoxyphenyl)-2-oxoacetamide (3.102)
Synthesized using the general procedure B described for
aryl oxalamate scaffolds. Pale yellow oil (18 mg, 24 %);
Rf = 0.80 (50:50 EtOAc: hexanes; stains red/pink with panisaldehyde);1H NMR (400 MHz, CDCl3) δ 8.98 (s, 3H), 8.48 (d, J = 9.0 Hz, 2H), 7.58 (d, J =
8.3 Hz, 1H), 7.51 (s, 1H), 7.30 (t, J = 8.2 Hz, 3H), 7.20 (d, J = 7.8 Hz, 3H), 7.02 (d, J = 7.5 Hz,
1H), 6.96 (d, J = 9.0 Hz, 2H), 4.00 (s, 2H), 3.89 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 185.18,
164.89, 159.43, 142.44, 140.62, 136.89, 134.27, 129.30, 128.94, 128.57, 126.26, 126.07, 125.81,
120.33, 117.70, 113.92, 55.62, 41.88; DEPT -135 (101 MHz, CDCl3) δ 134.27, 129.30, 128.94,
128.57, 126.26, 125.81, 120.33, 117.70, 113.95, 113.92, 55.63, 55.62, 41.89, 41.88.

2-oxo-2-(p-tolyl) acetic acid (S10)
Synthesized using the general procedure A described for aryl α-keto acids.
Golden yellow solid (402.8 mg, quantitative crude yield); Rf = 0.17 (50:50
EtOAc: hexanes); 1H NMR (400 MHz, CDCl3) δ 9.23 (s, 1H), 8.12 (d, J =
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8.1 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 2.44 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 184.88,
164.23, 147.05, 131.06, 129.72, 129.38, 21.96; DEPT-135 (101 MHz, CDCl3) δ 131.05, 129.70,
21.96; ESI- MS: m/z 163 [M-H]-.

2-oxo-N-phenyl-2-(p-tolyl) acetamide (3.103)
Synthesized using the general procedure B described for aryl
oxalamate scaffolds. Bright yellow solid (42 mg, 41%); Rf = 0.86
(30:70 EtOAc: hexanes) 1H NMR (400 MHz, CDCl3) δ 8.99 (s, 1H),
8.34 (d, J = 8.3 Hz, 2H), 7.81 – 7.58 (m, 2H), 7.40 (dd, J = 10.8, 5.2 Hz, 2H), 7.31 (d, J = 8.0
Hz, 2H), 7.19 (dd, J = 10.6, 4.2 Hz, 1H), 2.44 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 186.83,
159.13, 146.00, 136.69, 131.67, 130.54, 129.35, 129.22, 125.23, 119.89, 21.98; DEPT-135 13C
NMR (400 MHz, CDCl3) δ 197.38, 196.79, 196.76, 195.76, 194.42, 169.78; melting point: 119122 °C.

N-(3-benzylphenyl)-2-oxo-2-(p-tolyl) acetamide (3.104)
Synthesized using the general procedure B described for
aryl oxalamate scaffolds. Bright yellow crystalline solid
(43.8 mg, 72%); Rf = 0.75 (30:70 EtOAc: hexanes); 1H
NMR (400 MHz, CDCl3) δ 8.91 (s, 1H), 8.32 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 7.8 Hz, 1H), 7.50
(s, 1H), 7.28 (d, J = 8.1 Hz, 5H), 7.20 (d, J = 7.5 Hz, 2H), 7.01 (d, J = 7.5 Hz, 1H), 3.99 (s, 2H),
2.43 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 186.80, 159.11, 145.92, 142.45, 140.60, 136.86,
131.65, 130.60, 129.31, 128.93, 128.56, 126.26, 125.86, 120.37, 117.74, 41.88, 21.93; DEPT135 (101 MHz, CDCl3) δ 131.66, 129.31, 128.93, 128.56, 126.26, 125.86, 120.37, 117.74, 41.88,
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21.93; ESI+ MS: m/z 352 [MNa]+; ESI- MS: m/z 328 [MH]+; Elemental Analysis: Calc. for
C22H19NO2: C, 80.22; H, 5.81; N, 4.25. Found: C, 80.0; H, 5.65; N, 4.25.

2-oxo-2-(1H-pyrrol-2-yl) acetic acid (S11)
Synthesized using the general procedure A described for aryl α-keto acids.
Dark red-orange solid (318 mg, quantitative crude yield); Rf = 0.075 (90:10
DCM: MeOH; stains dark brown with p-anisaldehyde); 1H NMR (400 MHz,
DMSO) δ 12.22 (s, 1H), 7.28 (s, 1H), 7.12 (s, 1H), 6.27 (s, 1H); 13C NMR (101 MHz, DMSO) δ
175.39, 172.49, 165.35, 129.35, 128.88, 121.89, 111.62; DEPT-135 (101 MHz, DMSO) δ
129.34, 121.87, 111.61; ESI- MS: m/z 137 [MH]+.

N-(3-benzylphenyl)-2-oxo-2-(1H-pyrrol-2-yl) acetamide (3.105)
Synthesized using the general procedure B described for aryl
oxalamate scaffolds. Light yellow solid powder (45.5 mg,
22%); Rf = 0.59 (30:70 EtOAc: hexanes; stains dark orangebrown with p-anisaldehyde); 1H NMR (500 MHz, DMSO) δ 12.24 (s, 1H), 10.57 (s, 1H), 7.71
(s, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.38 – 7.15 (m, 8H), 7.02 (d, J = 7.5 Hz, 1H), 6.35 – 6.27 (m,
1H), 3.94 (s, 2H); 13C NMR (126 MHz, DMSO) δ 162.37, 142.34, 141.50, 138.46, 129.26,
129.17, 128.97, 128.91, 126.49, 125.29, 121.05, 118.54, 111.69, 41.68; DEPT-135 (126 MHz,
DMSO) δ 129.26, 129.17, 128.91, 126.49, 125.29, 122.34, 121.05, 118.54, 111.70, 41.68;
Elemental Analysis: Calc. for C19H16N2O2: C, 74.98; H, 5.30; N, 9.20. Found: C, 74.66; H,
5.31 N, 8.64; melting point: 148-150 °C.
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2-oxo-2-phenylacetic acid (S12)
Synthesized using the general procedure A described for aryl α-keto acids.
Pale yellow oil (312 mg, quantitative crude yield); Rf = 0.57 (20:80 EtOAc:
Hexanes); 1H NMR (400 MHz, CDCl3) δ 10.00 (s, 1H), 8.22 (d, J = 7.7 Hz,
2H), 7.77 – 7.64 (m, 1H), 7.58 – 7.43 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 185.20, 163.99,
135.55, 131.79, 130.90, 130.35, 128.99, 128.61; DEPT-135 (101 MHz, CDCl3) δ 135.55,
130.90, 130.35, 128.99, 128.61; ESI- MS: m/z 148 [M-H].

N-(3-benzylphenyl)-2-oxo-2-phenylacetamide (3.106)
Synthesized using the general procedure B described for aryl
oxalamate scaffolds. Light yellow solid (46 mg, 44%); Rf =
0.57 (20:80 EtOAc: hexanes); 1H NMR (400 MHz, ) δ 8.91 (s, 1H), 8.54 – 8.23 (m, 2H), 7.62
(dd, J = 15.7, 8.5 Hz, 2H), 7.53 – 7.44 (m, 3H), 7.34 – 7.25 (m, 3H), 7.21 (dd, J = 11.1, 6.7 Hz,
3H), 7.02 (d, J = 7.6 Hz, 1H), 3.99 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 187.45, 158.93,
142.51, 140.63, 136.84, 134.62, 133.13, 131.48, 129.34, 128.97, 128.60, 128.57, 126.31, 125.97,
120.44, 117.82, 41.91.DEPT-135 (101 MHz, CDCl3) δ 134.61, 131.47, 129.33, 128.96, 128.59,
128.56, 126.29, 125.96, 120.43, 117.80, 41.90; ESI-MS: m/z 313 [M-H].

2-(furan-2-yl)-2-oxoacetic acid (S13)
Synthesized using the general procedure A described for aryl α-keto acids.
Yellow solid (313 mg, quantitative crude yield); Rf = 0.15 (50:50 EtOAc:
hexanes); 1H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H), 8.15 (s, 1H), 7.86 (s,
1H), 6.70 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 169.76, 159.54, 150.67, 128.07, 120.12,
113.39; DEPT-135 (101 MHz, CDCl3) δ 150.68, 127.76, 113.09; ESI- MS: m/z 138[M-H].
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N-(3-benzylphenyl)-2-(furan-2-yl)-2-oxoacetamide (3.107)
Synthesized using the general procedure B described for aryl
oxalamate scaffolds. Bright yellow solid (15.3 mg, 14%) Rf =
0.55 (30:70 EtOAc: hexanes; stains purple with panisaldehyde); 1H NMR (400 MHz, CDCl3) δ 9.04 (s, 1H), 8.25 (d, J = 3.6 Hz, 1H), 7.76 (s,
1H), 7.58 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.30 (dd, J = 11.4, 5.5 Hz, 3H), 7.20 (t, J = 6.6 Hz,
3H), 7.02 (d, J = 7.6 Hz, 1H), 6.63 (dd, J = 3.5, 1.4 Hz, 1H), 3.99 (s, 2H); 13C NMR (101 MHz,
CDCl3) δ 173.50, 157.53, 149.73, 149.30, 142.51, 140.57, 136.56, 129.34, 128.94, 128.58,
127.39, 126.29, 126.05, 120.42, 117.79, 113.36, 41.86; DEPT-135 (101 MHz, CDCl3) δ 149.73,
129.34, 128.94, 128.58, 127.39, 126.29, 126.05, 120.42, 117.79, 113.36, 41.86; ESI+MS: m/z
328 [MNa]+. Elemental Analysis: Calc. for C15H13NO2: C, 75.30; H, 5.48; N, 5.85. Found: C,
73.68; H, 4.91; N, 4.52.

Diethyl (2-((3-benzylphenyl) amino)-1-(3-bromophenyl)-1-hydroxy-2-oxoethyl)
phosphonate (3.113)
Using an adapted procedure from Gooβen and Dezfuli,356
in a flame-dried round flask was added
Tetrakis(triphenylphosphine)palladium(0) (2 mol%) and
PPh3 (3.99 mg, 6 mol%). The reaction vessel was fitted
with a reflux condenser and purged with argon. Subsequently, anhydrous EtOH (3 mL), 3.96
(100 mg, 0.254 mmol, 1.0 eq), N, N-Diisopropylethylamine (49.5 mg, 66.7 µL, 0.381 mmol, 1.5
eq) and diethylphosphite (42.1 mg, 39.2 µL, 0.305mmol, 1.2 eq) were added. The reaction
mixture was heated to 80°C overnight (16 hours). After the disappearance of the starting
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material, the reaction was quenched with 1 N HCl (5 mL) and EtOAc was added (5 mL). The
mixture was transferred into a separatory funnel and the organic layer was washed with water (3
x 10 mL) and brine (2 x 10 mL). The organic layers were dried over Na2SO4 and concentrated by
rotary evaporation. The crude residue was purified by flash-column chromatography using a
gradient of 10:90 EtOAc:hexanes to 70:30 EtOAc:hexanes to yield 3.113 (80.8 mg, 70%) and
3.115 (10.9 mg, 11 %). 3.113: White crystalline solid Rf = 0.13 (30:70 EtOAc: Hexanes); 1H
NMR (500 MHz, CDCl3) δ 9.09 (s, 1H), 7.74 (s, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.48 – 7.38 (m,
7H), 7.28 – 7.11 (m, 7H), 6.91 (d, J = 7.5 Hz, 1H), 5.89 (d, J = 8.5 Hz, 1H), 4.10 (dddd, J = 24.8,
21.7, 11.0, 4.8 Hz, 4H), 3.90 (s, 2H), 1.43 – 1.11 (m, 2H); 13C NMR (126 MHz, CDCl3) δ
165.88, 165.83, 142.09, 140.77, 138.04, 138.00, 137.49, 132.24, 130.25, 130.05, 129.03, 128.88,
128.49, 126.16, 125.79, 125.38, 122.69, 120.50, 117.83, 77.82, 77.78, 64.90, 64.85, 64.73, 64.69,
41.92, 16.07, 16.04, 16.02, 15.99; DEPT-135 (126 MHz, CDCl3) δ 132.26, 132.24, 130.28,
130.25, 130.05, 129.08, 129.03, 128.90, 128.88, 128.50, 126.16, 125.79, 125.37, 120.50, 117.83,
77.82, 77.78, 77.75, 64.86, 64.74, 64.68, 41.93, 41.92; Elemental Analysis: Calc. for
C25H27BrNO5P: C, 56.40; H, 5.11; N, 2.63. Found: C, 56.37; H, 4.93 N, 2.52; melting point:
93-95 °C.

N-(3-benzylphenyl)-2-(3-bromophenyl) acetamide (3.115)
Prepared by procedure described for 3.113. White fluffy
powder (10.9 mg, 11 %).; Rf = 0.52 (30:70 EtOAc:
hexanes); 1H NMR (400 MHz, DMSO) δ 10.11 (s, 1H),
7.52 (s, 1H), 7.44 (dd, J = 8.4, 2.6 Hz, 3H), 7.29 (dt, J = 14.1, 7.1 Hz, 4H), 7.24 – 7.13 (m, 4H),
6.92 (d, J = 7.5 Hz, 1H), 3.89 (s, 2H), 3.62 (s, 2H); 13C NMR (101 MHz, DMSO) δ 168.91,
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142.30, 141.52, 139.63, 139.11, 132.37, 130.85, 129.86, 129.22, 129.14, 128.88, 128.75, 126.45,
121.89, 119.84, 117.35, 43.04, 41.62, 40.61, 40.40, 40.19, 39.99, 39.78, 39.57, 39.36; DEPT135 (101 MHz, DMSO) δ 132.36, 130.85, 129.85, 129.22, 129.14, 129.11, 128.87, 128.85,
128.74, 128.70, 126.44, 124.26, 124.23, 119.83, 119.81, 117.35, 117.31, 43.05, 43.02, 41.63,
41.61; ESI- MS: m/z 378, 380 [M-H]-.

Diethyl (2-((3-benzylphenyl) amino)-1-(4-bromophenyl)-1-hydroxy-2-oxoethyl)
phosphonate (3.114)
Using an adapted procedure from Gooβen and Dezfuli,356
in a flame-dried round flask was added Pd(OAc2) (2
mol%) and PPh3 (2.75 mg, 6 mol%). The reaction vessel
was fitted with a reflux condenser and purged with argon. Subsequently, anhydrous EtOH (4
mL), 3.95 (68.9 mg, 0.175 mmol, 1.0 eq), N, N-Diisopropylethylamine (33.93 mg, 45.7 µL,
0.263 mmol, 1.5 eq) and diethylphosphite (29 mg, 27.1 µL, 0.210mmol, 1.2 eq) were added. The
reaction mixture was heated to 80°C overnight (16 hours). After the disappearance of the starting
material, the reaction was quenched with 1 N HCl (5 mL) and EtOAc was added (5 mL). The
mixture was transferred into a separatory funnel and the organic layer was washed with water (3
x 10 mL) and brine (2 x 10 mL). The organic layers were dried over Na2SO4 and concentrated by
rotary evaporation. The crude residue was purified by flash-column chromatography using a
gradient of 10:90 EtOAc:hexanes to 70:30 EtOAc:hexanes to yield 3.114 (24.6 mg, 26%) and
3.116 (17.2 mg, 25%). 3.114: white crystalline solid; Rf = 0.13 (30:70 EtOAc: hexanes); 1H
NMR (500 MHz, CDCl3) δ 9.04 (s, 1H), 7.43 (dt, J = 24.3, 7.9 Hz, 6H), 7.24 (t, J = 7.4 Hz, 2H),
7.21 – 7.10 (m, 4H), 6.91 (d, J = 7.4 Hz, 1H), 5.87 (d, J = 8.5 Hz, 1H), 4.22 – 3.97 (m, 4H), 3.89
(s, 2H), 1.24 (dt, J = 14.4, 7.0 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 166.03, 165.98, 142.11,
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140.78, 137.48, 134.94, 134.90, 131.86, 129.06, 128.89, 128.81, 128.51, 126.18, 125.41, 123.41,
120.48, 117.82, 78.00, 77.96, 64.86, 64.81, 64.68, 64.63, 41.92, 16.09, 16.05, 16.03, 16.00;
DEPT-135 (126 MHz, CDCl3) δ 131.87, 129.06, 128.89, 128.81, 128.51, 126.18, 125.41,
120.48, 117.82, 78.00, 77.95, 64.86, 64.81, 64.68, 64.64, 41.92. Elemental Analysis: Calc. for
C25H27BrNO5P: C, 56.40; H, 5.11; N, 2.63. Found: C, 56.45; H, 5.02 N, 2.54; melting point:
97-100 °C.

N-(3-benzylphenyl)-2-(4-bromophenyl) acetamide (3.116)
Prepared by procedure described for 3.114. White fluffy
powder (17.2 mg, 25%); Rf = 0.52 (30:70 EtOAc:
hexanes); 1H NMR (400 MHz, DMSO) δ 10.15 (s, 1H),
7.57 – 7.39 (m, 4H), 7.32 – 7.23 (m, 4H), 7.24 – 7.13 (m, 4H), 6.92 (d, J = 7.4 Hz, 1H), 3.88 (s,
2H), 3.60 (s, 2H); 13C NMR (101 MHz, DMSO) δ 169.03, 142.29, 141.52, 139.67, 135.83,
131.87, 131.57, 129.22, 129.14, 128.88, 126.44, 124.23, 120.20, 119.78, 117.31, 42.94, 41.63;
DEPT-135 (101 MHz, DMSO) δ 131.87, 131.57, 129.22, 129.14, 128.87, 126.44, 124.22,
119.78, 117.31, 42.94, 41.63; ESI- MS: m/z 378, 380 [M-H]-.

Diethyl (3-acetylphenyl) phosphonate (3.119)
Using an adapted procedure from Gooβen and Dezfuli,356 a flame-dried round bottom flask
fitted with a reflux condenser charged with Pd(OAc)2 (13.5 mg, 2 mol%) and PPh3 (47.48 mg, 6
mol%) was evacuated and purged with argon. Subsequently, anhydrous EtOH (15 mL), 3’bromoacetophenone (600 mg, 3.014 mmol, 1.0 eq), N, N-Diisopropylethylamine (587 mg, 792
µL, 4.52 mmol, 1.5 eq) and diethylphosphite (500 mg, 466 µL, 3.62 mmol, 1.2 eq) were added.
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The reaction mixture was heated to 80°C overnight (16 hours). After the
disappearance of the starting material, the reaction was quenched with 1 N
HCl (5 mL) and EtOAc was added (5 mL). The mixture was transferred
into a separatory funnel and the organic layer was washed with water (3 x 10 mL) and brine (2 x
10 mL). The organic layers were dried over Na2SO4 and concentrated by rotary evaporation. The
crude residue was purified by flash-column chromatography using 75:25 EtOAc:hexanes to yield
3.119 as a colorless oil (563 mg, 73%); Rf = 0.30 (70:30 EtOAc: hexanes); 1H NMR (400 MHz,
CDCl3) δ 8.39 (d, J = 13.8 Hz, 1H), 8.16 (d, J = 7.8 Hz, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.61 (dd, J
= 7.6, 4.0 Hz, 1H), 4.17 (dddd, J = 24.2, 10.1, 7.3, 2.6 Hz, 4H), 2.65 (s, 3H), 1.35 (t, J = 7.0 Hz,
6H); 13C NMR (101 MHz, CDCl3) δ 197.08, 137.18, 137.04, 136.02, 135.92, 131.99, 131.84,
131.81, 131.68, 131.58, 130.29, 128.99, 128.84, 128.41, 62.44, 62.38, 26.63, 16.31, 16.25;
DEPT-135 (101 MHz, CDCl3) δ 136.02, 135.92, 131.99, 131.84, 131.81, 131.68, 131.58,
128.99, 128.84, 62.44, 62.38, 26.63, 16.31, 16.25; ESI+MS: m/z 257 [MH]+, m/z 279 [MNa]+.

Diethyl (4-acetylphenyl)phosphonate (3.120)
Same procedure for was used as described for 3.119 except using 4’bromoacetophenone as the starting material. Colorless oil (601 mg, 78%);
Rf = 0.32 (70:30 EtOAc: hexanes); 1H NMR (400 MHz, CDCl3) δ 8.08 –
7.99 (m, 2H), 7.92 (dd, J = 12.8, 8.4 Hz, 2H), 4.20 – 4.06 (m, 4H), 2.64 (s, 3H), 1.34 (t, J = 7.1
Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 197.49, 139.82, 134.20, 132.34, 132.10, 132.00,
128.57, 128.45, 128.10, 127.95, 62.48, 62.43, 26.77, 16.32, 16.26; DEPT-135 (101 MHz,
CDCl3) δ 132.08, 132.01, 131.98, 128.56, 128.44, 128.09, 127.94, 62.47, 62.42, 26.77, 16.33,
16.32, 16.25; ESI+MS: m/z 257 [MH]+, m/z 279 [MNa]+.
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Ethyl 2-(furan-2-yl)-2-oxoacetate (3.127)
Using an adapted procedure from Cheng et al.1 and Kim et al., 374 to a
solution of furan (0.191 mL, 3.00 mmol, 1.0 eq) in anhydrous THF (4
mL) was added slowly n-butyl lithium (2.373 mL, 3.15 mmol, 1.05 eq)
at -78°C. The reaction mixture was stirred at -78°C for 30 minutes. After 30 minutes, a solution
(cooled to -78°C) of ZnBr2 (532.0 mg, 3.6 mmol, 1.20 eq) in anhydrous THF (2 mL) was added
to the reaction flask slowly and stirred for 30 minutes. To a separate reaction flask containing
Ni(acac) (11.3 mg, 2 mol%) was added 6.9 mL of the ZnBr2 reagent mixture (6.9 mL, 2.197
mmol, 1.2 eq) at -78°C. This reaction stirred for 15 minutes and then a solution of ethyl oxalyl
chloride (0.205 mL, 1.831 mmol, 1.0 eq) in anhydrous THF (2 mL) was added and stirred for 30
minutes. After 30 minutes, the reaction was quenched with a saturated NH4Cl solution (10 mL)
and extracted with EtOAc. The combined organic layers were washed with a saturated Na2S2O3
solution (2 x 10 mL), brine (2 x 10 mL), dried over Na2SO4 and concentrated by rotary
evaporation to afford crude orange yellow oil. The crude oil was purified by flash-column
chromatography using a gradient of 10:90 EtOAc:hexanes to 50:50 EtOAc:hexanes to afford
3.129 as a dark yellow oil (21.4 mg, 4 %); Rf = 0.32 (10:90 EtOAc: hexanes; stains white with panisaldehyde); 1H NMR (400 MHz, CDCl3) δ 7.79 (dd, J = 1.6, 0.7 Hz, 1H), 7.74 (dd, J = 3.7,
0.6 Hz, 1H), 6.65 (dd, J = 3.7, 1.7 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 1.45 (td, J = 7.1, 2.8 Hz,
3H); 13C NMR (101 MHz, CDCl3) δ 171.12, 161.01, 149.75, 149.50, 149.49, 124.68, 112.99,
62.69, 13.98; ESI+ MS: m/z 169 [MH]+, m/z 191 [MNa]+.
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N-(3-benzylphenyl)-2-(5-methoxy-1H-indol-3-yl)-2oxoacetamide (3.143)
Using an adapted procedure from Lee et al.418 and
Marchand et al,419 a mixture of 5-methoxyindole (30
mg, 21.4 µL 0.204 mmol, 1.0 eq) and anhydrous ether
(1 mL) was cooled to 0°C and stirred for 30 minutes. After 30 minutes, oxalyl chloride (31.09
mg, 21 µL, 0.245 mmol, 1.2 eq) was added slowly dropwise at 0°C. Solution went from light
orange in color to an intense orange-red color. The mixture was stirred for 2 hours at 0°C. After
2 hours, the solvent was carefully removed by rotary evaporation and to the crude residue was
added anhydrous THF (1 mL) and 3-benzylaniline (37.38 mg, 0.204 mmol, 1.0 eq) and 1 drop
(catalytic amount) of triethylamine. The reaction mixture became golden yellow and cloudy and
was stirred at room temperature for 2 hours. The mixture was quenched with saturated NaHCO3
(10 mL) then extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried over
Na2SO4 and concentrated via rotary evaporation. The crude solid was then recrystallized from
EtOAc:hexanes to yield pure 3.121 as a golden yellow solid (27.6 mg, 35%); 1H NMR (400
MHz, CDCl3) δ 8.98 (s, 3H), 8.48 (d, J = 9.0 Hz, 2H), 7.58 (d, J = 8.3 Hz, 1H), 7.51 (s, 1H), 7.30
(t, J = 8.2 Hz, 3H), 7.20 (d, J = 7.8 Hz, 3H), 7.02 (d, J = 7.5 Hz, 1H), 6.96 (d, J = 9.0 Hz, 2H),
4.00 (s, 2H), 3.89 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 185.18, 164.89, 159.43, 142.44,
140.62, 136.89, 134.27, 129.30, 128.94, 128.57, 126.26, 126.07, 125.81, 120.33, 117.70, 113.92,
55.62, 41.88; DEPT-135 (101 MHz, CDCl3) δ 134.27, 129.30, 128.94, 128.57, 126.26, 125.81,
120.33, 117.70, 113.95, 113.92, 55.63, 55.62, 41.89, 41.88; ESI+MS: m/z 383 [MH]+;
Elemental Analysis: Calc. for C24H20N2O3: C, 74.98; H, 5.24; N, 7.29. Found: C, 73.49; H,
4.98 N, 7.08.
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N-(3-benzylphenyl)-2-(5-methoxy-1H-indol-3-yl)-2-oxoacetamide (3.144)
Using an adapted procedure from Lee et al.418 and Marchand et
al,419 a mixture of 5-methoxyindole (50 mg, 35.7 µL 0.339
mmol) and anhydrous ether (1 mL) was cooled to 0°C and
stirred for 30 minutes. After 30 minutes, oxalyl chloride (51.75
mg, 35 µL, 0.408 mmol) was added slowly dropwise at 0°C. Solution went from light orange in
color to an intense orange-red color. The mixture was stirred for 2 hours at 0°C. After 2 hours,
the solvent was carefully removed by rotary evaporation and to the crude residue was added
anhydrous THF (2 mL) and aniline (31.59 mg, 30.9 µL, 0.339 mmol, 1.0 eq) and 1 drop
(catalytic amount) of triethylamine. The reaction mixture became golden yellow and cloudy and
was stirred at room temperature for 2 hours. The mixture was quenched with saturated NaHCO3
then extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried over Na2SO4
and concentrated via rotary evaporation. The crude orange yellow solid was then recrystallized
from EtOAc:hexanes to yield pure 3.122 as a light tan powder (53.5 mg, 53%); Rf = 0.333 (20:80
EtOAc: hexanes);1H NMR (400 MHz, DMSO) δ 12.26 (s, 1H), 10.66 (s, 1H), 8.72 (s, 1H), 7.86
(dd, J = 17.6, 5.0 Hz, 3H), 7.48 (d, J = 8.8 Hz, 1H), 7.39 (t, J = 7.8 Hz, 2H), 7.15 (t, J = 7.3 Hz,
1H), 6.94 (dd, J = 8.7, 2.3 Hz, 1H), 3.83 (s, 3H); 13C NMR (101 MHz, DMSO) δ 182.22,
162.87, 156.56, 138.97, 138.53, 131.60, 129.19, 127.64, 124.67, 120.65, 113.89, 113.43, 112.30,
103.83, 55.71; DEPT-135 (101 MHz, DMSO) δ 138.97, 129.19, 124.67, 120.65, 113.89, 113.43,
103.83, 55.71; Elemental Analysis: Calc. for C23H18N2O2: C, 77.95; H, 5.12; N, 7.90. Found: C,
77.47; H, 4.92 N, 7.78; melting point: 243-245 °C (decomp).
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N-(3-benzylphenyl)-2-(1H-indol-3-yl)-2-oxoacetamide (3.140)
Using an adapted procedure from Lee et al.418 and Marchand
et al,419 a mixture of indole (50 mg, 0.427 mmol, 1.0 eq) and
anhydrous ether (1.14 mL) was cooled to 0°C and stirred for
30 minutes. After 30 minutes, oxalyl chloride (65 mg, 43.9
µL, 0.512 mmol, 1.2 eq) was added slowly dropwise at 0°C. Solution was bright yellow in color.
The mixture was stirred for 2 hours at 0°C. After 2 hours, the solvent was carefully removed by
rotary evaporation and to the crude residue was added anhydrous THF (2 mL) and 3benzylaniline (78.2 mg, 0.427 mmol, 1.0 eq) and 1 drop (catalytic amount) of triethylamine. The
reaction mixture became an orange brown color and was stirred at room temperature for 2 hours.
The mixture was quenched with saturated NaHCO3 (10 mL) then extracted with EtOAc (3 x 10
mL). The organic layers were combined, dried over Na2SO4 and concentrated via rotary
evaporation to yield 3.140 as a light tan powder (155.1 mg, quantitative yield); Rf = 0.333 (20:80
EtOAc: hexanes; stains light brown with p-anisaldehyde); 1H NMR (400 MHz, DMSO) δ 12.34
(s, 1H), 10.61 (s, 1H), 8.76 (s, 1H), 8.29 (dd, J = 6.2, 2.6 Hz, 1H), 7.79 (s, 1H), 7.69 (d, J = 8.1
Hz, 1H), 7.61 – 7.51 (m, 1H), 7.37 – 7.14 (m, 9H), 7.02 (d, J = 7.5 Hz, 1H), 3.95 (s, 2H); 13C
NMR (101 MHz, DMSO) δ 182.42, 162.80, 142.29, 141.52, 139.04, 138.62, 136.85, 129.23,
129.15, 128.89, 126.64, 126.47, 125.17, 124.02, 123.16, 121.69, 121.04, 118.53, 113.12, 112.41;
DEPT-135 101 MHz, DMSO) δ 139.04, 129.23, 129.15, 128.89, 126.47, 125.17, 124.02, 123.16,
121.69, 121.04, 118.53, 113.12; Elemental Analysis: Calc. for C23H18N2O2: C, 77.95; H, 5.12;
N, 7.90. Found: C, 77.47; H, 4.92 N, 7.78.
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N-(3-benzylphenyl)-2-(7-methyl-1H-indol-3-yl)-2-oxoacetamide (3.142)
Using an adapted procedure from Lee et al.418 and Marchand et
al,419 a mixture of 7-methylindole (30 mg, 0.229 mmol, 1.0 eq)
and anhydrous ether (1 mL) was cooled to 0°C and stirred for
30 minutes. After 30 minutes, oxalyl chloride (34.84 mg, 23.6
µL, 0.274 mmol, 1.2 eq) was added slowly dropwise at 0°C. The mixture was stirred for 2 hours
at 0°C. After 2 hours, the solvent was carefully removed by rotary evaporation and to the crude
residue was added anhydrous THF (2 mL) and 3-benzylaniline (41.9 mg, 0.229 mmol, 1.0 eq)
and 1 drop (catalytic amount) of triethylamine. The reaction mixture was stirred at room
temperature for 2 hours. The mixture was quenched with saturated NaHCO3 (10 mL) then
extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried over Na2SO4 and
concentrated via rotary evaporation to yield 3.142 as a brown tan solid (155.1 mg, quantitative
yield); Rf = 0.333 (20:80 EtOAc: hexanes; stains light brown with p-anisaldehyde); 1H NMR
(400 MHz, DMSO) δ 12.39 (s, 1H), 10.74 (s, 1H), 10.60 (s, 1H), 8.71 (s, 1H), 8.12 (d, J = 7.8
Hz, 1H), 7.78 (d, J = 6.1 Hz, 2H), 7.67 (t, J = 8.9 Hz, 2H), 7.32 – 7.19 (m, 5H), 7.09 (d, J = 7.1
Hz, 1H), 7.06 – 6.98 (m, 1H), 3.94 (d, J = 6.1 Hz, 2H), 2.53 (s, 2H); 13C NMR (101 MHz,
DMSO) δ 182.41, 162.80, 158.98, 142.35, 142.27, 141.53, 141.43, 138.62, 138.18, 136.28,
129.17, 128.90, 126.48, 125.47, 124.67, 123.37, 122.49, 121.17, 119.25, 118.64, 112.75, 41.70,
17.09; DEPT-135 (101 MHz, DMSO) δ 138.55, 129.21, 129.17, 128.90, 126.48, 125.47, 125.17,
124.67, 123.37, 121.17, 121.04, 119.25, 118.64, 118.53, 41.70, 17.09; ESI- MS: m/z 367 [MH]-;
Elemental Analysis: Calc. for C24H20N2O2: C, 78.24; H, 5.47; N, 7.60. Found: C, 77.98; H,
5.46 N, 7.02.
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2-(1H-indol-3-yl)-2-oxo-N-phenylacetamide (3.141)
Using an adapted procedure from Lee et al.418 and Marchand et al,419
a mixture of indole (200 mg, 1.71 mmol, 1.0 eq) and anhydrous ether
(4.57 mL) was cooled to 0°C and stirred for 30 minutes. After 30
minutes, oxalyl chloride (260.46 mg, 175 mL, 0.512 mmol, 1.2 eq) was added slowly dropwise
at 0°C. Solution was bright yellow in color. The mixture was stirred for 2 hours at 0°C. After 2
hours, the solvent was carefully removed by rotary evaporation and to the crude residue was
added anhydrous THF (4 mL) and freshly distilled aniline (54.5 mg, 53.4 µL, 0.1.71 mmol, 1.0
eq) and 1 drop (catalytic amount) of triethylamine. The reaction mixture became an orange
yellow color and was stirred at room temperature for 2 hours. The mixture was quenched with
saturated NaHCO3 (20 mL) then extracted with EtOAc (3 x 20 mL). The organic layers were
combined, dried over Na2SO4 and concentrated via rotary evaporation to yield 3.141 as a goldenyellow solid (335.9 mg, 94% yield); Rf = 0.77 (50:50 EtOAc: hexanes; stains purple/pink with
p-anisaldehyde); 1H NMR (400 MHz, DMSO) δ 12.37 (s, 1H), 10.69 (s, 1H), 8.80 (d, J = 2.3
Hz, 1H), 8.33 (dd, J = 5.8, 2.3 Hz, 1H), 7.90 (d, J = 8.0 Hz, 2H), 7.66 – 7.56 (m, 1H), 7.41 (t, J =
7.9 Hz, 2H), 7.37 – 7.30 (m, 2H), 7.17 (t, J = 7.3 Hz, 1H); 13C NMR (101 MHz, DMSO) δ
182.45, 162.82, 139.05, 138.52, 136.86, 129.19, 126.64, 124.69, 124.04, 123.18, 121.69, 120.72,
113.13, 112.43; DEPT-135 (101 MHz, DMSO) δ 139.05, 129.19, 124.69, 124.04, 123.18,
121.69, 120.73, 113.13.3; Elemental Analysis: Calc. for C16H12N2O2: C, 72.72; H, 4.58; N,
10.60. Found: C, 72.19; H, 4.30 N, 10.45; melting point: 240-242 °C (decomp).
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Ethyl 2-oxo-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)acetate (3.146)
Using an adapted procedure from Zhang et al.,383 azaindole (250 mg, 2.12
mmol, 1 eq) was added to a stirred suspension of AlCl3 (1.413 g, 10.6
mmol, 5 eq) in anhydrous DCM (50 mL). After the mixture stirred at
room temperature for 1 hour, ethyl oxalyl chloride (1.18 mL, 10.6 mmol, 5
eq) was added dropwise. It was noted that as the ethyl oxalyl chloride was added the solution
went from yellow color to an orange color. After 12 hours of stirring at room temperature the
reaction flask was placed in an ice-water and MeOH was slowly added dropwise to quench the
reaction. The color of the solution went from an orange yellow cloudy color to a light brownish
orange clear color. DCM was added and the organic layer was separated, washed with saturated
NaHCO3 (3 x 20 mL), H20 (2 x 20 mL) and brine (2 x 20 mL). The organic layers were
combined, dried over Na2SO4 and concentrated by rotary evaporation to afford an orange-yellow
solid. The solid was washed with ice-cold ether to obtain 3.146 as an off-white powder (186.9
mg, 40%); Rf = 0.77 (10:1 EtOAc: MeOH; stains white with p-anisaldehyde); 1H NMR (400
MHz, CDCl3) δ 13.51 (s, 1H), 8.76 (dd, J = 7.9, 1.4 Hz, 1H), 8.72 (s, 1H), 7.34 (dd, J = 7.9, 4.9
Hz, 1H), 4.45 (q, J = 7.1 Hz, 2H), 4.36 (q, J = 7.1 Hz, 1H), 1.46 (t, J = 7.1 Hz, 3H), 1.38 (t, J =
7.1 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 178.03, 162.31, 149.13, 144.00, 137.57, 131.99,
119.82, 119.12, 112.68, 63.16, 62.31, 14.09, 13.91; DEPT-135 (101 MHz, CDCl3) δ 143.99,
137.56, 131.98, 119.11, 63.15, 62.30, 14.09, 13.90; ESI+MS: m/z 219 [MH]+;
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Potassium 2-oxo-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)acetate (3.147)
Using an adapted procedure from Wang et al.,305 K2CO3 (151.36 mg, 0.916
mmol, 2.0 eq) was added to a solution of 3.126 (100 mg, 0.458 mmol, 1
eq) in 1:1 mixture of MeOH:H2O (2 mL), and the mixture stirred at room
temperature for 8 hours. The white precipitate was collected and washed
with cold H2O (5 mL) to afford 3.147 as an off-white crystalline powder (68.2 mg, 78%), which
was used in the next step without further purification; 1H NMR (400 MHz, DMSO) δ 8.35 (s,
1H), 8.18 (s, 1H), 7.07 (s, 1H); ESI- MS: m/z 189 [M-H]-;

N-(3-benzylphenyl)-2-oxo-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)acetamide (3.148)
Using an adapted procedure from Martyn et al.,306 to a
mixture of 3.148 (43.9 mg, 0.193 mmol, 1.0 eq) and 3benzylaniline (38.85 mg, 0.212 mmol, 1.1 eq) in anhydrous
DMF (2 mL) was added 1-(3-dimethylaminopropyl)-3ethylcarbodiimide hydrochloride (48.12, 0.251 mmol, 1.3eq) and 1-hydroxybenzotriazole
hydrate (HOBT) (39.12, 0.289, 1.5 eq) at room temperature. N, N-Diisopropylethylamine (37.0
µL, 27.40 mg, 0.212 mmol, 1.1 eq) was added dropwise and the reaction mixture stirred at room
temperature for 16 hours. The reaction was quenched with H2O (5 mL) and stirred for 30
minutes at room temperature. The solution was diluted with EtOAc (10 mL) and the organic
layer was washed with H2O (5 x 100 mL), saturated NaHCO3 and brine. The organic layers were
combined, dried over Na3SO4 and concentrated to afford an orange-yellow crude solid product
3.128 (66 mg, 96% crude yield); ESI- MS: m/z 354 [M-H]-.
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